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Arterial diseases are the leading cause of death and disability in the developed
world, and are rapidly increasing in importance in the developing world. The
incidence, case-fatality, and longer-term sequelae of transient ischaemic attack
(TIA), stroke, acute coronary syndromes (ACS) and peripheral vascular events
(PVE) have never been measured in the same population at the same time, and the
time-trends in incidence and case-fatality are uncertain.
Aims
• To develop the Oxford Vascular (OXVASC) Study protocol and ensure case
ascertainment was reliable and complete.
• To examine the effects of case definition and quality of methods of
ascertainment on stroke incidence rates.
• To examine the effect of definition on the risk of recurrent stroke
• To determine the early risk of stroke after a TIA or minor stroke.
• To compare the incidence and estimate time trends in stroke incidence by
comparison with the Oxfordshire Community Stroke Project (OCSP).
• To measure and compare the incidence and burden of stroke, ACS and PVE.
Methods
OXVASC is a population-based study of all acute vascular events (TIA, stroke, ACS
and PVE) and elective surgical and endovascular interventions for subacute or
chronic vascular disease in Oxfordshire. The pilot study covered a population of
90,542 in 9 general practices. Multiple overlapping sources of ascertainment were
used to identify cases from hospitals and the community. Retrospective data were
obtained for vascular deaths.
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Summary of main findings
• The methods used in OXVASC achieved near-complete ascertainment.
However, our analyses suggested that differences in case definition and
ascertainment strategies between studies could each lead to differences in
measured stroke incidence of up to 20% (Chapter 4, 5).
• The early risk of recurrence can vary two-fold depending on which definition is
used. The 90 day risks (95%CI) of recurrent stroke with a 24 hour definition of
recurrence were 18.3% (10.8-25.8) in OXVASC and 14.5% (11.5-17.5) in OCSP.
The equivalent risks using a 28 day definition of recurrence were 5.9% (1.0-10.9)
in OXVASC and 4.8% (2.8-6.7) in OCSP. Recurrences occurring after 24 hours
should be used as the standard to avoid underestimation and to allow valid
comparison between studies (Chapter 6).
• In OXVASC, the risks of stroke at 7 days after a TIA and minor stroke were 8.0%
(95%CI=2.3-13.7) and 11.5% (95%CI=4.8-21.2) respectively. This is much higher
than commonly quoted (Chapter 7).
• Recurrent stroke risk varies significantly between aetiological (TOAST) subtypes
(p<0.001). Strokes due to large artery atherosclerosis had the highest odds of
recurrence at 7 days (OR=3.3, 95%CI=1.5-7.0). They accounted for 37% of
recurrences within 7 days highlighting the importance of urgent carotid imaging
and endarterectomy (Chapter 8).
• The age-specific incidence of major stroke in Oxfordshire has fallen by 40% over
the past 20 years in association with increased use of preventive treatments and
major reductions in premorbid risk factors. Despite more complete case
ascertainment than in OCSP, age-adjusted and sex-adjusted incidence of first-ever
stroke fell by 29% (relative incidence 0-71, 95% CI 0-61-0-83, p=0-0002). Incidence
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declined by more than 50% for primary intracerebral haemorrhage (0-47, 0-27-
0-83, p=0-01) but was unchanged for subarachnoid haemorrhage (0-83, 0-44-1-57,
p=0-57). Major reductions were recorded in mortality rates for incident stroke
(0-63, 0-44-0-90, p=0-02) and in incidence of disabling or fatal stroke (0-60, 0-50-
0-73, p<0-0001), but no change was seen in case-fatality due to incident stroke
(17-2% vs 17-8%; age and sex adjusted relative risk 0-85, 95% CI 0-57-1-28, p=0-45).
Comparison of premorbid risk factors revealed substantial reductions in the
proportion of smokers, mean total cholesterol, and mean systolic and diastolic
blood pressures and major increases in premorbid treatment with antiplatelet,
lipid-lowering, and blood pressure lowering drugs (all p<0-0001).
• In OXVASC, non-fatal acute cerebrovascular events accounted for 46.7% of all
incident acute vascular events. Resources for clinical services and research
funding should reflect this (Chapter 10).
- 16-
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1.1. Purpose of study
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1.1. Purpose of study
The Oxford Vascular Study (OXVASC) is a study of all acute vascular events,
transient ischaemic attack (TIA), stroke, acute coronary syndrome (ACS) including
unstable angina (UA), myocardial infarction (MI) and cardiac death, and acute
peripheral vascular (PVE) events in a mainly urban population in Oxfordshire. The
pilot study covered a population of approximately 90,000 in nine general practices.
The main purpose of the pilot study was to ensure that case-ascertainment was
reliable before the main phase of the study. Data were also collected on patients
undergoing elective vascular interventions (e.g. angioplasty, endarterectomy,
bypass surgery).
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1.2. Aims of main study
• To determine the incidence and case-fatality of acute stroke, acute MI, and acute
PVE in the same population during the same time period.
• To determine time trends in incidence and case-fatality by comparison with
previous Oxford-based incidence studies of stroke - the Oxfordshire
Community Stroke Project (OCSP).1
• To perform case-control studies to compare clinical and molecular risk factors
for stroke, ACS, and PVE, and to further identify those risk factors associated
with specific pathological and aetiological subtypes of stroke.
• To perform case-control studies in patients with widespread atherosclerotic
disease comparing clinical and molecular risk factors of cases presenting with
acute thrombotic events with controls with no history of acute events (e.g.
patients with stable angina, asymptomatic carotid stenosis, and stable
claudication).
• To collect data on history of vascular disease in first-degree relatives of the
incident cases to compare the genetic epidemiology of vascular disease in
different territories. For example, we will determine whether the affected
vascular territory(s) in first-degree relatives with symptomatic vascular disease
predicts the vascular territory(s) affected in the proband.
1.3. Specific aims of pilot study
The specific aims of the first year of the study and of this thesis were:
• To refine the design of the study, make any necessary changes to the study
forms and databases, and identify the most efficient methods of communication
with the general practices and relevant hospital staff.
• To ensure that case ascertainment was reliable and complete.
• To examine the effects of case definition and quality of methods of
ascertainment on measured incidence of stroke.
• To study the different definitions used for recurrent stroke and determined the
effects of various definitions on the measured risk of recurrent stroke.
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• To examine the role of a daily TIA and minor stroke urgent assessment clinic
and determined the early risk of stroke after a TIA or minor stroke.
• To determine the risk of recurrence by aetiological stroke subtype (TOAST).2
• To make a provisional comparison of the overall incidence of stroke, ACS and
PVE.
• To estimated time trends in incidence. All of the GP practices included in the
pilot study were also in the OCSP. All the data collected contributed to the main
study of temporal trends in incidence of stroke.
• To determine the overall burden of acute vascular events in Oxfordshire.
1.4. Why study the incidence, case-fatality and disability due to acute vascular
events in a single population?
Arterial diseases are the leading cause of death and disability in the developed
world, and are rapidly increasing in importance in the developing world.3 Acute
coronary syndromes (ACS) including myocardial infarction (MI) and stroke are the
first and third leading causes of death in the developed world respectively, and the
two most common causes of death worldwide. 3 However, mortality data
underestimate the burden of vascular disease. Data from death certificates are often
easily available in developed countries but may not be accurate. Comparison of
OCSP and a population-based study of myocardial infarction (OXMIS),4 suggests
that mortality due to stroke is lower than that due to MI, but overall incidence is
similar, and the total clinical burden of stroke may be greater. Stroke, for example,
is the leading cause of neurological disability in the developed world5 and a
common cause of dementia, depression, epilepsy, falls and fractures. In order to
allocate expenditure and set priorities for clinical services it is necessary to have
data on the relative burden of different medical conditions.
High quality incidence studies provide greater detail on the burden of a particular
disease than mortality data. However, these are expensive, labour intensive and
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study populations need to be representative and reasonably large to make
comparisons between studies and over time more precise.
Burden can also be estimated by measuring the long-term sequelae. For example,
after a first stroke about 20% of patients will be dead within one month and a third
remain dependent on others after a year.6 However between stroke patients there is
considerable variation depending on pre-morbid disability, initial stroke severity,
stroke subtype and risk of recurrence. Knowledge of prognosis can allow estimates
of the needs for assessment and diagnostic services both in the short and long term
for community, out patient and hospital services.
Cost is another surrogate measure of the burden of the disease. However, both
stroke and ACS impact considerably on areas that are difficult to quantify including
costs to society from loss of national productivity, and cost to families from loss of
income and subsequent need to take on the role of informal carers. Although direct
hospital costs are important, the costs related to care for the subsequent disability is
likely to be much higher.
The incidence, case-fatality, longer-term sequelae of TIA and stroke, ACS and PVE
have never been measured in the whole population at the same time. This would
provide an overall measure of the burden of atherosclerotic disease in a high quality
population-based study. There is also uncertainty about the extent to which stroke,
ACS and PVE share the same risk factors. There are known to be differences in their
age and sex distributions, but little is known about the differential effects of other
risk factors. Age- and sex-specific incidence data are required to guide service
planning for the different needs of the population. A better understanding of
differences in risk factors between stroke, ACS and PVE would allow preventive
strategies to be targeted more effectively depending on the predominant pathology,
would help to refine individual risk prediction models, and would help develop
overall vascular prevention strategies. Type-specific data (TIA vs ischaemic stroke
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vs primary intracerebral haemorrhage vs subarachnoid haemorrhage; STEMI vs
NSTEMI vs unstable angina) is also important for detailed planning of the needs of
a population. A formal comparison of incidence and outcome would also provide a
firm basis on which local and national policy decisions about allocation of limited
NHS funding for clinical services and limited governmental funding for medical
research could be made. Rothwell has highlighted the considerable imbalance in
research funding between stroke and ML7 NHS clinical initiatives also tend to give a
higher priority to MI than to stroke. If funding for stroke is to be improved it is
important that the burden of stroke is properly compared with more "high-profile"
conditions such as MI.
1.5. Why measure time trends in incidence and sequelae of stroke and ACS?
Mortality due to stroke and ACS has fallen in most Western European countries and
in some Asian countries such as Japan over the past few decades.8-9 However there
has been recent worrying trends to increasing mortality rates in Eastern European
countries,8-10 and a potential emerging epidemic of cardiovascular disease in
developing countries.11 However, the relative contributions of changes in incidence
and case-fatality to mortality remain uncertain.12 Few studies have been able to
accurately measure time trends in a prospective population-based representative
sample. In Rochester, Minnesota, where strokes have been systematically identified
since 1945, there was an apparent fall in incidence until the end of the 1970s but this
rose again in the 1980s.13 However, the Rochester population has been criticised for
not being typical of the rest of the USA.14 This fall in incidence has been reproduced
in other populations.15"17 In contrast, incidence has risen in Sweden18 and
Denmark.19 and has stayed the same in New Zealand,20 Goteborg,21 and Dijon.22
Within these studies there may be additional differences depending on age and sex
but the small numbers studied have not allowed precise analysis. For developing
countries there is sparse information. The reasons behind these apparent changes in
stroke mortality remain uncertain but various hypothesis including the role of
successful primary prevention,23-24 a decline in case fatality25 and possible artefact
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through changes in case definition and methodology over time14 have all been
speculated.
There are no data from the UK on recent time trends in age and sex specific
incidence or disability rates for stroke and ACS. However, there have been major
changes over the last 20 years in life-style, primary and secondary prevention
treatments, and particularly in population demographics. Reliable data on the
current and projected future burdens of stroke and ACS will allow future clinical
and research funds to be targeted appropriately.
1.6. Why compare risk factors for stroke, ACS and PVE?
Little is known about the differences between risk factors for stroke and ACS.
Compared with MI, stroke patients are generally older and there are some
differences in the effects of blood pressure and cholesterol, and differences in
haematological risk factors.26-27 Moreover in previous studies, all strokes are often
lumped together and it is increasingly recognised that stroke is a heterogeneous
syndrome with each subtype likely to have different aetiologies, risk factors and
prognosis. On the other hand, the mechanisms of instability and rupture of
atherosclerotic plaque appear to be similar in different arterial beds.28-29 However,
more data are required. A better understanding of differences in risk factors would
allow preventive strategies to be targeted effectively depending on the predominant
pathology, would help to refine individual risk prediction models, and would help
develop joint prevention strategies.
1.7 Why study factors associated with acute thrombotic complications of
atherosclerosis?
There is a reasonable understanding of the processes that lead to the development
of atherosclerosis, and some of the important risk factors, such as smoking, diet,
lipid profile, diabetes and hypertension.30 However, the risks of the major
thrombotic and thromboembolic complications of atherosclerosis appear to be
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related more to the stability of atheromatous plaques than to the extent of disease.
Stable angina is associated with stable coronary artery plaques with a thick fibrous
cap, whereas unstable angina, acute myocardial infarction and sudden cardiac death
are associated with fissured or ruptured plaques.31-33 Similarly, in patients with
carotid artery atherosclerotic disease, plaque irregularity and rupture are closely
associated with the occurrence of cerebral ischaemic events3435 and patients with
irregular or ulcerated plaques on carotid angiography have a higher risk of
ischaemic stroke than those with smooth plaques.36-37 Although the blood flow
dynamics at the carotid bifurcation are different to those in the coronary arteries,
pathological studies of carotid plaques suggest that the processes of plaque
destabilisation and rupture that lead to acute clinical complications are very
similar.34-35
In order to reduce main clinical burden of atherosclerosis (i.e. risk of the acute
thrombotic and thromboembolic complications), it is important that we understand
the processes that control the stability of plaques. Local factors, such as sheer stress
or vessel and plaque anatomy may be important,38-39 but there is also evidence that
some systemic factor(s) must be involved40 Potentially important factors include
intra-plaque infection,41-42 and genetic polymorphisms that influence the expression
of cell adhesion molecules and lytic enzymes within plaques,43-44 but it is likely that
other mechanisms are also involved.
There is evidence that plaque stability is determined by non-traditional systemic
factors. Rothwell and colleagues studied 5393 carotid bifurcation angiograms from
3007 patients with symptomatic carotid stenosis in the European Carotid Surgery
Trial.45 Patients with irregular or ulcerated carotid plaques were twice as likely as
those with smooth plaques to have had a previous myocardial infarction and to
have subsequent acute coronary events, but there was no difference in the risk of
non-vascular events. Irregular/ulcerated plaque in the symptomatic carotid artery
was also strongly associated with irregular/ulcerated plaque in the contralateral
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carotid artery. These associations were independent of traditional vascular risk
factors, and support the hypothesis that plaque stability in the carotid and coronary
arteries are influenced in the same way by one or more non-traditional systemic
factors.
It is important to try and distinguish between risk factors that are associated with
the development of atherosclerosis, and risk factors associated with the
development of plaque instability in patients who have established atherosclerosis.
By comparison of patients who have widespread atherosclerotic disease but no
history of acute events (e.g. stable angina, asymptomatic carotid stenosis, and stable
claudication etc) with patients with acute thrombotic events, OXVASC has tried to
identify clinical and molecular risk factors specifically associated with the
development of acute thrombotic complications of atherosclerosis. OXVASC will
determine dose-response relationships between potential risk factors and the
predisposition to acute thrombotic events by comparing patients with no events,
patients with one event in one vascular territory, patients with multiple events in
one vascular territory, patients with events in two or more territories, and patients
with multiple events in multiple territories.
1.8. Timescale
Year 1 (01/04/01 - 31/03/02)
Design of study, preparation of protocol, recruitment of researchers, selection of
study general practices, and preparatory meetings with collaborating practices.
Year 2 (01/04/02 - 31/03/03)
Pilot case ascertainment study in nine general practices and start of follow-up study.
Years 3-5 (01/04/03 - 31/03/06)
Main phases of ascertainment study and follow-up study. Collection of data on
appropriate controls from practice populations.
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Year 6-10 (01/04/06 - 31/03/10)
Continued follow-up of study cohort, analysis of data from case-ascertainment
study, and publication and presentation of results.
1.9 Conclusions
There is a need for up to date information on the incidence, case fatality and long
term sequelae of stroke and atherosclerotic disease in general. This will provide the
evidence required guiding appropriate resources for service provision. OXVASC
will provide this data by studying all acute vascular events in the whole population
at the same time.
This thesis has aimed to concentrate on the aims, methods and preliminary results
from data collected in the first 18 months of OXVASC. For the incidence study
(Chapter 9) I have analysed the full two year data. Throughout, I have concentrated
on the analysis of data collected for TIA and stroke. However, a large amount of
data on both patients with ACS and PVE has been collected over the last two years
and there are a great deal many more future research opportunities.
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2.1. Plan of investigation
Case ascertainment was coordinated in collaboration with the Department of
Cardiology (Dr A Banning), the Department of Primary Care (Professor D Mant),
and the participating general practices. This phase included collection of blood
samples and documentation of 30-day outcome. The follow-up study was co¬
ordinated with the Department of Primary Care (Professor D Mant and colleagues).
2.2. Why Oxford?
There are several reasons why Oxford was ideally suited for this study. However,
the main reason for basing the study in Oxford was that we were uniquely fortunate
to have previous Oxford community-based incidence studies of TIA and acute
stroke (OCSP - 1981-86)1 and acute myocardial infarction (OXMIS - 1993/4).2 By
using the same case definition and methods of ascertainment in OCSP we have
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determined the time trends in stroke incidence and case-fatality. By comparison
with follow-up data from OCSP, we will be able to determine time trends in
disability rates and risk of recurrent vascular events. Comparison with OXMIS was
more difficult because of the changing diagnostic citeria for myocardial infarction.
2.3. General Practices participating in pilot phase (Appendix 1)
A liaison GP was appointed in each collaborating practice to provide a continuous
link between the ascertainment team and the practices. They assisted in identifying
cases and reminded colleagues of the study. A liaison administrator was also
appointed in each practice to assist with ascertainment, searches of GP databases
and review of death certificates.
The pilot study (01/04/02 - 31/03/03) included 9 GP practices that were involved in
the OCSP and OXMIS. Two practices (Thame and Deddington) that were involved
in OCSP were excluded (Figure 2.1). Thame Medical Practice now refers also to
Stoke Mandeville NHS Trust in Buckinghamshire. Deddington Health Centre now
refers predominantly to the Horton General Hospital in Banbury in North
Oxfordshire. For practical reasons our study was limited to using GP practices that
referred to the Oxford Radcliffe NHS Trust Hospitals including the John Radcliffe,
the Radcliffe Infirmary and the Churchill Hospital (ORH NHS Trust). Meetings with
all GPs were held during the first two weeks in March 2002, and a pre-pilot run-in
phase began on Monday 18th March. The main pilot study began at midnight on
Monday 1st April 2002 and continued until Midnight Monday 31sl March 2003.
Enrolment of patients has continued thereafter in the main phase of the study.
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Figure 2.1. Map of Oxfordshire with OCSP1 and OXVASC collaborating GP practices
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2.4. Study population
The population comprised all patients who were fully registered with 63 General
Practitioners (GP) based in 9 family health centres who collaborated in the study.
These same GP practices were involved in Oxfordshire Community Stroke Project
(OCSP).1 In the United Kingdom, patients register with a GP who provides their
primary health care and, when necessary, refers them to secondary care. The GP
receives all relevant information about specialist consultations and hospital
admissions even if these do not occur locally. Thus the information held by the GP
forms a lifelong record of all medical events as well as recording details of each
consultation with the GP (including blood pressure recordings, blood counts etc).
This individual record is transferred to a new GP if the patient moves residence. The
collaborating practices were chosen if they: a) routinely referred patients to Oxford
Hospitals; b) had an accurate computerised age-sex register (ASR) (Appendix 2); c)
were willing to refer any patient with a suspected acute cerebrovascular event and;
d) were computerised allowing searches for cerebrovascular diagnostic codes. The
ASR provided accurate and up-to-date estimates of the denominator allowing easy
identification of cross boundary flow and turnover within the population. The
population was made up of predominantly Caucasian (94%) as well as Asian (3.1%),
Chinese (1.5%) and Afro-Caribbean (1.4%).3
All patients in whom an acute vascular event was suspected were considered for
inclusion. Patients were ascertained prospectively from hospitals and the
community. For TIA and minor stroke not requiring hospital admission, case
ascertainment was very similar to OCSP in that collaborating GPs notified the study
office by telephone or facsimile of any patient whom they thought may have had an
episode of acute neurological dysfunction caused by cerebrovascular disease.
Patients who had a vascular event whilst temporarily away from Oxford were
included, but visitors to Oxford who were not normally resident and registered with
a GP were excluded. A liaison GP in each practice checked with colleagues regularly
to ensure that all relevant patients were referred. Clinical data were obtained
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retrospectively from case records, GP and relatives in those who died in the
community. Registration of patients began on 1st April 2002 and continues.
Oxford has been criticised as a location for a study of vascular disease in that the
population may not be representative of the UK as a whole ("too middle class") and
was on average less socially deprived than elsewhere in the UK and results may not
be generaliseable. Data to determine the level of deprivation at General Practice
level is scanty. To estimate social deprivation amongst the population served by our
practices we used an index of multiple deprivation.4 This index is comprised of 6
domains - Access, Education, Employment, Health, Housing and Income with each
domain containing at least 3 indicators from nationally available data. These data
were available only at the level of electoral ward, of which there are 8414 in
England. The lower the index the less deprived is the electoral ward. To ensure
complete coverage of our population we used the electoral wards immediately
surrounding our collaborating practices. The population of these electoral wards
approximated to 180 000. The wards around our practices were significantly less
deprived in comparison to the rest of England (mean Index of multiple deprivation
score: 8.69 vs 16.98, Mann Whitney, p<0.001). However, our practices served a broad
range of areas of deprivation with 2 serving electoral wards with ranking in the
lower third nationally.
A proxy measure of deprivation is available at the GP practice level using low
income scheme index (LISI) scores.5 This is a measure of deprivation based on
claims for exemption from the prescription charge on the basis of low income. The
score is the cost of prescriptions that are exempt on grounds of low income as a
percentage of the cost for all prescriptions. These figures are collected as part of a
5% sample of prescriptions for any practice with more than 1000 patients. The mean
LISI score for our practices was 7.2% (Range 3.8 - 11.9) compared to an Oxfordshire
average of 5.9% and a national average of 30.6%. However this score has
disadvantages as it excludes the elderly to whom prescriptions are free.
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2.5. Case definition and inclusion criteria
2.5.1. Acute cerebrovascular events
The definition of stroke was the same as in the OCSP.1 Where new diagnostic
techniques have been introduced (e.g. MRI scanning) cases were categorised as
incident using the original OCSP definitions as well as on the basis of new
techniques. All stroke cases were registered. Strokes were defined as "first-ever-in-
a-lifetime" or recurrent. Neonates were not included.
The WHO definition of stroke was used6: rapidly developing clinical symptoms
and/or signs of focal, and at times global (applied to patients in deep coma and to
those with subarachnoid haemorrhage), loss of cerebral function, with symptoms
lasting more than 24 hours or leading to death, with no apparent cause other than
that of vascular origin.
In fatal cases without clinical assessment the diagnosis of stroke was made only if
there was clear autopsy evidence of recent acute infarction or intracerebral or
subarachnoid haemorrhage as the primary cause of death.
In fatal non-autopsied cases, inclusion depended on a history of rapid onset with a
clear focal loss of neurological function. Unless haemorrhagic it is recognised that
stroke is an uncommon cause of sudden death.7 In the event of any suspected
stroke death, all available records were reviewed and the registered GP was
interviewed to try to confirm or exclude the diagnosis. Inadequately described
history without focal loss of neurological function or sudden death were not
included as stroke events.
A TIA was defined as an acute loss of focal cerebral or ocular function with
symptoms lasting less than 24 hours and which after adequate investigation was
presumed to be embolic or thrombotic vascular disease.8 Incident and recurrent
events were registered. As in the OCSP TIA study,9 our inclusion criteria were
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designed to measure the incidence of TIA in the population whose TIAs come to
medical attention. Our definitions were entirely comparable to OCSP. It required
close collaboration with GPs to ensure complete ascertainment. TIA cases in patients
with previous stroke were regarded as prevalent cases. Similarly if the patient had a
recognised TIA prior to the study period, further events were regarded as recurrent.
Incident cases were defined as any patient whose first TIA had led to medical
attention occurring during the study period. TIAs occurring prior to the study
period not brought to medical attention were ignored. If a patient had a further TIA
during the study period that led to seeking medical attention the most recent event
was taken as the incident TIA. If a patient had an event during the study period
entirely similar to an event that had occurred prior to the study period but had not
been yet diagnosed as a TIA, these events were regarded as prevalent. Patients
presenting to their doctor during the study period with their first TIA but who had
already suffered a stroke before or after the TIA were also excluded from the
incidence TIA study to ensure complete comparability with OCSP and to avoid
biasing prognosis. It is recognised that there is considerable inter-observer
variability in the diagnosis of TIA.10 Inter-observer reliability was optimised by
rapid assessment of patients (median 3 days), cases were all discussed by two study
physicians and to ensure direct comparability with OCSP, all cases were discussed
with OCSP lead investigator, Professor Charles Warlow.
Cases of all possible cerebrovascular events were reviewed. This included a number
of conditions that are often not included in TIA and stroke incidence studies. These
cases were identified to assess the potential burden of cerebrovascular disease.
Moreover, these 'possible' cases were followed up to determine their prognosis and
risk of further vascular events. This included cases of retinal artery occlusion,
subdural haematoma, venous and spinal stroke. We also identified cases of
hemisensory syndromes (sudden onset of symptoms affecting one side of the body,
including head and both limbs with no evidence of a neurological cause on brain
imaging), isolated cranial nerve palsies, isolated diplopia and dysarthria, amnestic
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syndromes not typical of transient global amnesia and non-arteritic ischaemic
anterior optic neuropathy. Bilateral blindness was not included in the OCSP TIA
study but subsequent analysis showed this to have a similar prognosis to definite
TIAs.11 These were registered. Once sufficient numbers of these cases have been
registered, it is hoped they can be compared in case-control studies with definite
cerebrovascular events to evaluate their prognosis. These events were not included
in any incidence comparisons with OCSP data (see Chapter 4).
2.5.2 Acute coronary syndrome
Acute coronary syndrome (ACS) incorporates the full spectrum of possible acute
presentations of ischaemic heart disease secondary to atherosclerotic coronary
artery disease including unstable angina (UA), non-ST elevation myocardial
infarction (NSTEMI) and ST-elevation myocardial infarction (STEMI). Specifically,
STEMI is diagnosed with an appropriate history, ST segment elevation of one or
more millimetres seen in two contiguous limb or two or more millimetres in chest
leads on an electrocardiogram (ECG) or new left bundle branch block and / or one
or more positive cardiac biochemical marker of cardiac necrosis. This includes
posterior myocardial infarction diagnosed with at least 2mm ST depression in two
consecutive right ventricular (VI, V2, V3) chest leads on ECG. NSTEMI is diagnosed
with an appropriate history in the presence of one or more positive biochemical
marker of necrosis without new ST segment elevation.
There is no universally accepted definition of unstable angina (UA) but it is thought
of as a clinical syndrome between stable angina and acute myocardial infarction.
Unstable angina was defined clinically as having a number of possible
presentations: symptoms of angina at rest (usually prolonged > 20 minutes; new-
onset (< 2 months) exertional angina or recent (< 2 months) acceleration of angina
that is clinically more severe, more prolonged; or more frequent based on a pre¬
existing stable pattern resulting in admission to hospital with no rise in cardiac
markers of necrosis.12
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Myocardial infarction (MI) was defined in three ways to assess the impact of
varying definitions on the burden of coronary artery disease in a population-based
study:
1. Clinically: Based on the discharge diagnosis assigned by physicians under whose
care the patients were assigned.
2. Epidemiologically: Based on the WHO definition13 requiring two of three of
symptoms, electrocardiographic findings and peak values of conventional enzyme
activities (CK-MB, CK, AST, LDH), autopsy findings, history of coronary artery
disease and history of previous MI. A definite MI was defined when:
• A diagnostic Q wave developed or ST elevation was followed by T wave
inversion in serial electrocardiograms.
• Symptoms were compatible with MI (chest pain or its equivalent) and any one
of the conventional enzymes was increased to > 2X the upper reference limit and
serial ECG changes showed ST-segment or T wave changes.
• A recent infarction or an occlusion of a coronary artery was found in cases of
fatal MI at autopsy.
A probable MI was defined as one of the following:
• Typical symptoms of chest pain > 20 minutes with either ST or T wave changes.
• Typical symptoms of chest pain > 20 minutes and any one of the conventional
enzymes increased to more than the upper reference limit but remained <= 2X
this limit.
• Atypical symptoms with both appropriate ECG and enzyme criteria.
In autopsied cases the diagnosis of probable MI was made if coronary artery disease
was verified at autopsy and no other cause of death was found.
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In fatal cases that did not undergo autopsy examination, a probable MI was defined
as symptoms that were typical, atypical, or inadequately described if there was a
history of previous coronary artery disease before death and no other cause of death
was detected.
A definite or probable MI was excluded if serially measured conventional enzyme
activities remained within normal limits and no evolution of Q wave abnormalities
occurred in serial ECGs. If there was insufficient information these cases were
excluded from the analysis.
3. European Society of Cardiology (ESC) and the American College of Cardiology
(ACC) criteria14 based on the use of more sensitive and specific markers of cardiac
necrosis such as troponin I or T or CK-MB into a new definition of myocardial
infarction.
Acute MI was defined as the presence of a biomarker of cardiac necrosis with one
of:
• Ischaemic symptoms
• New Q waves
• Ischaemic ECG changes
• Coronary intervention.
An established MI was defined as new Q waves and two of the above.
Patients were defined as incident (first-ever) or recurrent. Patients presenting with
UA with a previous history of MI were regarded as prevalent cases. A clear history
of an event was required for inclusion and patients had to seek medical attention
with symptoms compatible with an acute coronary syndrome. Suspected MI
diagnosed on the basis of an ECG done for other reasons or an echocardiogram
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showing a wall motion abnormality were not included. Patients with ECG changes
or raised cardiac enzymes post-procedurally were included to determine the entire
burden of ACS. If an area of myocardial scarring was recognised at autopsy, notes
were reviewed to ascertain whether a MI had been recognised during life. If there
had been no documented previous MI, the cardiac event leading to death would be
regarded as incident. Precipitating factors leading to excessive cardiac demand were
identified including inappropriate tachycardias, surgery and inotropic dependent
states.
2.5.2.1. Acute coronary syndrome - special considerations
The ability to measure the cardiac specific protein markers, cardiac troponin T
(cTnT) and cardiac troponin I (cTnl), has caused a paradigm shift in the assessment
of patients with ACS. Troponin measurement in ACS patients identifies
prognostically important myocardial damage when MI is excluded by conventional
cardiac enzymes.15 This has led to the proposed redefinition of acute MI,14
recognising troponin measurement as the biochemical diagnostic 'gold standard'.
The use of these biomarkers have been incorporated into management guidelines16-17
The prevalence of MI is dependent on the diagnostic criteria used. Other studies
have shown that troponin is elevated in 15% of patients with suspected MI in whom
conventional enzyme activities remain within normal limits.18 Such an apparent
increase in the number of patients diagnosed as MI may lead to a reduction in
overall mortality. The adoption of troponin in the routine diagnostics of MI has been
shown to 'increase' the diagnosis by 33% compared to a clinical diagnosis and by
23% compared to an epidemiological diagnosis.19 The ESC/ACC has suggested that
WHO MONICA should retain the established definitions of MI but simultaneously
use their MI definition to compare the effect of diagnostic classifications on the
epidemiology of coronary heart disease. Such a change would produce not only
major implications for epidemiologists and service providers with many more
patients potentially labelled with a diagnosis of myocardial infarction. Moreover,
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the WHO definition implies MI can be diagnosed without biochemical evidence of
myocardial necrosis while the ESC/ACC criteria mandate that troponin be elevated
and subsequently be shown to fall. Such changes in definitions may have major
epidemiological consequences.
Clinically troponins do have their limitations.20 They take several hours to rise,
peaking at 12-24 hours so values on admission may be misleading and if initially
negative a second troponin measurement should be performed 6-12 hours later.
Values may remain elevated for 2 weeks, limiting their usefulness in diagnosing
reinfarction.
Biochemically there is uncertainty about the robustness of the troponin assays
particularly between the different assays for cTnl that use different antibodies.21
Different cTnl methods do not always agree and may be measuring different
troponins. Moreover, reproducibility over time could also vary. The
recommendations from the ACC/ESC document were for a diagnostic cut-off
corresponding to the 99th centile of a normal reference population. Current assays
are unable to detect troponin in the majority of normal healthy individuals. This has
led to the proposal that an analytical target of percentage coefficient of variation of
10 (%CV of 10) is used as the cut-off for normal. This allows accurate separation of
the cardiac and normal populations. However improved assay performance has
paradoxically increased the number of patients with detectable troponin values
without a clinical diagnosis of MI. 'Normal' ranges are often determined by
manufacturers by testing in young adults with no evidence of coronary disease. It
may be possible to define for the general chest pain population a low level of
troponin that does not correspond to a clinically significant degree of risk. The level
of troponin that can be reliably measured by the laboratory can then be used as the
cut off point for definite myocardial damage. This corresponds to the functional
sensitivity (%CV of 10) for the assay. Levels below this and above the detection limit
of the assay indicate possible myocardial damage and should be repeated.
There is increasing evidence that troponin may be released in a range of other
clinical conditions, including stroke,22 subarachnoid haemorrhage,23 pulmonary
embolism,24-25 and patients who are critically ill,26 including septic shock.27 Indeed
troponin I rises have been attributed to tachycardia, congestive cardiac failure and
pericarditis in patients despite having normal or only mild coronary disease on
coronary angiography.28 Similarly minor rises have also been demonstrated in
muscle disorders, cardiomyopathies and chronic renal failure.29 Owing to these
concerns, some authors have urged caution in the wholesale adoption of troponin
measurement to redefine myocardial infarction.30
However, there is no evidence that these troponin rises are false positive results. A
recent editorial21 stresses that cardiac damage does not necessarily equate to
myocardial infarction. Acute MI remains a clinical diagnosis for which laboratory
measurement is required for diagnosis but is not the sole arbiter. It is recognised
that ACS arise from rupture of the atheromatous plaque resulting in platelet
thrombosis and subsequent distal embolisation with micro-infarction.31
Elevations of troponin can occur without primary ischaemic cardiac injury due to
secondary ischaemic cardiac injury (SICI) not caused by primary plaque rupture
such as can occur during cardiac procedures through direct cardiac damage. Post-
procedural elevation of troponin and CK-MB are related to the incidence of
subsequent cardiac events.32 Secondary ischaemic cardiac injury can also occur in
any situation with supply-demand mismatch, for example pulmonary embolus.
This may reflect underlying coronary disease but whether this is caused by
ischaemia and necrosis or ischaemia alone remains to be determined. In non
ischaemic cardiac injury (NICI), troponin rises may occur with direct myocardial
involvement in the primary pathological process such as might occur with
myocarditis.
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In OXVASC, we classified cases using ESC/ACC criteria.14 Practically this was
necessary as we identified cases on a daily basis using an electronically generated
list of all patients undergoing troponin I measurement. The team in charge of the
patient's care requested troponin measurement on suspicion of a cardiac event. In a
proportion of cases, we requested standard cardiac enzymes (CK and AST) if
troponin I was raised above the normal range. All these cases were discussed with
Dr Adrian Banning, Consultant Cardiologist to confirm or exclude a diagnosis of MI
and to make a clinical judgement whether the troponin rise was related to primary
plaque rupture, or due to secondary ischaemic cardiac injury or direct myocardial
pathology.
In 2000, troponin I was introduced as the main marker offered to detect cardiac
necrosis in the Oxford Hospitals NHS Trust. One specimen was sent when the
patient was first seen and a second was sent at 12 hours after onset of symptoms. If
a second infarction was suspected the same protocol was repeated. Troponin I was
regarded as abnormally raised if > 1 ng/ml using an Immulite 1 immunometric
assay. There has been concern with lack of standardisation of troponin I assays that
has led to inter-assay differences of up to 20-fold between assays. The assay used in
OXVASC was reliable across different labaratories according to UK National
External Quality assessment Service (UKNEQAS) data.33 Measurement of other
cardiac enzymes were not requested routinely. If measured, creatinine kinase (CK)
and aspartate transaminase (AST) were defined abnormal if at least one reading was
more than twice the upper limit of normal when measured within 72 hours or
within 3 calendar days of onset of symptoms.
2.5.3. Acute peripheral vascular events
Acute peripheral vascular events (PVE) were also identified. We defined acute limb
ischaemia as the rapidly developing, sudden decrease in limb perfusion, usually
producing a new or worsening symptoms or signs and often threatening limb
viability. This might occur in cases with known peripheral vascular disease or in a
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previously asymptomatic patient.34 Acute deterioration in claudication (claudication
to 'short distance' claudication) can occur as a result of an acute event but this, by
convention, does not qualify as acute limb ischaemia.
We also identified cases of critical limb ischaemia (CLI) to try and determine the
burden of peripheral vascular disease. It is recognised that only small proportions of
patients with intermittent claudication develop CLI.35 However, CLI threatens the
survival of an extremity, may cause lifelong pain and up to 60% undergo vascular
intervention and within 1 year 25% will have a major amputation and 20% will be
dead.35 Critical limb ischaemia was defined clinically as that which endangers the
leg or part of the leg. Clinically it required rest pain requiring regular adequate
analgesis for more than two weeks or ischaemic skin lesions, either ulcers or
gangrene. Arteriography or Doppler measurements to delineate the anatomy of the
large vessel disease throughout the leg and foot were desirable, as patients often
had multi-level arteriopathic disease. This clinical definition was compatible with
Fontaine's classification of patients with stage III peripheral vascular disease with
rest pain and stage IV disease with ischaemic skin lesions.37 It is recognised that this
definition encompasses a wide spectrum of cases and several attempts have been
made to subdivide this group into high and low risk cases using resting ankle
pressures and toe pressures.38'3940 All these post-Fontaine definitions have been
critisised for using arbitrary subdivisions, and excluding large groups of patients by
using different pressure definitions.35 Clearly, the term critical limb ischaemia
implies a chronic element and does not represent acute limb ischaemia. However,
we included critical limb ischaemia in our analysis of the burden of atherosclerotic
disease (See Chapter 10).
We also identified cases of acute aortic pathology, both thoracic and abdominal,
including leaking or ruptured aneurysms.
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Patients with acute mesenteric ischaemia and infarction were included.41 Cases were
ascertained through review of angiography registers and often through the
bereavement office or mortality coding. Cases of chronic mesenteric ischaemia,
ischaemic colitis and mesenteric venous thrombosis were not registered.
Patients were defined as incident (first-ever) or recurrent depending on whether
there had been a previous documented episode of critical or acute limb ischaemia or
aortic pathology. If a patient had an acute event with a previous history of critical
ischaemia, the recent event was regarded as incident. An episode of critical
ischaemia with a history of an acute event was regarded as a prevalent case. The
majority of cases were admitted to hospital or referred for urgent angiography. The
Consultant Vascular Surgeon caring for the patient confirmed all diagnoses.
2.5.4. Interventions for atherosclerotic disease
Patients were included if they attended for any coronary angiography including
angioplasty or stenting procedures. Patients attending for coronary artery bypass
grafting were also ascertained. Patients undergoing these procedures primarily for
other reasons such as valvular heart disease, cardiomyopathy or work-up for renal
transplantation or other surgical procedures were not included.
Those attending for any peripheral angiography including angioplasty or stenting
procedures were included. Patients attending for any other arterial vascular surgical
procedure including bypass, embolectomy, endarterectomy and amputation were
also included. Patients attending for 'screening' for example of abdominal
aneurysms were not included. Patients undergoing renal angiography were also not
included.
Patients were identified and enrolled if they attended for cerebral angiography for
routine review after endovascular procedures for survivors of subarachnoid
-55-
haemorrhage. Patients attending for carotid angiography or carotid endarterectomy
were also identified.
Procedures carried out for non-atherosclerotic indications were not included for
example venous or neuropathic ulceration. Patients undergoing amputation
primarily for sepsis and secondary osteomyelitis were not included even if there
was underlying macro or microvascular disease.
2.5.5. Acute vascular deaths in the community
A large number of patients with vascular disease particularly coronary disease die
suddenly in the community and never reach hospital. GP records, death certificates,
coroner's reports and post mortems were all scrutinised to identify cases of acute
vascular deaths. An electronically generated list of all patients dying from stroke,
ACS and PVE was provided on a quarterly basis by the Department of Public
Health. These cases were all scrutinised. If a patient died rapidly we attempted to
obtain an eyewitness account as well as reviewing information in all available
medical records.
2.6. Summary of case ascertainment
Case ascertainment of stroke was as similar as possible to OCSP. Multiple
overlapping sources were used for TIA and stroke, ACS and PVE so that the degree
of completeness of ascertainment could be compared.42
2.6.1. TIA and stroke
Collaborating GPs referred patients with TIA or minor stroke to our fast track clinic.
Patients with TIA were seen as many of these patients on further assessment are in
fact strokes. ORH admission and A&E registers were reviewed daily. Patients
referred for carotid and brain imaging were identified. Lists were reviewed for
cerebral angiography and carotid endarterectomy procedures. Admissions to
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rehabilitation wards were reviewed. Patients were identified from coding and death
certificate data.
2.6.2. Acute coronary syndrome
We aimed to identify all patients presenting with ACS. The majority of these
patients were admitted to hospital. A small number were managed at home or in
care homes were identified through their GPs. Patients were identified through
daily review of admission registers and troponin I list. We visited the Coronary
Care Unit (CCU) daily. Patients undergoing coronary angiography or bypass
surgery were identified. All hospital deaths were identified from the bereavement
office and deaths in the community were identified through GP death certificates
and the Department of Public Health.
2.6.3. Acute peripheral vascular events
Acute peripheral vascular events were identified through admission registers and
daily visits to the vascular unit. We were informed of all patients referred to the
Vascular Surgery team from other specialities and all patients presenting for
vascular interventions were identified. Out of hospital deaths were identified
through death certificate and Public Health data.
Each practice appointed a liaison GP, and a liaison nurse or administrator. They
assisted in searching computerised records for patients with suspected
cerebrovascular disease. The study team maintained frequent personal contact with
liaison GPs. A pager was carried between 8am and 6pm from Monday to Friday. At
other times contact with the study office was via an answer-phone or fax. A
quarterly newsletter was sent to all collaborators. Our study nurse visited each
practice on a regular basis twice per month. Regular contact was also made with
local care homes. The majority of ACS and PVE patients were ascertained after
hospitalisation. However if they were not admitted or unable to attend the clinic,
they were invited to participate in the study and were assessed at home.
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2.7. Specific methods of case ascertainment
Multiple overlapping sources of ascertainment were used to identify vascular cases.
Search strategies for TIA and stroke, ACS and PVE complemented one another.
Ascertainment was based in the community, clinic and hospital involving hot and
cold pursuit (Table 2.1).
2.7.1. Hot pursuit
Hot pursuit aimed to identify acute vascular events or vascular interventions
through the emergency and admission medical services and referral to the rapid
access TIA and minor stroke clinic using a prospective ascertainment strategy. Cases
were identified rapidly through specific search protocols and data collected by
direct interview or by extracting case notes while the patient was still in care. Hot
pursuit was useful for obtaining data on timing and informed consent could be
obtained. This was labour and time intensive often involving daily review of cases
to ensure diagnostic accuracy. Indeed patients and their notes were often moved
around the hospital and ended up being chased in 'hot pursuit'. On a weekday basis
there was:
• Rapid assessment TIA and minor stroke clinic
The following search strategies made up hot pursuit. The following registers were
searched daily:
• Oxford Radcliffe NHS Trust (ORH) admissions registers
• JRH Accident and Emergency admission register
• List of all patients undergoing troponin I measurement
Each of the following units were visited on a daily basis:
• Bereavement Office
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• Coronary Care Unit
• Cardiac Day Case Unit
• Cardiothoracic Unit
• Acute Stroke Unit
• Medical Admissions Unit
• Vascular Surgical Unit
• Visit to other wards as necessary
2.7.2. Cold pursuit
Cold pursuit was the opposite of hot pursuit with no direct involvement with acute
medical services. Potential cases with suspected acute vascular events or vascular
interventions were identified from routinely collected data. Hospital records were
reviewed to consider for inclusion. Because hospital and GP diagnoses of MI and
particularly TIA and stroke occasionally disagreed with standard criteria for
definition of these conditions, an excess of potential cases were screened. This data
were collected weekly, monthly or quarterly on a regular basis. Data were reviewed
to identify unknown vascular cases. It was recognised that identifying cases through
cold pursuit represented a challenge in obtaining informed consent from the
patients.
2.7.2.1. Weekly Ascertainment Protocol
The Surgical and Cardiac Directorates and the Patient Administration System
generated the following data:
• Vascular elective surgical and angiography list
• Mortality and morbidity data collected by vascular surgeons
• Coronary angiography list
• Clinic lists for other stroke physicians
• Weekly review of admissions to rehabilitation wards
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2H.1.2. Monthly Ascertainment Protocol
The following data were obtained:
• Peripheral angiography list
• Cerebral angiography register
• Brain imaging referrals
• Carotid Doppler referrals
• Discharge ORH coding data
The following were contacted on a monthly basis:
• Paediatric Neurology Registrar
• Paediatric Cardiology Registrar
• 'Silver Star' team for complex obstetric cases
• Local care homes
• GP practice visits to review death certificates and search GP databases
2.7.2.3. Quarterly Ascertainment Protocol
These data were collected from visits to the coroners office and mortality data were
electronically collated and provided by the Department of Public Health:
• Coroner post mortem results
• Public Health Department mortality ICD-10 coding data
• Rapid access chest pain clinic
• Vascular surgery out-patient clinics
2.8. Details of specific sources of case-ascertainment
Using hot pursuit cases were identified and assessed as soon as possible following
the suspected index event. Patients were reviewed on a daily basis to ensure early
assessment and accurate diagnosis.
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2.8.1. Oxford Radcliffe NHS Trust (ORH) admissions registers.
An electronically generated print out from the Patient Administration System (PAS)
of all patients admitted to any of the ORH, including private wards from any of our
collaborating GPs was scrutinised on a daily basis. Names, hospital number and
location of all appropriate cases admitted in previous 24 hours were logged in our
daily register. Patients admitted under orthopaedic, general surgery, paediatric and
gynaecology specialities were not specifically reviewed unless other information
suggested they may have had a vascular event (e.g. troponin I measurement, brain
imaging). We reviewed the medical notes of all suitable cases from the admission
register to identify acute vascular events.
2.8.2. John Radcliffe Hospital Accident and Emergency register.
PAS generated an electronic print out of all patients attending Accident and
Emergency department in the previous 24 hours. This list also included a one word
diagnostic label given at triage. We searched for patients admitted with labels of
'collapse', 'off legs', 'TIA', 'CVA', or 'stroke', 'arrhythmia', 'breathlessness',
'angina', 'heart attack', or 'MI', 'cardiac arrest' and 'PVD' or any othe label
suggestive of an acute vascular diagnosis. If patients had been discharged, their
notes were reviewed.
2.8.3. Bereavement Office
The JRH bereavement office manages all hospital deaths including those occurring
in Accident and Emergency. This office was visited on a daily basis. The cause of
death for all cases registered with our collaborating GPs was identified. For cases of
acute vascular events, details were recorded and notes reviewed. Cases were logged
to allow further data collection from next of kin at a later date. The Churchill
Hospital and Radcliffe Infirmary offices supplied the names of all deaths occurring
in these hospitals.
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2.8.4. Coronary Care Unit
The coronary care unit (CCU) kept a register of all patients admitted to their unit
that recorded details of registered GP. This register was reviewed on a daily basis.
Most patients had already been identified via admission registers, but some patients
had been transferred from other wards with a new diagnosis of ACS and these cases
were subsequently identified.
2.8.5. Cardiac Day Case Unit
The cardiac day case unit was visited on a daily basis. Identities of all patients due
to attend for cardiac investigation were available. Notes were scrutinised to identify
the type of cardiac investigation - predominantly coronary angiography - and the
indication for intervention. Only cases being investigated for atherosclerotic disease
were included. Patients attending for angiography were often identifiable in
advance when patients attended for pre-clerking. Once identified, these patients
were invited to participate in the study and assessed in the unit on the same day as
their pre-clerking. Occasionally patients were admitted to the private wards for
angiography and these were identified through the admission registers. If they
agreed, these patients were interviewed often on the same day as their procedure.
2.8.6. Cardiothoracic Unit
The cardiothoracic unit kept an accurate ward admission register complete with GP
details. This register was reviewed on a daily basis to identify patients admitted for
urgent or elective cardiothoracic surgery including coronary artery bypass surgery.
Many of these patients would have already been identified through the admission
register. Patients who had been referred from other speciality wards for cardiac
intervention such as angiography with stenting were occasionally admitted to the
cardiothoracic unit prior to discharge. Patients admitted for thoracic aorta surgery
were also identified through this mechanism. Patients were usually invited to
participate and assessed during their post-operative convalescence.
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Table2.1.Summaryofcasascertainment SearchtrategyD ilyWeeklMont3-monthl6 t lY r ORHAdmissionRegisterX JRHA&EregisterX BereavementofficeX CoronaryareUnitX CardiacD yaseUnitX CardiothoracicUnitX Brainim gingX CarotidDopplerX ORHdischargeataX. GPpracticevisitsX Localcarehomes....X Coroner'sofficeX PublicHea thcoding...X Chestpainclinic...X Vascularurgeryclinics...X RehabilitationwardsX
Searchtr tegyD ilyWeekl Peripheralangiography Cerebralangiography PaediatricNeurology PaediatricC r iology Obstetriclia on AcuteStrokUnitX MedicalAdmissionsUnitX VascularSurgic lUnitX TroponinIlistX OtherwardsX DailyTIA/strokeclinicX Electivesurg calli t.X Mortality&morbiditdat.X Coronaryangiogr ph.X Othercliniclists.X GPdatabasesearches
Monthly3-mont6 t ly X X X X X
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2.8.7. Acute Stroke Unit
A daily visit to acute stroke unit identified any new admissions from other wards.
Most of these patients were known through the admission register. The staff also
kept a record of any other stroke cases that had been referred for acute stroke care.
Several stroke cases that had their event during their hospital admission were
identified through this method.
2.8.8. Medical Admissions Unit (MAU)
The admission register identified patients admitted to MAU. Occasionally patients
from other wards were transferred to the unit with medical problems. The notes of
these patients were reviewed to identify patients with acute vascular events.
2.8.9. Acute Vascular Surgery Unit
The vascular unit kept a log of all patients admitted to their unit with GP details.
This was examined on a daily basis to identify cases of acute PVE. Patients admitted
for elective endovascular or vascular surgical interventions were also identified.
Patients referred from other specialities for vascular intervention were often
transferred to the vascular unit.
2.8.10. Troponin I measurements
An electronically generated list of all patients undergoing troponin I measurement
was obtained on a daily basis from the Department of Biochemistry. This list also
included GP details. In ORH, troponin I was the standard investigation for patients
with suspected ACS. All patients from the study practices having this investigation
were recorded in our daily logbook. Many patients had already been identified on
the admission register. At times, GP details were not available. Using the hospital
number, the PAS system was interrogated to identify the registered GP. All patients
having troponin I measurement in ORH were noted including patients on other
sites such as the Nuffield Orthopaedic Centre (NOC). For these latter patients it was
necessary to contact the admissions office in the NOC to find out GP details. If
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patients on other sites had an abnormal troponin I, medical staff caring for that
patient were contacted to obtain any evidence of an ACS. If this was the case
patients were visited and invited to participate in OXVASC. If patients had been
discharged medical notes were requested for review. If troponin I was carried out
by one of our study practices in the community, the GP was contacted and patient
details recorded.
2.8.11. Daily Ward Visits
The notes of any patients identified via the admission registers or a raised troponin I
on other wards or specialist units were specifically reviewed. This included any
patients admitted to wards on other sites such as the Churchill Hospital or the
Opthalmology, Neurology and Neurosurgery wards in the Radcliffe Infirmary.
Occasionally patients with subarachnoid haemorrhage were admitted directly to the
neurosurgical wards and were found through this mechanism. Patients transferred
to rehabilitation wards in the Radcliffe Infirmary were also identified and their
notes reviewed for acute vascular events.
2.8.12. Daily TIA / Minor Stroke Clinic
GPs were encouraged to refer all patients with possible acute cerebrovascular events
to our rapid access daily TIA and minor stroke clinic. Patients were referred
predominantly by facsimile or by leaving a message on the OXVASC answering
machine. GPs could contact the study team directly via a pager. GPs provided
demographic and contact details as well as summary encounter sheets for each
patient. Patients with amaurosis fugax or retinal infarction were also referred
directly from the Eye Hospital for further assessment if from one of the study
practices. Patients were telephoned directly and an appointment was made at the
earliest opportunity usually within two working days. Patients were seen each
afternoon in Thomas Rowney Out-Patients in the Radcliffe Infirmary. Patients had a
full clinical assessment, phlebotomy, ECG and CT scanning. Stroke patients had
brain imaging on the same day. TIA patients had CT within a week. Carotid
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Dopplers were organised within 72 hours. GPs were faxed a management plan
within two working days with preliminary results of all investigations. All patients
were seen in the clinic at one month for follow up. Subsequent follow up was
arranged partly in collaboration with the Department of Primary Care at 3, 6, and 12
months.
Using cold pursuit, cases of acute vascular events and those undergoing vascular
intervention were identified from routinely collected data collected weekly,
monthly or quarterly on a regular basis. Data was subsequently analysed to identify
any previously unknown vascular cases.
2.8.13. Vascular elective surgical and angiography list
The Vascular Surgery Directorate produced a weekly list of all patients with their
hospital numbers planned for admission for elective angiography or surgery for the
following week. This list was faxed on a weekly basis. The PAS system was used to
check their GP details. If they were registered from our study practices their names
were recorded in our daily logbook and they were approached when they were
admitted. This included patients attending the Vascular Day Case Unit for
angiography who were then identified on arrival, invited to participate in OXVASC
and interviewed on the same day.
2.8.14. Vascular surgery mortality and morbidity data
Patients admitted under the care of all the vascular surgeons were recorded and
discussed at their weekly morbidity and mortality meeting. This included patients
referred while in hospital to the vascular team including those from other hospitals.
This information was recorded and a list faxed to OXVASC on a weekly basis. The
hospital number was used to identify their GP details. Suitable patients were
reviewed and registered with the study.
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2.8.15. Coronary angiography list
All patients attending for coronary intervention were recorded on a Cardiac Unit
database. The names, hospital number and GP details including information on
their procedure were recorded. The identity of all patients attending for coronary
angiography was provided on a weekly basis. The majority had been ascertained
through daily visits to the day case unit. Any patients not known to the study but
registered with our study practices were recorded.
2.8.16. Clinic lists for other stroke physicians
A list of all patients attending the outpatient clinics of local stroke physicians was
generated using PAS. Their hospital numbers were used to identify their GP details.
If registered with our study practices, their notes were reviewed to ascertain any
TIA or stroke events that had not been referred to our rapid access clinic.
2.8.17. Weekly review of admissions to rehabilitation wards
Patients requiring further rehabilitation were often transferred to the Radcliffe
Infirmary Rehabilitation wards including the Stroke Rehabilitation ward. PAS
generated lists of patients from our study practices admitted to these wards and
their notes were subsequently reviewed.
2.8.18. Peripheral angiography register
The Radiology Department registered the demographic and GP details for all
patients undergoing vascular intervention. This information was reviewed on a
monthly basis to ascertain any patients having endovascular intervention. This
search strategy identified cases that had been referred for further vascular
investigation from non-vascular surgery teams and those referred for investigation
of small bowel ischaemia. Once identified these patients were logged and
subsequently invited to participate in OXVASC. If ascertained late, their cases were
discussed with their GPs and they were subsequently invited to participate if
appropriate.
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2.8.19. Cerebral angiography register
All investigations and interventions for subarachnoid haemorrhage or primary
intracerebral haemorrhage were carried out at the Radcliffe Infirmary. A register
was kept of all patients undergoing cerebral angiography. This register recorded
demographic details, hospital number and procedure undertaken. This register was
reviewed on a monthly basis. Details were logged of any patients from our study
area that had cerebral angiography. PAS was used to identify their registered GP.
Patients were invited for study participation if registered with our GP practices.
2.8.20. Paediatric liaison
On a monthly basis both the Paediatric Neurology and Cardiology Registrars were
contacted personally to request information on any children admitted or seen in
outpatients with acute vascular events. It was assumed that these cases were so rare
and would require such intensive investigation that they would have been
remembered. Discharge letters from the unit were also reviewed. Other methods of
ascertainment for these groups included brain imaging referrals and coding. In
addition, regular contact was maintained with one of the Paediatric Neurology
Consultants who held records of all the cases children who presented with stroke in
the Oxford Region. These records were reviewed.
2.8.21. Obstetric liaison
In Oxford, all complicated pregnancies are managed by the 'Silver Star' team based
at the JRH. This team has a centralised referral system and telephone contact. On a
monthly basis the team was contacted and information was requested on any
pregnancies complicated by acute vascular events.
2.8.22. Brain imaging
All patients who undergo any type of imaging are recorded on the ORH Radiology
database. Searches were set up for any patients registered with our study practices,
having brain or spine imaging, including CT, MRI or angiography. This list was
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provided on a monthly basis. For previously unknown patients, a report of their
imaging was generated which often included the indication for the scan. If there
was a suspicion the scan was performed because of an acute cerebrovascular event
the patient notes were reviewed. If no report was available, notes were reviewed. If
any TIA or stroke patients were identified, they were invited for inclusion after
consultation with their GP.
2.8.23. Carotid Doppler referrals
Many patients suspected of having acute cerebrovascular events were referred for
carotid imaging including referrals from the Ophthalmologists, other stroke
physicians, neurologists and cardiologists. The vascular laboratory provided copies
of carotid imaging reports of any patient registered with our collaborating GPs. The
notes of these patients were subsequently reviewed to ascertain any TIA or stroke
cases. If this was the case, their GPs were consulted and the patients invited for
inclusion if appropriate.
2.8.24. Coding data
All patients admitted or dying in ORH NHS Trust were ICD-10 or OPCS-4 coded for
medical diagnoses and surgical intervention respectively. On a monthly basis, a list
of all patients from our collaborating practices discharged or dying with an ICD-10
vascular diagnosis or coded as having an OPCS-4 vascular intervention was
generated by the coding department (Appendix 3). This list was cross-referenced
with any patients already identified using admission registers. The medical notes of
any cases that had not been identified were scrutinised. Acute vascular event cases
were invited to participate if their GP thought appropriate. The coding team also
supplied data on all patients seen in the Oxford Eye Hospital Casualty Department
with a diagnosis of amaurosis fugax, retinal infarction, anterior ischaemic optic
neuropathy or visual loss unspecified.
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2.8.25. GP practice visits
Collaborating GP practices were visited on a monthly basis. GPs were encouraged
to continue referring all possible cerebrovascular events to the daily clinic. In the
majority of practices, a list of all patients who had died was kept. On each visit, a
search was made to ascertain any acute vascular deaths through review of these lists
and searching through all the death certificates. Cases ascertained elsewhere could
also be clarified. GPs were also encouraged to inform us about any vascular events
that may have occurred or been investigated out of area. Pre-morbid data were
collected on patients that had agreed to be enrolled in the study. These visits also
provided an opportunity to feedback to GPs regarding the study. Their involvement
was critical to the success of the study. On a six-monthly basis the GP databases
were systematically searched for all patients who had been coded as amaurosis
fugax, retinal infarction, TIA, stroke, myocardial infarction or peripheral vascular
disease. If this search identified cases that were not known, their notes were
reviewed and their GP interviewed to identify further acute cases. In many cases,
this coding search identified patients who were on cerebrovascular or ischaemic
heart disease registers who had events prior to the study period and thus were not
eligible for the study. In other cases, such as TIA the diagnosis was less secure. This
database search was useful for cases of MI or stroke that had occurred out of area or
abroad. If cases were identified in this way they were discussed with the
collaborating GP and subsequently invited for inclusion if the GP thought this was
appropriate. Regular contact was also made with local care homes to ascertain any
acute vascular cases that may have been managed in the community. However,
these events were often also recorded on GP databases.
2.8.26. Coroners Office
All sudden or suspicious deaths or deaths abroad of an Oxfordshire resident were
reported to the Oxfordshire coroner. The coroner holds records of all such patients
in a written register. The office also holds any coroner reports and the results of any
coroner held post mortems. This office was visited on a three-monthly basis to
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ascertain any patients from our collaborating practices that had been referred to the
coroner that had died of an acute vascular event. Their details were collected.
2.8.27. Department of Public Health
All deaths in England and Wales are recorded through a central register with the
majority of cases having a unique NHS number. Cause of death is coded using ICD-
10 and the registered GP is identified using a unique GP code (Appendix 4). These
data are then passed on to Health Authorities and their local Department of Public
Health. Data can then be updated in local hospital and GP databases. A list of all
deaths occurring in Oxfordshire with a vascular ICD-10 code in any position on the
death certificate was generated by the local Department of Public Health (Appendix
5). These anonymised data were provided on a three-monthly basis. Diagnostic
codes were placed as 'underlying cause of death' corresponding to part la on the
death certificate. Further codes were apportioned to 'cause of death (1)' to 'cause of
death (7)' with cause of death (1) and (2) corresponding to part I b and I c on the
death certificate. Cause of death (3) - (7) corresponded to those contributary causes
of death but not causing death normally put in part II of the death certificate.
Patients registered with our collaborating practices with a vascular diagnostic code
in the 'underlying cause of death', 'cause of death (1)' and 'cause of death (2)'
position were investigated in detail. The predominant vascular codes used were:
• 164 - cerebral diseases
• 1219 - acute myocardial infarction
• 1251 - atherosclerotic heart disease (often used for sudden death)
• 1718 - diseases of arteries, arterioles and capillaries
1259 - chronic ischaemic heart disease was often used to denote heart failure
secondary to ischaemic heart disease and was not included as an acute vascular
event unless there was other supportive information from reviewing the notes that
they may have had an acute vascular event. NHS numbers were cross-referenced
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with cases already known to the study. If not known to the study, PAS was used to
identify demographic details. If cases were not known to the hospital-based PAS,
GP databases were searched using the NHS number to identify patients. When cases
of acute vascular deaths were identified, their registered GP was interviewed and
their GP and hospital notes reviewed to ensure diagnostic accuracy of cause of
death and for further premorbid information. All patients included in the study
were flagged to facilitate follow up.
2.8.28. Rapid access chest pain clinic
The coding department generated a list of all patients from our study practices who
were referred to the Rapid Access Chest Pain Clinic. Review of the clinic database
identified core risk factors and final clinical diagnosis. Cases of unstable angina or
myocardial infarction were identified. There were very few patients who were not
admitted and had thus been identified through hot pursuit.
2.8.29. Vascular surgery clinics
The coding department generated a list of all patients attending a vascular surgery
clinic. All the letters of correspondence from these clinic visits were reviewed. The
demographic details and clinical histories of any patients with suspected critical
limb ischaemia were identified. The majority were subsequently admitted for
vascular intervention and ascertained through other methods. A few who were not
admitted were included in the analysis of burden of vascular disease. Cases of acute
peripheral vascular events were all admitted.
2.9. Protocols for inclusion
All potential TIAs, strokes, ACS and PVE were assessed as soon as possible after
notification in a dedicated clinic, in hospital or in their home. Information from
patient interviews was subsequently entered on to a computerised database. Data
were extracted from medical records for cases first identified only after death or
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after a prolonged delay (e.g. if their stroke occurred whilst temporarily out of
Oxford).
To facilitate assessment of patients at home or in care homes an equipment box was
available consisting of mediswabs, vacutainers, needles, 10ml blood bottles, request
cards, tourniquet, plasters, sharps box, and plastic specimen bags.
2.9.1. Accident and Emergency Register
On a daily basis the JRH admissions office generated an Admission Register for all
ORH sites, an Admission Register specific to our collaborating practices, and an
Accident and Emergency Register to identify potential study patients. The
Admission Register for all ORH sites provides a means of locating cases already
enrolled for continuing follow-up.
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Figure 2.2. Protocol for using Accident and Emergency Register
Check for patients admitted with possible TIA or stroke, ACS or PVE
I
Unique hospital number used to check registered GP
1
If registered to study practice patient
record reviewed for diagnosis
Admitted Discharged
Acute vascular event Acute vascular event
I I
Data collection Review A&E notes
Discuss with GP
Invite to participate
2.9.2. GP-specific admission register
This daily list was generated of all in-patients of the ORH sites including the
community hospitals specifically for our collaborating practices. This list was
searched to identify any patients admitted in the 24 hours prior to the generated list.
Lists on Monday morning were reviewed to record admissions over the weekend.
This provided a patient name, unique hospital number, admission ward and
consultant in charge of ongoing care.
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Figure 2.3. Protocol for using practice-specific admission register










Review patient record Not routinely
reviewed
Include acute vascular events
2.9.3. Troponin I list
The Department of Biochemistry generated a daily list of all patients having
troponin I measurement to identify possible ACS patients. Some were already
identified through the GP admission register and a daily visit to CCU. However
patients admitted with other diagnoses subsequently developing ACS were
ascertained. Cases of unstable angina, NSTEMI and STEMI were enrolled into
OXVASC for further follow-up. Possible cases and those patients with raised
troponin I but no other evidence of myocardial infarction were discussed with a
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collaborating Consultant Cardiologist. If MI was diagnosed, these cases were
subsequently invited to participate in the study.
Figure 2.4. Protocol for using troponin I list
Registered with collaborating GP
Troponin I <= 0.2
1
Excluded











Typical history No history
ST elevation +/- ECG change
or LBBB Troponin I > 1
+/- Trop>l






2.9.4. TIA and minor stroke daily clinic
GPs were encouraged to refer all possible acute cerebrovascular events to our daily
weekday TIA and minor stroke rapid access clinic based at the Radcliffe Infirmary.
All cases were discussed with Dr Rothwell. Definite or probable TIA and strokes
were enrolled into OXVASC. Possible TIA and strokes were also followed up using
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the OXVASC protocol. All these cases were subsequently discussed with Professor
Warlow - lead investigator in OCSP to ensure comparability with OCSP. Non
vascular cases underwent a thorough assessment and were referred back to their GP
for ongoing management or onto another speciality.
2.9.5. Late case ascertainment from cold pursuit
The majority of cases were ascertained from hot pursuit as hospital admissions or in
the daily clinic. However, some were ascertained using cold pursuit methods some
time after their acute event. Several TIA and stroke cases were ascertained through
brain and carotid imaging referrals, coding data, searching of GP databases and the
mortality file. Several ACS cases were identified if a troponin I had been measured
in the community, by searching GP databases and the mortality file. Several cases of
critical limb ischaemia were ascertained through review of the medical records of all
patients seen in the vascular surgery clinics. Some of the vascular interventions
were missed during their short stays in hospital as day cases. The hospital and GP
records were scrutinised prior to consideration of inclusion. GPs were subsequently
interviewed to assess the suitability of their patient for inclusion and interview. If
felt unsuitable for interview, the history was discussed between two stroke
physicians and a decision made on inclusion. If eligible, annonymised core risk
factor data were collected from GP records. If the GP felt interview was suitable,
TIA and stroke cases were telephoned directly and invited for assessment. ACS
cases were written to, along with subsequent telephone contact if there was no
reply. As we were offering a specialist assessment service we felt it was reasonable
to contact TIA and stroke patients directly by telephone if we had the GP's
permission. If patients did not agree to interview, permission was sought to record
anonymised core risk factor data from their GP records and subsequent follow-up.
Therefore patients had the option of 'picking and choosing' what type of assessment
they encountered - interview, follow-up, record review alone or any combination.
-77-
Figure 2.5. Protocol for daily TIA and minor stroke clinic
GP telephones or faxes details of patient with TIA or Stroke
i
Patient contacted to arrange time and date for clinic or home assessment. Transport
organised if necessary.
1
Clinical diagnosis of TIA or stroke
Data collection
I
Routine and study bloods
ECG
Same day CT head
Carotid Doppler within 48 hours
1
Management plan faxed to GP within 48hours
One month follow up at Radcliffe Infirmary
1
Follow up at 3 and 6 months at home by
Department of Primary Care
1
1 year follow up at Radcliffe Infirmary or at home
Yearly telephone follow-up
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Figure 2.6. Case ascertainment of TIA and stroke using cold pursuit
Case ascertainment
I
Review of hospital and GP records
1
Contact GP by telephone
Confirm diagnosis of TIA or stroke


























Figure 2.7. Case ascertainment of ACS using cold pursuit
Case ascertainment
1
Review of hospital and GP records
i
Contact GP by telephone
Confirm diagnosis of ACS
































2.9.6. Procedure for deaths in the community
It was envisaged that a significant number of potential OXVASC patients would die
of their acute vascular events prior to admission to hospital, particularly those with
ACS or intracerebral haemorrhage. The bereavement office was visited daily to
ascertain any patients 'dead on arrival' to hospital. Death certificates from each
study practice were examined on a monthly basis. The coroner's office and coroner
post mortem results were reviewed on a three-monthly basis. Several intracerebral
haemorrhages were ascertained as they had undergone urgent brain imaging prior
to death. The Department of Public Health provided a list of all patients in our
study practices who died and were ICD-10 coded with a vascular event. It is
envisaged that the relatives of these patients wil be invited by letter and follow-up
telephone call to provide premorbid information on their relative once a suitable
time has elapsed (Appendix 7). Relatives were only invited to participate if the
registered GP of the deceased believed this to be appropriate. Clearly this is
important to ensure that data such as family history information is available for
those who die suddenly in the community. This sensitive work was coordinated by
a research nurse with an experienced background in community nursing. After a
patient dies their GP notes are sent to central storage at the Thames Valley Health
Authority headquarters. These notes were requested to collect further past medical
history, supplement missing data on family history and ensure accurate diagnosis of
cause of death.
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Figure 2.8. Procedure for deaths in the community
Acute vascular death - late ascertainment
I
Interview with registered GP
and review of GP / hospital
records to confirm diagnosis
I
Discuss with GP suitability






Letter to next of kin seeking








Data collection No action
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2.10. Information Sheet
Patients were invited to participate in OXVASC. Patients and their carers were
offered a verbal explanation of the study for both the ascertainment and the follow
up phases of the study. A written information sheet describing both parts of the
study was provided to the patient or their carer or relative (Appendix 8). The
information sheet was read to patients who had problems reading due to stroke
(visual field defect or alexia), or for other reasons.
2.11. Consent
If the patient was happy to make a decision about participation in the study
immediately, then written consent was obtained (Appendix 9). If the patient
required a period of time to consider the decision then this was respected.
Consent was more complicated in certain circumstances. Firstly, there were
problems obtaining a normal signature from some patients with dominant
hemisphere strokes. In such cases we tried to obtain a signature with the patient's
non-dominant hand, and have this signature witnessed by a relative, carer or
member of the nursing staff. Some potential participants were unable to give
informed consent due to their neurological deficit, or other acute complication. In
this situation, we attempted to contact the next-of-kin to obtain surrogate consent
(Appendix 10). If the next-of-kin was not available we assumed consent for the
purposes of recording basic clinical information from the medical records, but not
for clinical examination or any venepuncture in excess of what was clinically
indicated. The participant was informed that they were at liberty to abstain from
participation in the study at any time.
Approximately 15-20% of stroke patients have some degree of either dysphasia or
cognitive impairment. Surrogate consent is not legally well defined, but since our
study is purely observational we thought that consent from next-of-kin was
reasonable. This is standard practice in acute stroke research. Where consent from
-83-
neither the patient nor the next-of-kin was available, the Declaration of Helsinki43
allows for research in this area if the specific reasons for not obtaining consent are
reviewed by an independent ethics committee. Doyal44 has argued that where
informed consent is not possible, a common occurrence in stroke patients, then it
should be clear there are important potential benefits from the research, and the
risks of involvement should not exceed those associated with everyday life. If the
research is epidemiological and medical records are to be used but consent cannot
be obtained then this would be acceptable in light of potential benefits for patient or
in the public interest provided confidentiality is maintained and there are no further
consequences for the patient. Such research should be essential and permission
granted from the patient's primary carer. Our study was approved by our local
Oxfordshire Clinical Research Ethics Committee (OxREC C02.043).
2.12. Sample size
In the pilot phase, we expected to identify 40-50 TIAs and 175 - 200 first strokes
(based on OCSP data).1-9 150-200 first definite or probable Mis (based on OXMIS
definition)2 out of 500-600 acute coronary syndromes, and 50-100 acute peripheral
vascular events. In the main phase of the study, these numbers should increase five¬
fold. Within the original OCSP general practices we will have 80% power (alpha =
0.05, 2 tail) to detect a 16% reduction in the overall incidence of first stroke. All of
our study practices are within the original OXMIS study area, and all incident Mis
will therefore contribute to the study of time trends. We will have 80% power to
detect a 10% reduction or increase in incidence.
2.13. Conclusions
Multiple overlapping sources of ascertainment were used to ensure accurate case
ascertainment of all acute vascular events and those undergoing vascular
interventions. This is the first time the incidence, case fatality and outcome of all
acute vascular events have been measured in the same population at the same time.
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Once eligibility criteria for inclusion had been met, patients were given information
on the study. If they consented to interview, we proceeded to data collection.
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Chapter 3
Study methods II - Data collection
3.1. Data collection
3.2. Data storage
3.3. Data collection forms
3.4. Clinical management
3.5. Procedure for blood collection
3.6. Procedure for further data collection of investigations
3.7. Diagnosis and classification
3.8. Follow-up
3.9. Pre-morbid risk factors
3.10. Feasibility and details of difficulties
3.1. Data collection
Cases were ascertained as described and considered for inclusion (see Chapter 2). If
patients were eligible for the study, a patient information sheet was provided and
explained. Formal written patient consent or relative assent was obtained. If
inclusion criteria were initially unclear then patients were reviewed on a daily basis
to facilitate an accurate final diagnosis. Close liaison with the medical team caring
for the patient was kept throughout. The patient was interviewed and examined
within 48 hours of inclusion (usually on the same day). Data were collected by
interview with the patient primarily, relative and review of medical notes. Data
were collected using specific forms for each type of vascular event. The same core
data were on all forms.
3.2. Data storage
Anonymised data were initially stored on paper copies of data collection forms
labelled with a unique identification number and the ethics (COREC) approval
reference number. Data collection forms contained demographic details including
name and contact details for the patient and their next of kin. Details of registered
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GP were also recorded. Paper copies of the data collection forms were kept in locked
filing cabinets in the Stroke Prevention Research Unit.
Data were stored on a password-protected Excel spreadsheet. This had an
administrative purpose with the unique identification number allocated to each
patient starting at 0001. The same unique number was applied if a patient returned
with another vascular event or intervention. Recurrences of any vascular event or
procedure were identified and recorded. Date of birth, hospital number, NHS
number and date of the study entry with GP details were stored. Cases were
categorised according to their vascular event, timing of events and core risk factors
were also recorded.
A Microsoft Access database was designed in parallel to the data collection forms to
ease data entry and facilitate data storage. All data storage conformed to the Data
Protection Act and was only accessible by study investigators.
3.3. Data collection forms
Data were collected using event-specific forms. Detailed data (timing, history of
presenting condition, diagnostic information, and subsequent management) were
collected on data collection forms for TIA and stroke (Appendix 11), STEMI
(Appendix 12) and PVE (Appendix 13). The same core risk factor data were
collected on all events including patients with UA or NSTEMI (Appendix 14) and
vascular interventions (Appendix 15). Those cases with no typical history or ECG
changes but a raised troponin I had core risk factor data recorded (Appendix 16).
3.3.1. Case ascertainment
Careful note was made of the methods of case ascertainment for each patient. When
a suspected case was identified the source of such identification was recorded
together with the date on which the case was identified. All subsequent methods of
case finding were recorded. If ascertainment was delayed, the date on which the
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information was received was recorded. For example copies of all brain imaging
referrals were received on a monthly basis. The date of ascertainment for any case
identified through this method was the date that these reports were received. The
accurate recording of these methods of ascertainment allowed the application of the
capture-recapture technique to assess completeness of ascertainment1 (See Chapter
5).
3.3.2. History and timing of presentation
The history and examination were recorded as a brief narrative consisting of the
salient points perhaps not well conveyed on computer database. Particular note was
taken of any pre-existing disability, the speed of onset, any specific triggers or other
associated symptoms.
Detailed information on the date and timing of the acute event and subsequent
presentation to medical attention were recorded in 24-hour format. This included
the date and time of event onset, initial call for assistance, first call to medical
services, first seen by medical services, identification by the OXVASC team,
admission if applicable and assessment. Detailed information was recorded on any
progression of TIA and stroke cases within the first 24 hours and prior to
presentation. From these data we have studied the effect of different definitions of
recurrent stroke on the measured early risk of recurrence (See Chapter 6).
3.3.3. Potential triggers
The exact circumstances surrounding the onset of any acute vascular event were
detailed in order to identify any triggering factors. Previous studies in this area have
often been anecdotal, uncontrolled and tend to suffer from the possibility of recall
bias. There may also be publication bias of positive results. However it is
increasingly recognized that the onset of cardiovascular events follows a circadian
periodicity with morning peaks in myocardial infarction, sudden cardiac death and
ischaemic stroke.2 Several case control and self-control studies have reported risks
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of myocardial infarction two to six times greater during heavy physical exertion
than during less strenuous activity or no activity particularly evident in persons
who did not exercise regularly.3-4 It is hypothesized that such events may trigger the
disruption of coronary atherosclerotic plaques.5-6 The highest level of activity before
30-120 minutes of onset of symptoms was recorded. To attempt to get control data
the same question was asked for the contemporaneous 2 hours on the day before
event. We used the following scale to classify levels of activity.
Minimal Asleep or within 30 minutes of waking 3 METS
METS = metabolic equivalents required to perform the activity.
One MET is equal to 3.5 milliliters of oxygen consumed per kilogram of body weight per
minute, the average valuefor oxygen consumption at rest.
In collaboration with the University of Oxford Environmental Change Unit, we plan
to study any association between the onset of acute vascular events and seasonality
and temperature. Any association remains controversial.7
3.3.4. Past medical history and vascular risk factors
Previous acute vascular events were recorded to assess whether the presenting
event was first-in-a-lifetime or recurrent. A history of myocardial infarction was
recorded based on patient, hospital or GP records. A previous STEMI was recorded
only if the patient gave a history of having thrombolysis or ECG evidence in the
medical record. Otherwise a documented history of MI was recorded as a NSTEMI.
Any history of previous TIA or stroke was interrogated closely. Dates, duration and
vascular territory of TIAs and strokes were judged from patient history and medical
record. Critical limb ishaemia was not recorded as an acute event. Only if acute
Light activity Walking, golf
Moderate activity Mowing, digging, climbing stairs





PVE were previously documented would the notifying event be regarded as
prevalent. Risk factors were recorded as present if known to patient or recorded in
GP or hospital notes or on relevant medication for that condition.
Hypertension was defined as present if the patient or the medical record gave a
history of high blood pressure for which the patient had been provided with
treatment whether lifestyle changes or pharmaceutical management. Care was taken
to ensure that where patients were on medication with multiple indications that
hypertension was only recorded if these medications were being used for
hypertension. All blood pressures taken over the ten years prior to the vascular
event were collected from the GP record.
A history of diabetes was recorded including age of diagnosis, type of diabetes and
treatment used. A clinical or echocardiographic history of valvular heart disease
was recorded. Previous endovascular or vascular surgical interventions were also
recorded.
Hyperlipidaemia was regarded as present if the patient or the medical records
showed any evidence that the patient had been given lifestyle advice or drug
management for lipid lowering. Moreover if patients were taking lipid lowering
therapy even if this was for secondary prevention post myocardial infarction
despite a 'normal' cholesterol then patients would be recorded as having a history
of hyperlipidaemia. Pre-morbid blood pressures and cholesterol measurements
were collected from GP records where available that will allow a more powerful
analysis of the association of blood pressure and cholesterol with acute vascular
events.
Any history of atrial fibrillation was recorded whether paroxsymal, persistent or
permanent. Clinical or echocardiographic diagnosis of heart failure was recorded.
Enquiry was made regarding migraine, epilepsy, peptic ulcer and chest disease.
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Enquiries were made regarding a history of bleeding or clotting disorder and
autoimmune disease. For women, history of pregnancy, miscarriage, menopause
and use of the oral contraceptive pill (OCP) or hormone replacement therapy (HRT)
was obtained. Information was obtained on age in years when any diagnosis was
made. A detailed family history was obtained for any previous history of vascular
events or risk factors. This was obtained from relatives if necessary.
Cigarette smoking (including "roll-ups"), pipe and cigar smoking were recorded.
Patients were asked if they had ever smoked. For current smokers, the number of
cigarettes smoked in a 24 hour day or the number of ounces smoked in a 7-day
week and the number of years smoked was recorded. For ex-smokers, the calendar
year when gave up smoking and the number of years smoked was recorded.
3.3.5. Medication usage
The names of all medications the patient was taking on a regular basis up to the
time the event began were recorded. These were classified into therapeutic
categories. Detailed information was collected on prior use of anti-platelet,
anticoagulant or anti-inflammatory medication.
3.3.6. Modified Rankin scale
The modified Rankin scale8 has been used extensively in both stroke trials and
epidemiological studies. It measures independence rather than being task oriented
and gives a better impression of self-care than disability indices such as Barthel and
represents handicap rather than disability. Interobserver reliability has been
reported as reasonable (k=0.56; weighted k=0.91) when completed by health
professionals.8
3.3.7. Cardiovascular Rose Questionnaire
The cardiovascular Rose questionnaire9 was used as a screening method to identify
classical or typical angina in men aged over 35, myocardial infarction and
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intermittent claudication.10 It is a popular and simple screening tool and regarded as
reliable, valid and reproducible. The questionnaire is highly specific (99.8%) in
excluding healthy individuals but only moderately sensitive (67.5%) in detecting
those with intermittent claudication.10 The definitions of a positive classification are:
A Angina 'yes' to a and b, 'stop' or 'slow down' to d, 'yes' to e, '10 minutes or
less ' to f. Site must include either sternum (any level) or left anterior chest
and left arm. Grade 1 = 'no' to c, Grade 2='yes' to c.
B Possible infarction Yes
C Intermittent claudication 'yes' to a, 'no' to b, 'yes' to c and d, 'no' to f, 'stop'
or 'slow down' to g, and 'usually disappears in 10 minutes or less' to h.
Grade l='no' to e, Grade 2- yes' to e
3.3.8. Barthel Index
The Barthel Index11 was used to measure functional ability. It is based on observed
functions. The scale covers feeding, mobility, personal toilet, bathing, continence
and dressing. It omits tasks of daily living such as cooking and it was primarily
designed for institutionalised populations. It is quick to score but is crude and may
not be sensitive to improvements or deteriorations beyond the end-points of the
scale (floor and ceiling effect) and within dimensions not represented by the scale.12
However the scale has face validity and appears to assess ADL and correlates with
other measures as expected and has predictive validity. Inter-observer reliability is
generally high.12
3.3.9. Cognitive impairment
Folstein's mini-mental state examination (MMSE) was used to assess cognitive
impairment.13 The MMSE has been used extensively and has good inter-observer
reliability. It takes 5-10 minutes to administer. The test covers orientation,
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registration, attention and calculation, recall and language. The total score is 30 with
the cut-off score of 23-24 suggesting cognitive impairment.
3.3.10. Informant Questionnaire on Cognitive Decline
There has been considerable interest in the relationship between vascular risk
factors and Alzheimer's disease.14 To determine the frequency of pre-existing
dementia in patients with stroke in comparison to those with other acute vascular
events, we administered an Informant Questionnaire on Cognitive Decline
(IQCODE - Appendix 22).15 It has been validated in elderly and Alzheimer patients
using DSMIIIR criteria. It is made up of 16 questions scored on a five strand anchor
of much improved (scores 1) to much worse (scores 5) given to relative or close
friend. That person should have known the patient for 10 years and met them at
least once a week. It consists of questions comparing the changes experienced by the
patient over the last ten years in aspects of daily living requiring memory and other
intellectual abilities. Global score ranges between 16 and 90. It has good interrater
reliability and there is good correlation with MMSE.15 It is not influenced by
previous intelligence, educational level or social class.15
3.3.11. Onset anger scale
There have been several uncontrolled case series reporting an association between
precipitating stressful events and anger and the triggering of acute vascular events.
Previous studies have suggested a relationship between anger expression16 and trait
anger,17 with the risk of incident stroke. However, such studies potentially suffer
from confounding factors.18 In the interview-based Determinants of Myocardial
Infarction Onset Study,19 Mittleman used a self-control design to apply an onset
anger scale to patients with myocardial infarction. Patients were asked to report
their state of emotion on a single item, seven-level, self-report scale. The relative risk
of myocardial infarction in the 2 hours after an episode of 'anger' was reported to be
2.3. We used similar methods to collect these data for patients presenting with all
acute vascular events. We also collected data for the same two hours time on the
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preceding day. Patients were considered exposed if they reported a peak level of
anger greater than or equal to level 5 (very angry, furious, enraged) during interval
of interest 2 hours before event.19 The control data were their actual exposure in the
comparable 2 hour period at the same time on the same day before event. If the
onset of event came on wakening, the time of waking up and events in 2 hours prior
to going to bed were recorded.
3.3.12. Stress
There has also been considerable interest in the association of stress with acute
vascular events. In the early 1990s the concept of type A coronary prone behaviour
dominated thinking about psychosocial factors and coronary heart disease.
Increasingly it has been shown that this concept is too diffuse and the concept of
hostility has been implicated.20 In the Caerphilly Study,21 the association between a
measure of psychological distress and the incidence of stroke was studied
prospectively in a middle-aged group of men. Psychological distress was reported
to be a predictor of fatal ischaemic stroke but not of non-fatal stroke or TIA.
However, in a Danish study22 of nearly 13000 subjects of all ages there was no
significant independent association of self-reported stress intensity with risk of
stroke. These studies are difficult to interpret from a methodological standpoint and
in the definition of the nature of psychological distress.23 The evidence for 'stress'
being a risk factor for stroke remains inconclusive. 'Stress' may be more associated
with behavioural differences with other high-risk behaviour or socioeconomic
status. In an attempt to keep this area of interest simple and quick, all patients were
asked what sort of person they thought they were in terms of a stressful personality.
The interviewer also made a clinical judgement of the patient's stress level. Both
patient and interviewer were given a choice of five responses between 'very
relaxed', 'fairly relaxed', 'average', 'prone to stress', and 'highly stressed'.
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3.3.13. Social networks
Social networks have been considered to be a risk factor for vascular disease but
studies have often been poorly controlled for confounding factors. In a US study24
examining association of low social networks with cause specific mortality and
morbidity, 30000 middle-aged men were followed up prospectively. It was reported
that social networks were associated with lower total mortality by reducing deaths
from cardiovascular disease and accidents / suicides. Strong social networks have
been associated with reduced incidence of stroke though not of coronary heart
disease.25 Data were collected on marital status and contacts with friends or relatives
to determine any association between social networks and acute vascular events in
our population.
3.3.14. Social history
Socioeconomic status is a powerful predictor of cardiovascular risk,26 but the
association with stroke is less certain,27 as it is not clear whether these associations
with an increased stroke risk can be accounted for by differences in health
behaviour and vascular risk factors.28 However recent reports using occupation as a
measure of social class have suggested poor socioeconomic circumstances were
independently associated with greater stroke risk.29 Moreover, when an area-based
deprivation score was used in a West of Scotland population, socioeconomic
deprivation was associated with stroke risk factors and stroke at a younger age.
Deprivation had an independent effect on baseline stroke severity.30 In OXVASC,
information was gathered on place of residence, most recent occupation,
socioeconomic class, ethnic origin and age of leaving full time education. Social
Class was coded using the Standard Occupational Classification Scheme.31 If retired,
the participants' last job was recorded. In the case of a child or a spouse who did not
work the occupation of the father or partner was taken respectively.
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3.3.15. Sleep disorders
An association between sleep disorders and vascular disease including stroke has
been difficult to define. Studies in acute stroke are difficult to interpret as acute
stroke is a common cause of irregular breathing. However in a recent case-control
study examining the prevalence of obstructive sleep apneas among TIA patients
there was no increased prevalence of disordered breathing in TIA patients.32
Questions from a previously validated clinical prediction model incorporating some
of the features of the Epworth scale were asked of all patients.33 These
questionnaires have been used to try and prioritise patients with sleep disorder for
polysomnography. These models have shown reasonable sensitivity but lack
specificity but do have a role in prioritising further investigation.33 Hip, waist and
collar size were all measured at assessment. Most recent weight, height and body
mass index were collected from the GP records.
3.3.16 Nutrition and exercise
Observational studies have suggested a relationship between lifestyle factors
including diet and the risk of cardiovascular disease and stroke.34 However, such
associations may be explained by confounding variables.35 Previous observational
studies have suggested the risk of stroke and coronary disease are associated with
anti-oxidants,36 low intake of fresh fruit and vegetables37 and fish.38 However a
recent randomised trial of antioxidant vitamins in high risk vascular patients has
showed no benefit.39 The pre-morbid dietary lifestyle of patients presenting with
acute vascular events was recorded specifically examining the intake of fish, fruit
and vegetables, addition of salt and use of reduced fat milk.
Data now suggest raised homocysteine is a risk factor for vascular disease,40 and
treatment with homocysteine lowering folic acid supplements is currently being
studied in a randomised controlled trial.41 We have collected data on the oral intake
of vitamin and mineral supplements.
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Lack of physical exercise is associated with coronary events42 and may be associated
with stroke.43 Participants were questioned on any physical exercise and a clinical
judgement was made on the amount of exercise corrected for any pre-existing
disability. The interviewer was given a choice of 'none', 'below average', 'normal'
and 'above average'.
3.3.17 Depression
Depression may be an important prognostic factor after vascular events. However,
the role of depression as a causative risk factor for acute vascular events has not
been determined. Depression has been recognised as a poor prognostic factor for
patients post myocardial infarction but it is unclear whether individuals with
depression are more likely to develop coronary events over time.44 Other studies
have reported an association of increasing depressive symptoms over time with
significant excess risk of death and stroke or myocardial infarction.45 In two large
prospective cohorts46-47 pre-existing depressive symptoms were reported to be
associated with a doubling of risk of incident stroke. Different studies have used
different methods of diagnosing pre-existing depression. In OXVASC, the one
question Yale Depression screen,48 'Do you often feel sad or depressed?' was used
to screen for pre-existing depression. This has been shown to be as accurate as the
Geriatric Depression Scale in screening for depression in a clinic setting49 and in
stroke patients.50
3.3.18 Life events
Previous studies have examined associations between the onset of acute vascular
events and major life events and proposed a mechanism.51 However, studies have
been anecdotal, poorly controlled and results have been conflicting. A case control
study looking at the association between stroke and severely threatening life events
in the preceding year showed these events to be significantly more common in the
stroke patients.52 Similarly patients with myocardial infarction have been shown to
have significantly more life events in the preceding 3 months than case controls.53 In
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OXVASC, patients were interviewed to determine preceding life events and the
degree of stress caused to the patient was graded ('very much', 'moderately' or 'not
too much'). It is envisaged that patients with other vascular events may be used as
controls to determine any association between life events and stroke. In the next
phase of the study, it is planned to enrol community controls.
3.3.19 General examination
All patients were asked if they would agree to a general examination including
weight, height, hip, waist and collar measurements. Patients were examined for
evidence of vascular disease including bruits and murmurs. Routine observations of
temperature, pulse and heart rhythm, blood pressure were made. If admitted blood
sugar and oxygen saturation were recorded.
3.3.20 TIA and stroke examination
Patients with TIA and stroke were given a thorough neurological examination and
the National Institute of Health Stroke Scale (NIHSS)54 was recorded. This is broader
than the disability and handicap scales such as Rankin. It is a 15-item scale covering
level of consciousness, pupillary response, gaze, visual loss, facial palsy, motor-arm,
motor-leg, plantar reflex, limb ataxia, sensory loss, neglect, dysarthria, and
language. It is observer rated and takes 5-8 minutes. Items have 3- or 4- point
response scales, scored 0-3 (0=normal) Change is measured as same, better or worse.
There is reasonable validity and inter-rater agreement, and the 7 day score is related
to eventual outcome. However, it has been criticized for trying to summarise all
impairments in a single score.
3.3.21 Prognostic models for acute stroke recovery
Prognostic models in stroke may be useful in clinical practice and research. In a
recent systematic review,55 the only variables shown in multivariate models to be
independently associated with one year survival were cardiac failure, conscious
level and the level of impairment at baseline whereas age was more important in
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long term survival. Impairment and conscious level in the acute stage also
influenced the functional outcome as did the degree of weakness, whereas younger
age and urinary continence appeared to be important predictors of getting home.
Counsell65 points out however that many of the studies were of poor quality and
interpretation had to be cautious. Tilling56 has developed models of functional
recovery after stroke to assist in predicting outcome using prognostic variables such
as urinary incontinence, sex, pre-stroke disability and dysarthria along with age,
dysphasia and limb deficit. Such models may assist in medical management during
rehabilitation. More complex factors have also been examined. NIHSS score, time in
hours from stroke onset to brain imaging and volume of ischaemic brain tissue on
DWI MRI have been shown in combination to provide better prediction of stroke
recovery than any factor alone.57 In OXVASC, data consistent with the Royal
College of Physicians stroke audit were also collected.58
3.3.22. Myocardial infarction
Data were collected consistent with the core dataset for myocardial infarction
developed by the Royal College of Physicians and the British Cardiac Society.59
ECGs were studied and reported. All cases of myocardial infarction were risk
stratified using TIMI scores.60-61 All difficult cases were discussed with a Consultant
Cardiologist for confirmation of diagnosis.
3.3.23. Peripheral vascular events
Data were collected on site, nature and management of acute PVE. This included
cases of critical limb ischaemia who subsequently underwent peripheral
angiography or other vascular intervention. Cases of acute peripheral vascular
events related to acute on chronic thrombosis or embolic episodes were also
identified as were cases of ruptured or leaking, abdominal or thoracic aorta.
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3.4 Clinical management
Clinical progress was monitored for recurrent events or other complications. All
relevant reports of investigations past and present including ECGs were
photocopied. All subsequent treatments were recorded including lifestyle advice,
drug treatment or further vascular interventions. If admitted then length of stay and
discharge destination were recorded.
3.5 Procedure for blood collection
3.5.1. Routine blood investigations
For patients attending the TIA and minor stroke clinic blood was taken for routine
investigations including urea and electrolytes, liver function tests, calcium and
albumin, thyroid function tests, C reactive protein, random glucose, lipid profile,
full blood count and erythrocyte sedimentation rate (ESR). Autoimmune profile,
clotting and thrombophilia screening were carried out if indicated.
For TIA and stroke patients under the care of other medical teams no additional
blood investigations were requested by the study team but the investigations
carried out by the medical team were recorded. For a proportion of patients with
NSTEMI or STEMI, serial cardiac enzymes were requested retrospectively to allow
comparison with OXMIS.62
3.5.2. Study blood
Patients attending the clinic for assessment and those admitted with an acute
vascular event (TIA, stroke, STEMI, PVE) who consented to the study had the
following samples collected at the same time as clinical bloods:
• 1 x plasma (green)
• 1 x serum (yellow)
• 2 x EDTA (purple)
• 2 x citrate (blue)
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Serum, plasma and citrate blood samples were centrifuged for 10 minutes at 4000
revolutions per minute. The supernatant was stored in plastic cryotubes. Whole
blood was also pipetted into cryotubes. Each was labelled with a unique
identification number, recorded in the specimen logbook and frozen at -85 °C.
If patient has been on aspirin prior to admission, the two citrate blue samples were
sent directly to Haemophilia Centre at Churchill Hospital. The date and time of
collection was stated clearly on the red haematology card, together with the date
and dose of the last aspirin taken prior to collection. Any other anti-platelets or anti¬
coagulation or statins were also recorded (Fragmin, Streptokinase and/or TPA).
Patients with unstable angina did not have any study blood taken. Patients
admitted with NSTEMI had two citrate samples sent to the Haemophilia Centre at
the Churchill Hospital for aspirin resistance studies. They did not have any other
study bloods taken.
3.5.3. Study blood at 1-month follow-up clinic
Study patients attending the clinic for 1-month follow-up had blood taken for
aspirin resistance studies at the Haemophilia Centre. Two full citrate (blue) tubes
were taken with the date and time of collection stated clearly on the red
haematology card, together with the date and dose of the last aspirin taken prior to
collection. Any other anti-platelet or anti-coagulation or statin medication was also
recorded. The blood was tested within 4-6 hours after venepuncture. If patients who
had not had aspirin resistance blood taken at their initial event, if they were
subsequently admitted and were on aspirin further citrate samples were taken and
sent for analysis at the Haemophilia Centre.
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3.5.4. Study blood at 1-year follow-up clinic
Study patients attending the clinic for 1-year follow-up had blood taken for aspirin
resistance. Two full blue tubes (lx 3.2 citrate and lx 3.8 citrate) with details as
above. Further serum and plasma samples were also taken. Clinical bloods for FBC,
TSF1, LFT U&Es and cholesterol were sent routinely for analysis.
3.5.5. Collection of acute blood samples from Biochemistry
Blood samples could be collected from Biochemistry if a fresh sample of blood was
not collected from the patient within 48 hours of event. Acute serum and plasma
were generally available for collection as these were only discarded routinely 7 days
after collection. A list of samples required, including the patients name, hospital
number and date of collection were handed in to biochemistry on Friday for
collection on Monday. Patients were ascertained rapidly and this method of
obtaining blood was not often necessary.
3.6. Procedure for further data collection of investigations
All patients were assigned a unique folder with an identification number. These
folders held data collection forms, consent or assent, follow-up data and copies of
results of relevant investigations. Copies of relevant information from the hospital
or GP record were also obtained. This was relatively easy for patients attending the
daily clinic were notes were easily accessible. For in-patients, notes were requested
after the patient's discharge and the following information copied as indicated and
incorporated into the patient's folder:
• Relevant history and examination.
• Correspondence regarding any vascular history.
• Blood results were printed off from the ORFf intranet.
• Premorbid ECG if available and serial ECGs day 1-3.
• Radiology reports of CXR, brain imaging and carotid Doppler.
• Cardiac investigation results.
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• Ankle-brachial pressure index results and Duplex results.
• Coronary, peripheral, carotid or cerebral angiography results.
3.7. Diagnosis and classification
To ensure accurate phenotyping and classification using TOAST criteria,53 all TIA
and stroke cases had a full clinical assessment, ECG, carotid Doppler and brain
imaging. Echocardiography was carried out if clinically appropriate. CT and MRI
brain imaging were formally reported and coded by the OCSP neuroradiologist
(Appendix 17). If there was no brain imaging cases were classified using the Allen
score for clinical differentiation between ischaemia and haemorrhage.64 Post mortem
reports were obtained and reviewed.
TIA and stroke cases were classified using the OCSP classification65 and TOAST
criteria63 by two study physicians. Details of all potential strokes were reviewed
regularly with Dr Rothwell (Neurologist), Professor Warlow and Dr Anslow
(Neuroradiologist).
Clinical history, serial ECGs and cardiac enzymes of all suspected MI were
reviewed at regular meetings with Dr Adrian Banning (Consultant Cardiologist). MI
cases were classified clinically, epidemiologically using OXMIS criteria62 and using
the troponin based definition advocated by ESC/ACC criteria.66
Any diagnosis of critical limb ischaemia or acute peripheral vascular events was
confirmed by the Consultant Vascular Surgeon caring for the patient.
3.8. Follow-up
Follow-up of patients presenting with acute events was coordinated with the
Department of Primary Care (Professor D Mant and colleagues). Follow-up assessed
clinical, functional and psychological outcomes, documented health services use,
and identified reasons for failure to utilise effective strategies for secondary
prevention.
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The follow-up strategy (Appendix 18) depended on the nature of the incident event.
All patients were contacted at 1, 3, 6, and 12 months from incident event either by
telephone or personal contact. ACS and PVE patients were followed up in
collaboration with the Department of Primary Care by a Research Nurse. All TIA
and stroke patients attending the daily clinic were seen at 1 and 12 months in a
follow-up clinic at the Radcliffe Infirmary (Appendix 19) by Research Nurses. A
physiotherapist saw patients at home at 3 and 6 months as part of her own D Phil
research project into TIA and stroke recovery. Hospitalised TIA or stroke patients
were invited to our 1 and 12 month follow-up clinic at the Radcliffe Infirmary and
were seen at 3 and 6 months by the physiotherapist or research nurses in the
patients own home. At follow-up patients were screened for recurrent events
(Appendix 20). Any patient considered to have a recurrent event was reassessed by
a study physician. All patients were interviewed on treatment concordance and
health resource usage. Cognition was retested using MMSE. The Rivermead
Mobility Index67 was administered focussing intentionally on disability not
impairment. This index focuses on fundamental activities such as walking or going
up stairs. It is simple to use and reasonably reliable and valid.67 The Nottingham
Extended ADL index68 was also administered. This is a 22-item interviewer
administered questionnaire covering mobility, kitchen and other domestic tasks and
leisure activities. Respondents have their level of activity assessed rather than their
capability. The Hamilton Anxiety Depression Scale69 was also applied to TIA and
stroke cases. It has the advantage that it does not contain any somatic items that
could reflect physical rather than psychological morbidity. This has been used
previously in stroke patients.70 These measurements will allow the study of stroke
recovery comparing adaptation to disability versus true motor recovery.
The timing of follow-up related to the date of the incident event that led to
notification. In the case of patients with ACS and PVE the date of ascertainment was
often close to the date of the incident event. However owing to the multiple
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overlapping sources of ascertainment there were occasions where ascertainment
was delayed. In these circumstances follow-up at 1, 3, or 6 months were missed.
In circumstances where different acute vascular events occurred close together in
time the follow-up schedule of TIA and stroke patients took priority, then ACS then
PVE. Patients undergoing vascular interventions were not followed-up. However
acute vascular events occurring in these patients were picked up through normal
ascertainment protocols.
Any recurrence leading to hospital admission led to ascertainment through normal
hot pursuit. A study physician reassessed recurrent strokes. To avoid duplication of
data, if a patient had a recurrent vascular event in a different vascular territory
within 1 year of the incident event a detailed recurrent event form was completed.
Major changes in risk factors and drug history were noted. If such a recurrence was
over a year from the incident event a new data collection form was completed. If a
recurrence in the same vascular territory occurred only a recurrent form was
completed whatever the time period.
In the second year of the study follow-up was scaled down and became more
unified owing to changes in skill mix of the staff in the unit. Follow-up of all acute
vascular events became the responsibility of the Stroke Prevention Research Unit.
From 1st April 2003, all TIA, stroke, ACS and PVE patients were followed up at 1, 6
and 12 months with yearly telephone follow up thereafter. TIA and stroke patients
were seen at all time points. ACS and PVE patients were seen at home at 1 and 12
months with a telephone follow-up at 6 months. This work was carried out by
research nurses and a physiotherapist. Recurrent events, blood pressure, Barthel
and Rankin were all collected and information was fed back to GP practices.
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3.9. Pre-morbid risk factors
All patients included in OXVASC had premorbid data collected on pre-existing risk
factors. These data were collected from GP records if available by research nurses.
Data collection was facilitated by the increased computerisation of this information
in most of the study practices. However written GP records were also scrutinised to
identify premorbid risk factors such as measured blood pressures and cholesterols
(Appendix 21). If patients died prior to ascertainment the patient record was
requested from the Family Health Strategic Authority and subsequently reviewed.
A GP encounter or summary form was obtained for all study participants. It is
envisaged that all previous blood investigations will be made available from the
Department of Biochemistry for patients registered in OXVASC.
3.10. Conclusions
The OXVASC study is the first population-based study of the incidence, case-fatality
and long term sequelae of all atherosclerotic events in the same population at the
same time. It will provide a wealth of high quality data for future analysis.
This population-based incidence study was not possible without the active
participation of GPs and other primary care staff. All of the study practices were
active collaborators. This confirms experience from OCSP71 and OXMIS62 that high
quality population-based research is feasible in Oxford.
Multiple overlapping methods of ascertainment achieved accurate and complete
identification of all acute vascular events in our population-based study (See
chapter 5). However there were several cases that occurred while the patient was an
inpatient for another indication. These patients would have already been excluded
on the basis of the initial reason for their admission and would not routinely be
subsequently reviewed. If they suffered a MI, it would be likely we would identify
them from their troponin measurement. If they had a stroke, there were many other
potential methods these events would have been ascertained including hospital
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coding, subsequently GP referral or found on brain imaging or GP searches. None
of these search strategies were fully effective and it is possible a small number were
not ascertained. In addition we were heavily reliant on our collaborating GP
practices to inform us of TIA and stroke cases that may have occurred and been
investigated out of area. Myocardial infarction managed elsewhere were often
identified through the GP searches.
Assessment of time trends of stroke incidence was possible as the OXVASC
definitions were comparable with OCSP70 (See chapter 9). This was faciltated by
regular discussion with the OCSP principal investigator and all imaging reviewed
by the OCSP neuroradiologist.
Comparison was much more difficult with respect to MI as troponin I measurement
has become the routinely measured marker of cardiac necrosis in ORH and
measurement of standard cardiac enzymes such as creatinine kinase (CK) and
aspartate transaminase (AST) were no longer routine (See chapter 2). Standard
cardiac enzymes were requested in a proportion of patients with abnormally raised
troponin I to determine the impact of troponin I on the measured incidence of
myocardial infarction.
The detailed data collected will provide a measure of the burden of vascular disease
on a population-based level (See chapter 10) and will provide welcome up to date
data that will guide funding for provision of clinical services.
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Chapter 4







Epidemiological studies are essential in order to measure the burden of stroke and
to accurately guide clinical priorities, resource provision, and help target further
research funding. A pre-requisite for comparing measured stroke incidence between
studies is identical case definition in population-based, high-quality studies
satisfying the Malmgren criteria.1-11 Variation in case definition may have important
effects on measured incidence rates.
Most stroke incidence studies have used the World Health Organisation (WHO)
case definition.12 This was developed in meetings held in 1971,1314 from which the
WHO Stroke Register protocol was developed.15 Cerebrovascular diseases were
initially defined as diseases of the brain and spinal cord of a vascular origin,13 but
the definition of 'stroke' was limited to the clinical syndrome of 'rapidly developing
clinical signs of focal or global disturbance of cerebral function leading to death or
lasting more than 24 hours with no apparent cause other than a vascular one'.1213
This excluded transient cerebral ischaemia, systemic circulatory failure,
hypertensive encephalopathy, chronic brain conditions with mental deterioration
and gradually developing neurological abnormalities and cerebrovascular lesions
discovered at autopsy that had not shown clinical manifestations in life.14 'By
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convention/ this definition has excluded subdural, extradural or intracerebral
haemorrhage caused by trauma, infection or tumour, and retinal infarction.16
In 1990, the WHO MONICA manual17 listed definite focal signs suggestive of a
stroke. It catalogued specific symptoms not acceptable as sole evidence of focal
dysfunction such as localised headache, dysarthria and vertigo. 'Stroke events' in
the context of blood disease (e.g. leukaemia, polycythaemia vera), or brain tumour
and stroke caused by trauma were also excluded.1819
In the same year the National Institute of Neurological Disorders and Stroke
(NINDS)20 published their case definition of stroke. Some groups21"22 have used this
and one group has presented its results using both WHO and NINDS definitions.3-22
Stroke was used as a generic term including infarction, haemorrhage or
subarachnoid haemorrhage (SAH). This included all disorders in which there was
an area of brain permanently affected by ischaemia or bleeding and / or in which
one or more blood vessels of the brain were primarily impaired by a pathological
process. It noted brain haemorrhage was predisposed to by blood dyscrasia and
anticoagulants but excluded traumatic associated intracranial haemorrhage.20
There are subtle differences between the commonly used stroke definitions that can
be open to interpretation. For example the WHO definition12-17 would imply that
SAH with headache and meningism and no focal neurological disturbance should
be excluded. In practice, most include these cases. Secondly, stroke is increasingly
recognised as a highly heterogeneous disorder and there are a number of conditions
that could now be considered to satisfy inclusion in a stroke (Table 4.1) incidence
study. Other cerebrovascular syndromes might also be considered to reflect the
burden of acute cerebrovascular events (Table 4.2).
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4. Syndrome without focal neurological symptoms but an appropriate vascular
cause on cranial imaging (e.g. intracranial haemorrhage with headache only but
no focal symptoms or signs).
5. Migraine with neurological symptoms lasting more than 7 days without
infarction on radiographic imaging.
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Table 4.2. Syndromes that might be considered to reflect the burden of acute
cerebrovascular events
1. Stroke syndromes without a clear ictus (e.g. history suggestive of
cerebrovascular disease but no clear acute event.
2. Persistent neurological symptoms such as isolated vertigo, diplopia, dysarthria
or hemisensory symptoms with no appropriate lesion on brain imaging.
3. Sudden deterioration in patients with significant cognitive impairment.
4. Encephalopathic syndromes that are associated with cerebral infarction on brain
imaging (e.g. cerebral vasculitis, post-partum angiopathy).
5. Sudden death certified as stroke without post mortem.
6. Diffuse hypoxic brain injury or diffuse ischaemic brain injury without focal
infarction (eg. post CABG).
7. Iatrogenic stroke in coronary or peripheral vascular intervention (e.g. during or
post coronary angiography).
8. Isolated cranial nerve palsies of presumed ischaemic aetiology.
9. Non-traumatic subdural haematoma with focal neurological symptoms or signs.
10. Cerebral venous thrombosis without cerebral infarction.
We have determined the effect of different inclusion criteria on measured stroke
incidence rates using the Oxford Vascular (OXVASC) Study. This is a large
prospective population based study of all acute vascular events including the active
pursuit of all suspected cerebrovascular events.
4.2. Methods
In the first year of OXVASC all potential acute cerebrovascular events were
identified using hot and cold pursuit with multiple overlapping sources of
ascertainment.23 The study population comprised all patients who were fully
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registered with 63 General Practitioners (FPs) based in 9 family health centres. These
collaborating practices routinely referred patients to the Oxford Hospitals, had
accurate computerised age-sex registers (ASR) and were willing to refer any patient
with a suspected acute cerebrovascular event. The population was made up of
predominantly Caucasian (94%) as well as Asian (3.1%), Chinese (1.5%) and Afro-
Caribbean (1.4%)24 and 45% were over the age of 40.
Collaborating FPs were encouraged to refer any patient whom they thought may
have had an episode of acute neurological dysfunction caused by cerebrovascular
disease. Electronically generated hospital admission registers were reviewed daily.
Patients admitted to the Medical Admissions Unit, Acute Stroke Unit, Neurology
and Neurosurgical and Rehabilitation wards were identified on a daily basis.
Causes of hospital deaths were recorded. Cases of retinal ischaemia referred to the
Eye Hospital were reviewed. All referrals for brain and carotid imaging were
identified and their notes reviewed. Monthly discharge coding data were provided
for all patients with diagnoses coded to the International Classification of Diseases
(10th Revision) (ICD-10) for cerebrovascular disease. The regional Department of
Public Health provided a list of all patients with an ICD-10 vascular code cause of
death on a quarterly basis. GP-databases were searched for all patients coded with a
cerebrovascular diagnosis and all deaths occurring in the community were
identified on regular visits to the practices. Patients were assessed as soon as
possible after the event by a study clinician at home hospital or in a dedicated clinic.
All available medical records were reviewed. Two study physicians discussed the
cases and agreed on each diagnosis.
We have determined the burden of all potential acute cerebrovascular events and
considered what might be included in a stroke incidence study depending on case
definition. We have also examined the inclusion and exclusion criteria detailed in
other published population-based studies. We have studied the effect of case
definition on measured stroke incidence rates.
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4.3. Results
In the first year of OXVASC, 1213 presumed vascular events were considered for
inclusion in this study of all incident and recurrent acute vascular events and
patients undergoing endovascular or vascular surgical procedures. There were 424
possible cerebrovascular syndromes of which 112 were assessed at the clinic and
were felt not to have a cerebrovascular aetiology (Table 4.3). There were 107
transient cerebrovascular episodes. There were 205 patients with acute
cerebrovascular events of which 161 were incident. 128 stroke syndromes were
directly comparable with WHO17 and OCSP.2
Table 4.4 describes all of the incident acute cerebrovascular events considered for
study inclusion. Of the 34 possible strokes, 1 was recurrent. Many studies did not
publish details on their inclusion and exclusion criteria with a few notable
exceptions.7-11'25 Others may have done the same but this was not published. A few
reported cerebrovascular disorders such as diffuse brain injury, 6'7'" sudden
deterioration in cognition,710-11 subdural haematoma,4-7'1011 and sudden death
certified as stroke without autopsy,21 that were subsequently excluded from their
further analysis.
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Table 4.3. Diagnoses of all incident and recurrent acute cerebrovascular events














Transient global amnesia 6
Syncope 5
Tumour or metastases 4










Table 4.4. Possible stroke-like syndromes ascertained in OXVASC and the reporting











Retinal infarction (4) 11 2 7,11
Venous infarction (1) 13 0
Spinal infarction (1) 13 0
Diffuse brain injury (5) 10 3 6-7-n
No focal deficit (1) 13 0





























In OXVASC there were 4 cases each of retinal infarction, 4 cases of presumed
ischaemic cranial nerve palsies, and 3 cases of sudden cognitive deterioration in
patients with pre-existing dementia without any other identifiable cause. There
were one case each of venous and spinal infarction and migrainous stroke. Several
other syndromes could not be ascribed to a non-vascular cause. There were also 2
patients had been certified as strokes that had died suddenly without any positive
features of a stroke diagnosis (Table 4.4).
The adjusted overall annual stroke incidence rates per 1000 England and Wales
population using the standard WHO definition17 was 1.6 (95%CI, 1.32-1.88). If all
other possible stroke syndromes were included the adjusted rate was 2.01 (95%CI,
1.70-2.32) / 1000 population (p = 0.05). (Figure 4.1)
Figure 4.1. Age adjusted incidence rates per 1000 population for all definte and




To ensure comparability between different stroke incidence studies there needs to
be similar case definitions. Heterogeneous stroke syndromes have been increasingly
recognised with better brain imaging, but it is uncertain whether some of these have
been included in published 'ideal' stroke incidence studies. We have shown that the
burden of incident acute cerebrovascular events may vary by 20% depending on
case definition.
Certain stroke syndromes are worthy of consideration for inclusion or
documentation in future incidence studies. It is likely that some of these have not
been included purely as they may present to other specialities. For example retinal
infarction has been included as an outcome in an intervention study26 but has not
been included in incidence studies. Venous stroke has been increasingly recognised
as a cause of haemorrhagic infarction. Spinal infarction has traditionally been
excluded because of its location. Migrainous strokes were included in OCSP2 but it
is uncertain whether cases were included in other incidence studies and it is not
clear whether migraine with prolonged neurological deficit without infarction on
cranial imaging should be included in incidence studies.
Although the WHO definition is the broadly accepted standard, there remain
uncertainties. Firstly, it would imply that subarachnoid haemorrhage (SAH) with
sudden onset headache, meningism and no focal or global disturbance of cerebral
function should be excluded. However, in practice most investigators include all
SAH cases. Secondly, with improved brain imaging, the diagnosis of small
intracerebral haemorrhage in patients with lone headache is increasingly recognised
and it is not clear whether this should be included. One of our cases was a 70 year
old man who had thrombolysis for a myocardial infarction. Several days later he
complained of a localised headache with no other focal neurological disturbance. CT
showed a small lobar haemorrhage. Thirdly, none of our subdural cases were
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associated with trauma but all had focal neurology. Their brain imaging led to their
exclusion.
Both the Perth7 and Melbourne11 groups described their exclusion criteria in detail
and the Rochester group25 clearly defined their inclusion criteria. The latter included
non-haemorrhagic infarction secondary to vasculitis or haematological disease but
excluded intracranial haemorrhage in the setting of haematological abnormality,
encephalitis or tumour. SAH occurring in the presence of a haematological
disturbance was excluded if no arteriovenous malformation or aneurysm was
found. The WHO MONICA register17 also excludes stroke events (implying both
cerebral infarction and haemorrhages) in cases of blood disease but the NINDS
definition20 lists blood dyscrasia as a predisposing factor to brain haemorrhage in its
classification of stroke types.
There are clinical syndromes that should continue not to be included in incidence
studies. For example, patients with diffuse ischaemic brain injury without focal
infarction after interventions such as coronary artery bypass grafting or cases where
there is no clear ictus but may have relevant evidence of ischaemic damage on
cranial imaging. Patients with acute hemisensory symptoms and no signs of
infarction on cranial imaging reflect a difficult diagnostic group. Those presenting
with sudden confusion are commonly labelled as TIA or stroke, and in those with
significant pre-existing cognitive impairment, neurological assessment is often
difficult and a vascular cause to the deterioration may be difficult to rule out
particularly if no other systemic cause is found. More research is required to clarify
the burden of such events and the prognosis for these groups.
There is considerable variation in the definition of fatal stroke cases. Most studies2_
n,i9,21,,25 reviewed death certificates and autopsy reports. Several6-9'10-25 specifically
excluded patients certificated as stroke but who died within 24 hours of onset and
had no clinical evidence of focal neurological deficit, no brain imaging and no
- 128 -
autopsy. The Novosibirsk study21 excluded certificated cases of stroke if the period
between onset of symptoms and death was less than 2 hours, there was no autopsy
or no clinical record. However, this issue remains difficult clinically and
epidemiologically. We identified an 83-year old lady admitted with an acute
coronary syndrome and severe biventricular heart failure complicated by asystolic
cardiac arrest. Her autopsy showed signs of severe heart failure with large bilateral
pleural effusions and hepatic engorgement. However, there was also an acute
parietal haemorrhagic infarction. A fairly consistent decline in stroke mortality has
been reported27 that has stabilised more recently.28 However, secular trends in stroke
types based on routine mortality data are strongly affected by changes in diagnostic
fashion.29 For ideal incidence studies, a positive diagnosis of stroke either clinically
before death, on brain imaging or autopsy should be a obligatory.
In conclusion, we have described the type of acute cerebrovascular events identified
in a well-designed population-based study fulfilling the criteria for an ideal
incidence study.1 There are potential difficulties in the interpretation of the
commonly used stroke definitions and the impact of different interpretation is
unclear. In many studies, there is a lack of published detail on inclusion and
exclusion criteria. There are a number of syndromes including retinal, venous and
spinal infarction that should be considered for inclusion or at least documented if
possible. Finally there needs to be clarity as to which stroke events should be
included in the context of haematological disease.
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Background: Validity of comparisons of stroke incidence between studies or time
periods depends on the completeness of ascertainment. Ascertainment cannot be
reliably assessed indirectly by statistical methods, such as capture-recapture. We
report the first use of direct methods to determine the completeness of different
ascertainment strategies in a population-based stroke incidence study (Oxford
Vascular Study).
Methods: We assessed completeness of two different ascertainment strategies: the
core methods common to most previous incidence studies; and core plus
supplementary methods used in some studies (including access to carotid and brain
imaging referrals and assessment of patients referred as "TIA" or "recurrent
stroke"). We assessed completeness of ascertainment in two ways. First, we
searched anonymised primary care electronic patient records of the whole study
population (n=90,542). Second, we interviewed and followed-up a high-risk subset
of our study population: all patients who had an acute coronary or peripheral
vascular event or a related elective investigation or intervention.
Results: 126 strokes were ascertained by the core plus supplementary methods, of
which only 108 were identified by the core methods alone. Only two additional
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incident strokes were identified by access to primary care electronic patient records
of the whole study population. Assessment and follow-up of 1103 high risk
individuals (5.5% of our total study population aged over 60 years) identified 16
incident strokes. However, all 16 had already been ascertained by the core plus
supplementary methods.
Conclusions: The core methods of ascertainment used in some stroke incidence
studies lead to significant under-ascertainment. However, direct assessment of
ascertainment suggests that the supplementary methods used in recent studies can
lead to near-complete ascertainment.
5.2. Introduction
Comparing stroke incidence between studies and measuring changes in incidence
over time requires studies to use the same case definitions and methods of
ascertainment.1 However, there are few published data on the effect of different
methods and intensity of ascertainment on measured incidence rates. Several stroke
and/or transient ischaemic attack (TIA) incidence studies220 have fulfilled the
methodological criteria published by Malmgren et al22 and refined by Sudlow and
Warlow,23 but there is still considerable variation in methods of ascertainment
between these studies (Table 5.1). Some differences will be related to the
organization of health care in the particular country or area, but others are more
generic. For example, the studies in Table 5.1 differed in relation to whether patients
referred as "TIA" or "recurrent stroke" were reviewed, and only half used carotid
and brain imaging referrals as a method of ascertainment. These supplementary
search strategies may have important effects on ascertainment and hence measured
incidence rates.
Assessment of the completeness of ascertainment is very difficult. Several indirect
statistical modelling methods, including capture-recapture,24 have been proposed,
but these are poorly validated and are based on several assumptions the validity of
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which is often uncertain.25 29 Indeed, capture-recapture models have frequently been
shown to be unreliable in situations where these assumptions do not hold.27 29 For
example, when sources are dependent,30 or some sources have a very low
probability of capture,31 capture-recapture methods are inapplicable. It is possible to
allow for the violation of these assumptions using covariates, but when some
categories have small numbers, the resulting estimates are unstable.32
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Table 5.1. Use of supplementary methods of ascertainment in recent 'ideal' stroke incidence
studies
TIAs TLAs Recurrent Carotid
Assessed followed strokes & brain
Reviewed up assessed scan
referrals
OXVASC (2002-)21 Y Y Y Y
OCSP (1981-86)2'3 Y Y N N
Dijon (1985/1994)4 Y Y Y N
Rochester (1985-89)5 Y N Y N
Umbria (1986-89)® Y Y Y N
Valle D'Asto (1989)7 Y N Y Y
Fredericksburg8
(1989-90)
N N Y N
Perth (1989/1995)9'10 Y Y Y Y
Warsaw (1991-92)11 N N Y N
Auckland (1991 )12 N N Y Y
Novosibirsk (1992)13 Y N Y Y
Erlangen (1994-98)14 Y N N N
Greece (1993-95)15 N N N N
Melbourne (1996)16 Y N Y Y
L' Aquila (1994-98)17 Y N Y Y
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Direct assessment of the completeness of ascertainment is time-consuming and
expensive, and has not previously been attempted in a stroke incidence study, but is
likely to be more reliable. We used two direct methods to estimate potential under-
ascertainment in the Oxford Vascular Study (OXVASC). First, to identify non-
ascertained patients who had presented to medical attention but had not been
notified to the study, we accessed anonymised primary care electronic patient
records of all of our study population. Second, to estimate the number of
individuals who had had a stroke but were not ascertained because they had not
been notified to the study or had not presented to medical attention after their
stroke, we interviewed and followed-up a subset of our population which we
considered to be at high risk of stroke: all patients who had an acute coronary or
peripheral vascular event or a related elective investigation or intervention.
5.3. Methods
Study Population: The population (mid-year n=90,542) comprised all patients who
were fully registered with 63 Family Physicians (FP) in nine primary health care
centres in Oxfordshire, UK. In the UK, patients register with a FP who provides
their primary health care and, when necessary, refers them to secondary care. The
FP receives all relevant information about specialist consultations, emergency
department attendance and hospital admissions even if these do not occur locally.
Thus, the FP holds a lifelong record of all medical events as well as details of each
consultation with the FP. This individual record is transferred to a new FP if the
patient moves residence. The collaborating FP practices were chosen if they were in
Oxfordshire routinely referring patients to the Oxford Hospitals, had an accurate
computerised age-sex register (ASR), were willing to refer any patient with a
suspected acute cerebrovascular event, and were computerised, allowing searches
for cerebrovascular diagnostic codes. The ASR provided accurate and up-to-date
estimates of the denominator allowing easy identification of cross boundary flow
and turnover within the population. The population was 94% Caucasian, 3.1%
Asian, 1.5% Chinese, and 1.4% Afro-Caribbean.33
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Case Ascertainment: We attempted to ascertain all incident or recurrent strokes and
TIAs occurring between 01/04/02 and 31/03/03. Ascertainment continued for 3
months until 30/06/03 for patients presenting late with a TIA or stroke that had
occurred on or before 31/03/03. Case ascertainment included patients who had an
event whilst temporarily away from Oxford, but not visitors to Oxford who were
not normally resident or registered with a FP. A liaison FP in each practice checked
with colleagues regularly to ensure that all relevant patients were referred, and a
study nurse visited each practice monthly. A quarterly newsletter was sent to all
FPs. The study was approved by the Oxfordshire Research Ethics Committee.
Multiple overlapping sources of case ascertainment were used to identify potential
patients using hot and cold pursuit. These are listed below as either core methods,
common to most previous incidence studies that satisfy the Malmgren criteria (table
5.1), and supplementary methods, used in some previous studies.
Core methods of case ascertainment:
Hot pursuit
• FP referral of all possible acute cerebrovascular events to daily TIA and stroke
clinic.
• Daily review of computer-generated Hospital and Emergency Department
admission registers.
• Daily review of acute medical wards and case note review.
• Daily review of all case notes of patients dying in hospital.
Cold pursuit:
• Weekly review of case notes of patients attending clinics of other local
physicians.
• Monthly contact with Paediatrics, Obstetrics and other relevant departments to
identify stroke cases.
• Monthly review of hospital diagnostic coding data.
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• Monthly visit to Coroners office and review of post mortem results.
• Monthly visits to FP practices with regular contact with liaison FP.
• Quarterly review of Department of Public Health generated mortality file of all
ICD-10 (164) stroke deaths.
Supplementary methods of case ascertainment:
• Ascertainment of all patients referred as "TIAs".
• Follow-up of all patients with incident or recurrent TIA.
• Ascertainment of all cases referred as "recurrent strokes".
• Review of all referrals for brain, carotid or cerebral vascular imaging.
Clinical assessment, investigation and case definition
The patients were assessed as soon as possible after the event by a study clinician in
a daily stroke and TIA clinic, in hospital or at home. We attempted to obtain a CT
brain scan in every case. Informed consent was sought if possible. Otherwise,
relatives were contacted to obtain assent. If a patient died prior to assessment, we
attempted to obtain an eyewitness account from a relative as well as reviewing
information in FP and hospital notes. For patients with sudden death the post
mortem result was reviewed.
The WHO definition of stroke34 was used: rapidly developing clinical symptoms
and/or signs of focal, and at times global (applied to patients in deep coma and to
those with subarachnoid haemorrhage), loss of cerebral function, with symptoms
lasting more than 24 hours or leading to death, with no apparent cause other than
that of vascular origin. A TIA was defined as an acute loss of focal cerebral or
ocular function with symptoms lasting less than 24 hours and which after adequate
investigation was presumed to be embolic or thrombotic vascular disease.35
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Direct assessment of under-ascertainment
We used two direct methods to assess under-ascertainment of stroke. First, to detect
under-ascertainment of patients who had presented to medical attention, we
searched anonymised electronic patient records of all of our study population in
each of the FP practices. Any patients with a diagnostic code related to
cerebrovascular disease were identified. If they were not already known to the
study, they were contacted after obtaining permission from the FP, and assessed.
Second, to determine under-ascertainment due possibly to patients not presenting
to medical attention after their stroke, we interviewed a subset of our population
who we considered to be at high risk of stroke. Using similar overlapping hospital
and community-based methods of case-ascertainment to those described above for
TIA and stroke, we attempted to identify all patients in our study population
presenting during the study period or the next six months with an acute coronary
syndrome (myocardial infarction or unstable angina) or an acute peripheral
vascular event (peripheral thromboembolism or critical limb ischaemia, aortic
aneurysm etc), or a related elective investigation (e.g. exercise testing and coronary
or peripheral angiography) or intervention (e.g. coronary, aortic or peripheral
angioplasty/surgery). All of these patients were interviewed by a study physician
and asked about previous diagnoses of TIA or stroke and about neurological
symptoms that might be suggestive of TIA or stroke during the study period. Their
hospital and FP medical records were also reviewed. All patients were also
followed-up for the duration of the study period by face to face interview with a
study nurse at 1, 3, 6 and 12 months after the event/intervention.
Analysis
All strokes were categorised as incident ("first-ever-in-a-lifetime") or recurrent. All
analyses of ascertainment were confined to incident strokes. We determined the
effect of core versus core plus supplementary methods of ascertainment on the
completeness and speed of ascertainment of incident strokes. We cross-referenced
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all strokes that were ascertained by the direct methods of assessment of
completeness with those identified by the core plus supplementary methods.
5.4. Results
A total of 128 incident strokes were identified by all methods of ascertainment,
including the direct methods of assessment of completeness, 115 (90%) of which
were assessed by a study physician. Twelve patients died prior to being seen and
one had their event whilst abroad, was fully investigated, but refused further
follow-up. 117 (91%) were ascertained by hot pursuit. 73 (57%) were hospitalised.
126 (98%) incident strokes were identified by the core plus supplementary methods of
ascertainment, but only 108 (84%) were identified by the core methods alone. 18
(14%) patients were referred by their GP as "TIA" but were found on assessment to
be minor strokes, of which 16 would not have been identified by core methods alone.
All of these patients were also identified from referrals for brain and carotid
imaging. Assessing all patients who were referred as "recurrent" strokes did not
identify any first-ever-in-a-lifetime strokes. Follow-up of 118 incident and recurrent
TIAs identified six incident strokes during the study period, all of which had also
been ascertained by core plus supplementary methods.
Using the core plus supplementary methods of case ascertainment, 5 incident strokes
were identified from only one source, whereas 41 cases had only one source of
ascertainment by core methods alone (table 5.2), of which 28 (71.8%) were identified
only through referral by our collaborating FPs. For 18 incident strokes the
supplementary methods of ascertainment were the first source and lead to earlier
clinical assessment than would have been the case if ascertainment had depended
on the core methods alone.
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Table 5.2. The effect of the use of different search strategies on the number of
overlapping sources of ascertainment
Core methods only Core and supplementary methods
n = 108 n = 126
One source only 41
>= 2 sources 34 37
>= 3 sources 26 48




Direct assessment of under-ascertainment
The direct tests of completeness of ascertainment identified only two incident
strokes that had not been ascertained by core plus supplementary methods. Access to
primary care electronic patient records of the whole study population identified 252
patients with a diagnostic code for cerebrovascular disease during the study period,
of which 162 were possible strokes. Further investigations of these cases identified
113 incident strokes, of which only two had not been otherwise ascertained. One
was a 66 year-old man who had a stroke while visiting the USA, where he was fully
investigated and had not wanted any further assessment on his return to the UK.
The other case was an 81 year-old woman who had a minor ischaemic stroke
following gynaecological surgery, which was not identified on hospital discharge
coding, but which was reported to her FP.
In addition, we assessed and followed up 1103 individuals who had a total of 1676
non-cerebral vascular events, investigations or interventions during the study
period or the subsequent six months. The majority (78%) of these individuals were
over 60 years of age, and comprised 5.5% of our total study population in this age
range. 146 of these individuals presented with a rapidly fatal vascular event and
could not therefore be questioned or examined. However, the hospital and FP
records of all of these individuals were reviewed. 39 patients refused to consent to
questioning or examination and a further 20 refused to consent to follow-up, and all
but 5 of these individuals allowed us to review their hospital and FP records.
As expected these patients did represent a high-risk group. We found 16 patients
who had had an incident stroke during the study period, giving a crude incidence of
nearly 15 per 1000, which was approximately double the age/sex adjusted rate
expected from the incidence rate of the study population as a whole. However, all of
these incident strokes had been ascertained by the core plus supplementary methods.
Moreover, we found no patients with a clinical history or signs suggestive of a
stroke during the study period who had not presented to medical attention.
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5.5. Discussion
The Malmgren criteria2 for "ideal" stroke incidence studies were published 17 years
ago and may no longer reflect current practice. Those studies that have satisfied the
criteria have used a commonly accepted set of multiple overlapping sources of
ascertainment, including collaboration with FPs, that we have termed the core
methods. There is usually direct collaboration with primary care physicians,
although the large population covered by the Auckland study12 meant that contact
was only possible with a random subset of FPs, and the Rochester study5 used the
unique Epidemiological Project Medical Record Linkage System, which includes
primary care. However, additional methods of ascertainment have been used in
some studies. Several studies assessed patients referred as TIA in addition to
strokes, 3-7,9,10,12,14 ancj some Qf these studies also followed-up patients with TIA.2"
4,6,9,10,21 Several studies also assessed "recurrent" strokes,413-16'21 and about half
reviewed all requests for carotid and brain imaging. 7,9,10,12,13,16,17,21 Since all of these
supplementary methods were used in OXVASC, we were able to assess their
usefulness in comparison with the core methods alone.
We found that the core methods alone failed to ascertain 15% of incident strokes.
Nearly all of these strokes were, however, identified by the supplementary methods.
Assessment of patients referred as TIAs and reviewing brain and carotid imaging
referrals were particularly important sources of additional cases and should
probably become the norm in planning future 'ideal' stroke incidence studies. These
supplementary methods also allowed more rapid ascertainment and hence earlier
clinical assessment, which is important in terms of accurate diagnosis and clinical
phenotyping.
The most novel aspect of our study was the attempt to directly assess the likely
completeness of ascertainment. We were fortunate to have access to the
anonymised electronic medical records of our whole study population. Although,
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this source did not identify all incident strokes, 90% (113/126) of incident strokes
that we identified by our core plus supplementary methods of ascertainment were
recorded on the electronic FP patient record showing that the recording of
diagnoses by FPs was reasonably efficient. It is reassuring, therefore, that only two
additional strokes were identified by this method that had not been ascertained by
our core plus supplementary methods.
We also assessed completeness of ascertainment by interview and follow-up of all
patients in our study population presenting during the study period or the next six
months with an acute coronary syndrome (myocardial infarction or unstable
angina) or an acute peripheral vascular event (peripheral thromboembolism or
critical limb ischaemia, aortic aneurysm etc), or a related elective investigation (e.g.
exercise testing and coronary or peripheral angiography) or intervention (e.g.
coronary, aortic or peripheral angioplasty/surgery). Virtually all of these patients
were interviewed and examined by a study physician, and their hospital and FP
medical records were assessed, or they agreed to review of their records, and the
vast majority consented to be followed-up regularly by face-to-face interview.
Although this group included 5.5% of our total study population aged over 60 years
and had a high incidence of stroke, we did not identify any individuals with
incident stroke who were not ascertained by our core plus supplementary methods or
any individuals who had not presented to medical attention after an incident stroke
during the study period. It is highly likely that we did miss some incident strokes in
the remainder of our study population, but our findings in the high-risk subset
suggest that ascertainment was very close to complete.
Potential shortcomings
Although we believe that our results are internally valid, the main shortcoming of
studies of methods of ascertainment in stroke incidence studies is the potential
difficulty in generalising the findings. There are likely to be subtle differences in the
way in which the core and supplementary methods of ascertainment are used in
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different studies and there are many differences between health care systems that
could influence the effectiveness of particular methods of ascertainment. For
example, in OXVASC we are fortunate to have a highly motivated group of
collaborating FPs, many of whom were also involved in the previous Oxfordshire
Community Stroke Project (OCSP).2 Completeness of ascertainment by direct
notification from FPs might be lower in studies with less collaborative colleagues in
primary care or less cohesive health care systems. Similarly, health care systems
differ in the proportion of patients with stroke, particularly minor stroke, who are
admitted to hospital for investigation and treatment. This proportion varied from
54% to 95% in the studies listed in table 1. The relative utility of the different
methods of ascertainment will therefore differ between studies. The method of
assessment of potential stroke patients who are ascertained also differs.
Despite these differences between studies, we believe that some useful and
generalisable conclusions can be drawn from our findings. Firstly, the core methods
of ascertainment that are regarded as acceptable for an "ideal" incidence study
should be supplemented where possible. For example, assessment of all referrals for
brain and cerebrovascular imaging was a very useful source of ascertainment in
OXVASC and should be possible in most studies. Similarly, assessment of patients
referred to secondary care or recorded in primary care as having had a "TIA"
identified several patients in OXVASC who had, in fact, had a minor stroke. Two
other studies reported similar proportions of strokes that were initially referred as
"TIA " (7% and 14%).3'9'10
Secondly, our direct methods of assessment of completeness of ascertainment were
time consuming and expensive but identified few additional incident strokes. We
therefore conclude that if the same core and supplementary methods of ascertainment
that were used in OXVASC are used in other stroke incidence studies in similar
heath care systems, ascertainment is likely to be close to complete. The previous
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Perth study9-10 falls into this category, and with the exception of follow-up of
patients with TIA, several other studies used comparable methods.7-16-17
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Chapter 6
Under-estimation of the early risk of recurrent stroke:









Background: There is considerable variation in the definitions used for recurrent
stroke. Most epidemiological studies exclude events within the first 28 days (e.g.
MONICA) or in the same territory as the presenting event within 21 days (e.g. most
stroke incidence studies). However, recurrence is most common during this early
period and these restrictive definitions could underestimate the benefits of early
prevention.
Methods: We determined the 90-day risk of recurrence after incident ischaemic
stroke in two population-based cohorts (Oxford Vascular Study - OXVASC;
Oxfordshire Community Stroke Project - OCSP) with the three most common
definitions: any stroke >24 hours after the incident event excluding early
deterioration not due to a stroke (definition A); as above, but excluding any stroke
within 21 days in the same territory as the incident event (definition B); and any
stroke >28 days after the incident event (definition C).
Results: 657 patients had 93 recurrent strokes during 24 hours to 90 days after the
incident event. The 90-day recurrence risks (95%CI) using definition A were 14.5%
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(11.5-17.5) in OCSP and 18.3% (10.8-25.8) in OXVASC. The equivalent risks using
definitions B and C were 8.3% (5.9-10.8) and 4.8% (2.8-6.7) respectively in OCSP and
7.0% (1.6-12.4) and 5.9% (1.0-10.9) in OXVASC. The definition A risk of recurrence
was particularly high after partial anterior (22.9%, 17.5-28.2) and posterior (19.5%,
13.0-25.9) circulation strokes.
Conclusions: The three most widely used definitions of recurrent stroke yield
markedly different 90-day risks. We suggest that, where possible, "definition A" be
adopted as the standard to avoid underestimation of risk and to allow valid
comparison of different studies.
6.2. Introduction
Approximately 30% of strokes in population-based studies are recurrent events, and
these recurrent strokes are more likely than first strokes to be disabling or fatal.
Prevention of recurrent stroke is therefore of considerable importance to both
individual and public health. Reliable data are required on the absolute risk of
recurrent stroke so that stroke prevention services can be organised appropriately
and the likely cost-effectiveness of preventive treatments can be assessed. A
standard definition of recurrent stroke is also required so that different studies can
be compared or meta-analysed appropriately, time trends in risk can be determined
accurately, and absolute risk reductions with treatment can be properly compared
across trials.
The risk of stroke in the 3 months after a TIA is as much as 15-20% in population-
based studies,1- 2 whereas the equivalent risk after a first-ever ischaemic stroke is
usually reported as 2-6%.35 However, the majority of studies reporting these low
risks excluded any potential recurrences that occurred within 21 days6-7 or 28 days8-9
after the incident stroke. The 28-day definition used in the MONICA study,8 and
other influential population-based studies,9 excludes all strokes within 28 days,
whereas other studies exclude only those events in the same vascular territory as the
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original event.10-11 The same distinction is made in studies which use the 21-day
definition, either excluding all strokes within 21 days,6-7 or only those strokes in the
same vascular territory as the original stroke.3-12-13 However, the distinction is
relatively unimportant since most early recurrences are in the same territory as the
initial stroke, particularly in patients with large artery atherosclerosis, in whom the
risk of early recurrence is highest.14 In contrast, other studies have used definitions
that included all events occurring more than 24 hours after stroke, requiring only 24
hours of neurological stability prior to any recurrence,14-16 and some appear to have
also included new episodes occurring in a different vascular territory within 24
hours of the index stroke, either a new focal neurological deficit 'occurring at any
time after the index stroke'12 or an event that is 'clearly in another part of the brain
after the preceding stroke'V11-17 Finally, some studies have given no definition and
relied on the clinical judgment of collaborating physicians,18 or have not specified
any time restriction.19
Given the importance of accurate determination of the risk of recurrent stroke, the
potential for confusion due to the widespread use of very different definitions, and
the possibility that some definitions underestimate the risk, we determined the
effect of the most widely used definitions on the measured early risk of recurrent
stroke in two high-quality population-based stroke incidence studies. Population-
based data are necessary in order to minimise selection bias.
6.3. Methods
The methods of the Oxfordshire Community Stroke Project (OCSP) and the Oxford
Vascular Study (OXVASC) are similar and have been described in detail elsewhere
(see Chapter 2).20-21 Both studies aimed to determine the incidence, risk factors and
outcome of first-ever stroke in a prospective population-based study fulfilling the
standard methodological criteria.22 In OCSP (1981-1986), all patients in a population
of 105,000 registered with 50 Family Physicians (FP) in ten practices in both urban
and rural settings. The OXVASC population covered 90,542 registered with 63 FPs
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from 9 practices, all of which had taken part in the OCSP. Each study developed
multiple comprehensive overlapping search strategies to ensure as complete
ascertainment as possible, and collaborated very closely with FPs, who were
encouraged to report all patients with a suspected acute cerebrovascular event
during the study periods. Collaborating practices provided an accurate age sex
register with accurate and up-to-date estimates of the denominator allowing easy
identification of cross boundary flow and turnover within the population.
In both studies, patients were assessed as soon as possible after the acute event by a
study physician in a study clinic, in a hospital ward, or in the community. If a
patient died prior to being seen, we attempted to obtain an eyewitness account as
well as reviewing information with FP and in hospital or ambulance service notes.
In addition to a detailed clinical assessment and routine blood tests, patients in both
studies had CT brain imaging and all incident strokes were subtyped as ischaemic
or haemorrhagic and according to the OCSP classification.23
In both studies, the date and time of onset of first stroke and the date and time of
any acute neurological deterioration in the acute phase or suspected stroke during
follow-up were recorded. In OXVASC all hospitalised patients were reviewed if any
neurological deterioration was suspected. After discharge, or for patients who were
not admitted to hospital, follow-up was of two kinds. Firstly, patients presenting to
medical attention with a recurrent stroke would be re-ascertained by the same
multiple overlapping search strategies as for incident strokes. Second, all patients
were also reviewed face to face at 1, 6 and 12 months after the incident stroke by a
research nurse. A study physician reassessed any patient in whom a recurrent
vascular event was suspected and investigations, including brain imaging, were
repeated.
A potential recurrent stroke was defined as any new acute neurological event with
symptoms lasting longer than 24 hours occurring after the initial ictus of the
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incident stroke (i.e. a definite acute worsening of an established non-progressive
deficit) that was not attributable to oedema, brain shift, haemorrhagic
transformation, intercurrent illness, hypoxia, seizures or drug toxicity. Sudden
worsening was required for consideration as a potential recurrent event, and
gradual progression of an acute deficit was excluded. Strokes occurring in patients
who had a definite TIA (i.e. they returned entirely to normal within 24 hours) but
had a subsequent stroke within 24 hours of onset of the TIA were also excluded.
Analysis
Based on the above criteria for a potential recurrent stroke, we applied the three
most widely definitions of what constituted a recurrent stroke:
Definition A. Any recurrent stroke occurring more than 24 hours after the onset of
the incident stroke, irrespective of vascular territory.14-16
Definition B. Any recurrent stroke occurring more than 24 hours after the onset of
the incident stroke in a different vascular territory and any recurrent stroke
occurring in the same territory more than 21 days after the incident stroke.3-12-13
Territories were defined as left carotid, right carotid and posterior circulation. Note
that previous users of this definition have varied in their interpretation. Most3-12-13
stated that any recurrence within 21 days should be 'clearly in another part of the
brain (eg contralateral hemisphere)'. Others classified all acute events occurring
within 21 days as part of the same event.6-7 In none of these reports is it clear
whether strokes that occurred in other vascular territories within 24 hours of the
incident stroke were included.
Definition C. Any recurrent stroke occurring more than 28 days after the incident
stroke.8-9
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Survival free of recurrent stroke was calculated from the time of onset of incident
stroke by Kaplan-Meier analysis. Survival curves were produced for the definitions
outlined above. The risk of recurrent stroke at 3 months was also determined for the
different clinical subtypes.
6.4. Results
OXVASC enrolled 128 first-ever strokes, of whom 123 (96%) had brain imaging or
post mortem. OCSP registered 675 first-ever strokes, of whom 542 (80%) had brain
imaging or post-mortem. 13 OXVASC patients and 104 OCSP patients presented
with primary intracerebral (PICH) or subarachnoid haemorrhage (SAH) and were
excluded. A further 29 (5%) OCSP patients were excluded because of inadequate
documentation of the course of the acute phase after the incident stroke. A total of
657 patients (OXVASC 115, OCSP 542) with a first-ever ischaemic stroke were
therefore studied. The mean (SD) age and proportion of females were 75 (11.6) years
and 54% (n=62) respectively in OXVASC and 73.2 (12.8) years and 50% (n=272) in
OCSP. The vascular territories of incident strokes were carotid territory in 498
(75.8%; OXVASC 91, OCSP 407) and posterior circulation in 150 (22.8%; OXVASC
24, OCSP 126). Vascular territory was uncertain in 9 (1.4%) OCSP strokes. The
OCSP classification of incident strokes was as follows: 154 (23.4%; OXVASC 28
(24.3%), OCSP 126 (23.2%)) lacunar infarcts (LACI); 230 (35.1%; OXVASC 49
(42.6%), OCSP 181 (33.4%)) partial anterior circulation infarcts (PACI), 152 (23.1%;
OXVASC 25 (21.7%), OCSP 127 (23.4%)) posterior circulation infarcts (POCI); and
121 (18.4%; OXVASC 13 (11.3%), OCSP 108 (19.9%)) total anterior circulation infarcts
(TACI).
The risks of recurrent stroke at 3 months based on the three different definitions
were highly consistent across the two studies (table 6.1). If recurrence was confined
to strokes occurring more than 28 days after the incident stroke (definition C), the 3-
month risk was 4.8% (95%CI, 2.8 - 6.7) in OCSP and 5.9% (1.0 - 10.9) in OXVASC.
The corresponding risks using the 21-day exclusion (definition B) were 8.3% (5.9 -
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10.8) and 7.0% (1.6 - 12.4) respectively. In contrast, if only events within the first 24
hours after initial ictus were excluded (Definition A) the risks increased to 14.5%
(11.5 - 17.5) and 18.3% (10.8 - 25.8) respectively. Figure 6.1 shows the Kaplan-Meier
curves for survival free of stroke for each of the definitions of recurrence.
Table 6.1. The risk of recurrent stroke 3 months after a first-ever ischaemic stroke
according to the three different definitions in two population-based studies
(OXVASC and OCSP).






Any recurrence > 24 hours
not attributable to oedema 18.3



















Figure 6.1. Kaplan-Meier curves for survival free of stroke after a first-ever




































Figure 6.2 shows the 3-month risk of recurrent stroke according to the clinical
subtype. There was no statistically significant heterogeneity in risks between
OXVASC and OCSP for any subtype and the data from the two studies were
therefore pooled. The difference in prognosis between the different subtypes was
qualitatively similar with each definition, but was most clear cut for definition A.
Patients presenting with a PACI and POCI were at highest risk of an early
recurrence with each of the different definitions, the 3-month risk ranging from 8.1%
(0.7-16.2) and 6.6% (2.2-11.0) respectively for definition C to 22.9% (17.5-28.2) and
19.5% (13.0-25.9) respectively with definition A. TACIs and LACIs had the lowest
risk of early recurrence. These differences in risk were non-significant with
definition C (p=0.07), moderately significant with definition B (p=0.01), but highly
statistically significant with definition A (p<0.0001).
- 159-
Figure 6.2. The 3 month risk of recurrent stroke according to OCSP clinical
subtype23 in OXVASC and OCSP combined.
Subgroup R^tfente Risk(%> 95% Cl
Definition A
PACI 54/ 264 22.9 17.5-28.2
POCI 28/ 151 19.5 13.0-25.9
LACI 7/ 132 5.4 1.5-9.3
TACI 4/ 110 3.9 0.1-7.6
TOTAL 93/ 657 15.1 12.3-17.9
Definition C
PACI 16/ 264 8.1 4.3-12.0
POCI 8/151 6.6 2.2-11.0
LACI 3/ 132 2.4 0-5.0
TACI 1/110 1.0 0-3.0
TOTAL 27/ 657 5.0 3.1-6.8
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% Risk (95% CI)
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PACI 26/ 264 12.5 8.0-16.9 HI
POCI 13/151 10.1 4.9-15.3 4*
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TACI 3/ 110 3.0 0.0-6.3 <•- j
TOTAL 46/ 657 8.1 5.9-10.4 ^
0 10 20 30
% Risk (95% CI)
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6.5. Discussion
Analysis of data from two population-based studies with well-defined inclusion
criteria and detailed follow-up has demonstrated that the definition used for
recurrent stroke has a major effect on the measured risk of stroke risk at 3 months.
The use of these different definitions partly explains the differences in risks of
recurrent stroke that have been reported after a first-ever ischaemic stroke (e.g. one
year risks of 7%,7 10%,10 12%,3-12 and 15%15). We believe that the 24-hour exclusion
definition of recurrence (definition A) is most clinically valid. The use of data from
previous epidemiological studies that have used the more restrictive definitions in
health economic and other effectiveness analyses will underestimate the potential
benefits of early preventive treatment.
A standard definition of recurrent stroke is also required so that different studies
can be compared or meta-analysed appropriately, time trends in risk can be
determined accurately, and absolute risk reductions with treatment can be properly
compared across trials. Our data suggest that comparisons are likely to be highly
biased unless definitions of recurrence are the same. If information on the early
clinical course of patients is insufficiently detailed to use definition A reliably in
certain types of large-scale epidemiological studies, for example, and more
restrictive definitions are therefore necessary, it is important that researchers be
aware of the potential underestimation of risk.
It is, of course, important that progression of the initial stroke, haemorrhagic
transformation of infarction, systemic disturbances, or oedema and mass effect
resulting in fluctuations in cerebral perfusion, are not misclassified as recurrent
strokes.24-25 For this reason, it has been argued that neurological deterioration
occurring after 24 hours should only be included as a potential recurrent stroke if
the neurological deficit was clearly different from the index stroke or was of a
different clinical subtype,17 or if it occurred after an unequivocal period of
neurological stability for 24 hours.14"16 These stipulations are reasonable, although it
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should be noted that early recurrence is most common after minor ischaemic stroke,
in which haemorrhagic transformation, oedema and mass effect, and systemic
disturbances are least likely.
It is also important to note the use of the different definitions also leads to biases in
analyses of the relationships between risk of recurrence and subtype of stroke. For
clinical subtype, there was no significant difference in risk of recurrence when
definition C was used, but there was highly significant heterogeneity with definition
A, with higher risks in patients with PACI and POCI strokes. This difference is due
to the fact that recurrent events tend to occur early in these subtypes of stroke.
Patients with PACI have the highest prevalence of carotid stenosis, which has been
shown to be associated with a high early risk of stroke,and a high proportion
of POCI strokes are thought to be due to large artery atherosclerosis.26 Indeed, the
risk of recurrent stroke following a posterior circulation TIA or minor stroke in
published studies is significantly higher than that in patients with carotid territory
events in studies with follow-up which commenced at the time of the event, but
significantly lower in studies in which patients were recruited after the acute
phase.27
Our study has a number of potential shortcomings. First, we were reliant on the
accuracy of the clinical recording of recurrent events. However, we were
conservative in our definition of possible recurrent stroke, only including sudden
acute neurological deterioration if there was considered to be a low probability that
it was due to oedema, brain swelling, seizures, drugs or other potential
complications of stroke, or if there was definite evidence of recurrent stroke on brain
imaging. The low early risk of recurrent stroke in patients with TACI syndromes
suggests that we were not misdiagnosing non-specific neurological deterioration as
stroke. If anything, we may have underestimated the early risk of recurrent events,
particularly minor strokes, because patients were not reviewed between hospital
discharge and one month unless they sought medical attention with a further event.
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Second, we excluded sudden acute neurological deterioration that occurred within
24 hours of the onset of the initial stroke. Such early events have not previously
been regarded as recurrent strokes, partly because the initial event cannot strictly be
called a stroke based on current definitions before 24 hours have elapsed.28
However, early deteriorations do occur in over 10% of patients randomised in acute
stroke trials, in the absence of signs of raised intracranial pressure or haemorrhagic
transformation,29 and are often associated with new ischaemic lesions of brain
imaging.30 Sudden deterioration within 24 hours in patients who had not recovered
from their initial event may therefore represent potentially preventable recurrent
ischaemic episodes. Interestingly, in the NINDS rt-tPA Stroke Trial placebo arm
patients not on aspirin at the time of their stroke were more likely to have early
clinical deterioration.31
6.6. Conclusion
We have shown that the risk of recurrence after first-ever ischaemic stroke varies
several-fold depending on the definition used, and that the definitions that are most
widely used in epidemiological studies substantially underestimate the risk,
particularly in patients with PACI and POCI syndromes. A standard definition of
recurrent stroke is required so that different studies can be compared or meta-
analysed appropriately, time trends in risk can be determined accurately, and
absolute risk reductions with treatment can be properly compared across trials.
Comparisons are likely to be highly biased unless definitions of recurrence are the
same.
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Chapter 7
A population-based study of the early risk of stroke after a TIA or minor stroke:








Objectives: To estimate the very early stroke risk after a transient ischaemic attack
(TIA) or minor stroke and thereby inform the planning of effective stroke
prevention services.
Design: Population-based prospective cohort study of patients with TIA or stroke.
Setting: Nine general practices in Oxfordshire, UK, from April 2002 to April 2003.
Participants: All patients who had a TIA (n=87) or minor stroke (n=87) during the
study period and who presented to medical attention.
Main outcome measures: The risk of recurrent stroke at 7 days, 1 month and 3
months of TIAs and minor strokes.
Results: The estimated recurrent stroke risks at seven days, one month and three
months were 8.0% (95%CI=2.3-13.7), 11.5% (95%CI=4.8-18.2) and 17.3% (95%CI=9.3-
25.3) respectively after a TIA, and 11.5% (95%CI=4.8-21.2), 15.0% (95%CI=7.5-22.5)
and 18.5% (95%CI=10.3-26.7) respectively after a minor stroke.
Conclusions: The early risks of stroke after a TIA or minor stroke are much higher
than commonly quoted. More research is required to determine whether these risks
can be reduced by more rapid instigation of prevention treatment.
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7.2. Introduction
Approximately 15% of ischaemic strokes are preceded by a transient ischaemic
attack (TIA).1 This "warning" event provides an opportunity to prevent stroke, and
guidelines highlight the need for rapid-access clinics.2"4 However, although there has
been much work on the causes and dangers of delayed assessment after acute major
stroke,56 there have been few studies of TIA or minor stroke, and it is therefore
uncertain how urgently patients must be seen for these clinics to be effective. North
American guidelines suggest that assessment and investigation should be
completed within one week of a TIA or minor stroke,7-8 and UK guidelines
recommend assessment within two weeks,2-3 but there is great variation in routine
practice.9 In the UK, the National Service Framework for older people requires that
rapid access stroke prevention services are in place by April 2004.4 However, no
guidance is given for how rapidly patients should be seen.
The danger of delaying investigation and treatment after a TIA or minor stroke
depends on the early risk of subsequent stroke. Commonly quoted risks, of 1-2% at
seven days, and 4% at one month,1-1014 are underestimates because patients were
usually recruited several weeks after the TIA. Any patients who had a major stroke
during this period were excluded. An emergency department study of patients
presenting within 24 hours of TIA, reported a stroke risk of 5.3% at two days,15 but
there are no recent data from population-based studies, and there are no data on the
risk of recurrence after minor stroke, which is also usually investigated in "TIA"
clinics.
We have studied the early risk of stroke after a TIA or minor stroke in a prospective
population based study (Oxford Vascular Study, OXVASC), in which patients are
enrolled as soon as possible after their symptoms and detailed information is
collected on the timing of symptom onset and early recurrent events.
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7.3. Methods
The OXVASC study is a population-based study of the incidence and prognosis of
TIA and stroke.16 The methods and population are similar to those in the
Oxfordshire Community Stroke Project (OCSP; 1981-1986).17 The study covers a
population of 90,542, registered with 63 general practitioners (GPs), in 9 family
health centres in Oxfordshire, UK. Registration of patients into the first year began
on 1st April 2002 and continued until 31st March 2003, and was approved by the
Oxfordshire Clinical Research Ethics Committee (Ret: CO.043).
Collaborating GPs were encouraged to immediately notify the study physician by
telephone, pager or facsimile of any patient whom they thought might have had a
TIA or stroke. Regular checks were made to ensure that all relevant patients were
referred, by means of a liason GP in each practice, a bimonthly visit to each practice
from the study research nurse, frequent personal contact between the study
physicians and the GPs, and practice diagnostic code searches. Patients presenting
to hospital were ascertained by daily review of hospital admission registers,
emergency department attendance records, the John Radcliffe Hospital stroke unit,
medical admissions and other relevant wards, and by regularly checking all brain
and carotid imaging requests. Patients not requiring hospital admission were seen
as soon as possible by a study physician in a daily (Monday to Friday) clinic, or
assessed in the community. The date and time of onset of each vascular event, and
the date and time that each patient first sought medical attention, were recorded. In
addition to standard ascertainment, follow-up was performed by face-to-face
interview with a study nurse at one and three months. If a recurrent event was
suspected the patient was re-examined by a study neurologist (PMR).
Patients were included in this analysis if they presented with a first or recurrent TIA
or minor stroke during the study period, diagnosed according to standard
criteria.1819 Minor stroke was defined as <3 on the NIH stroke scale20 at time of initial
assessment. Patients were excluded if they did not give informed consent or if
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assent from the nearest relative was unavailable. Actuarial survival free of stroke
was calculated from the time of onset of the first TIA or the first minor stroke during
the study period.
7.4. Results
We recruited 87 patients with a TIA, and 87 patients with a minor stroke (table 7.1).
83 OXVASC patients with major stroke (NIH score >3) were excluded. All patients
were followed up for 3 months. During this time 15 TIA patients had a subsequent
stroke, two of which were fatal and three of which resulted in an increased Rankin
score21 at three months follow-up. The remaining ten were minor strokes and were
therefore entered into the minor stroke analysis from the date of the minor stroke
onwards. Sixteen minor stroke patients had a subsequent stroke, of which four were
fatal and two resulted in increased disability at three months. For TIA patients, the
estimated stroke risks were 8.0% (95%CI=2.3-13.7) at seven days, 11.5% (95%CI=4.8-
18.2) at one month, and 17.3% (95%CI=9.3-25.3) at three months. These risks were
similar (log rank p=0.8, figure 7.1) in minor stroke patients: 11.5% (95%CI=4.8-21.2),
15.0% (95%CI=7.5-22.5) and 18.5% (95%CI=10.3-26.7), respectively.
Five TIA patients and three minor stroke patients had their subsequent stroke
before seeking medical attention after the initial event. If these patients are excluded
to produce more conservative estimates, the seven-day, one-month and three-month
stroke risks are 7.2% (95%CI=1.7-12.8), 8.4% (95%CI=2.4-14.4), and 13.3%
(95%CI=6.0-20.6), respectively, after a TIA, and 7.2% (95%CI=1.7-12.8), 10.9%
(95%CI=4.2-17.6), and 14.6% (95%CI=7.0-22.2), respectively, after a minor stroke.
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Table 7.1. Characteristics of patients included in the analyses
Characteristics TIA patients Minor stroke patients
Mean age (SD) 75.0 (10.8) 73.0 (12.5)
Male Sex 38 (44%) 41 (47%)
Previous TIA or stroke 36(41%) 19(22%)
Treated hypertension 48 (55%) 47 (54%)
Current smoking 5 (6%) 19 (22%)
Treated Diabetes Mellitus 10 (12%) 10 (12%)
Angina 18 (21%) 16 (18%)





Anticoagulated before event 6 (7%) 1 (1%)
Total: 87 87
28 (32%) 21 (24%)
44(51%) 36(42%)
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Figure 7.1. Cumulative risk of stroke following TIA or minor stroke
Days
7.5. Discussion
Our results support the findings of a recent re-analysis of the OCSP data which
showed similarly high risks of stroke after a first ever TIA.22 However, the OCSP
analysis was based on data collected 20 years ago, when fewer patients were likely
to be taking stroke prevention treatments, and did not include patients with minor
stroke. Our more recent data have important clinical implications. If patients
present to medical attention very soon after TIA or minor stroke, either in general
practice or in the emergency department, the risk of stroke is high and urgent
preventive treatment is required. This is particularly important for patients in
whom specific treatments are indicated, such as those with cardiac embolism or
carotid stenosis. Patients with atrial fibrillation require anticoagulation,23 and benefit
from carotid endarterectomy falls rapidly with time after a TIA or non-disabling
stroke.24 UK guidelines recommend that TIA and minor stroke patients should be
seen in clinics within two weeks,2-3 but our data show that a substantial number of
patients will have a stroke prior to being seen in such clinics. For stroke prevention
to be most effective, patients will need to be seen within the first few hours or days.
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Delays before patients are included into studies lead to underestimation of the risk
because strokes occurring during this time are excluded. We minimised these delays
in our study by prompt evaluation of patients in a daily clinic. Nevertheless, a short
delay is unavoidable, and a few patients in our study who had a recurrent stroke
before seeking medical attention for the initial TIA or minor stroke were therefore
included retrospectively. This can result in an overestimation of the risk, because an
unknown number of patients who had no recurrent event and who never presented
to the study are excluded. However, only eight patients were ascertained
retrospectively, and exclusion of these cases did not significantly alter our results.
7.6. Conclusion
The estimated risk of stroke after a TIA or minor stroke is 8-12% at seven days, and
11-15% at one month. For stroke prevention to be effective, the public would need to
be educated to seek medical attention urgently, and services organised such that all
patients with TIA or minor stroke are seen immediately. Further research is
required to determine the most effective strategy to prevent early recurrent stroke.
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Chapter 8










Data on the early risk of recurrent stroke by aetiological subtype are important for
the organization of stroke prevention.
Objective
To study the early risk of recurrent stroke by aetiological subtype.
Methods
We studied risk of recurrent stroke by aetiological subtype (TOAST classification) in
patients in two population-based studies: the Oxford Vascular Study and the
Oxfordshire Community Stroke Project. We performed a meta-analysis with data
from the only two other published studies reporting equivalent data.
Results
The four studies included 1709 strokes with 30 recurrences at 7 days, 72 at 30 days
and 113 at 3 months. Recurrent stroke risk varied between subtypes (p<0.001).
Compared with other subtypes, patients with stroke due to large artery
atherosclerosis (LAA) had the highest odds of recurrence at 7 days (OR=3.3,
95%CI=1.5-7.0), 30 days (OR=2.9, 95%CI=1.7-4.9) and 3 months (OR=2.9, 95%CI=1.9-
4.5). Odds of recurrence at 30 days for other subtypes were: cardioembolic (OR=1.0,
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95%CI=0.6-1.7); undetermined (OR=1.0, 95%CI=0.6-1.6); and small vessel stroke
(OR=0.2, 95%CI=0.1-0.6). There was no significant heterogeneity between the
studies. Although only 14% of strokes were associated with LAA, this subtype
accounted for 37% of recurrences within 7 days.
Conclusions
The risk of early recurrent stroke is highest in patients with large artery
atherosclerosis. This supports the need for urgent carotid imaging and prompt
endarterectomy.
8.2. Introduction
The risk of recurrent stroke is highest in the first few weeks after a first TIA or
1-3
stroke. Guidelines suggest that assessment and investigation of TIA or minor
stroke should be completed quickly: 1 week in North America/ and 2 weeks in the
UK.6 However, there is variation in routine practice.6 It is important to obtain more
information about which patients are at highest early risk of stroke and which
investigations are therefore most urgent. The risk of early recurrent stroke is likely
to be related to the underlying pathology. For example, the risk of stroke in patients
with symptomatic severe carotid stenosis can be as high as 5% per week during the
period prior to endarterectomy.7 However, in previous population-based studies on
the early risk of recurrent stroke by aetiological subtypes,8-9 the numbers are too
small to reliably compare subtypes or to determine the risk of recurrence within
seven days. Therefore, we compared the early risk of stroke in different aetiological
subtypes of ischaemic stroke using all available data from high-quality population
based studies. We report new data from two UK studies and have combined these




Oxford Vascular Study (OXVASC) and Oxfordshire Community Stroke Project
(OCSP)
We studied the early risk of recurrent stroke according to subtype of ischaemic
stroke in two UK population-based studies: the OCSP (1981-1986) and the first year
of the OXVASC study (2002-2003). The methods and results of the OCSP have been
previously published.310 The OXVASC pilot study used identical methods of
ascertainment of stroke and TIA to the OCSP (see chapter 2).10'11 Briefly, by
collaboration with Family Physicians (FPs) (63 in OXVASC, 50 in the OCSP), an
urban and rural population (91,000 in OXVASC, 105,000 in OCSP) was studied. FPs
were encouraged to report all patients who might have suffered a TIA or stroke
during the study periods. Strokes were also identified by daily assessment of
hospital registers, hospital diagnostic coding, review of referrals for brain and
vascular imaging, regular visits to all general practices, and review of all death
certificates and coroner's reports where relevant. In both studies, a study physician
assessed all cases as soon as possible after notification. Details of the presenting
event, clinical characteristics, and medical history were recorded from the patient,
FP records and hospital records. Study methods conformed to the quality criteria for
population-based stroke incidence studies.12
Investigation an d stroke prevention treatments
In OXVASC, all patients had neuroimaging (normally CT), ECG, and carotid
ultrasound, when possible and usually on the day of the clinical assessment. In the
OCSP, patients also routinely had CT brain imaging and ECG. However, Doppler
ultrasound was not available, and patients underwent intra-arterial carotid
angiography if there was a clinical suspicion of large vessel disease. In both studies,
echocardiography and 24 hour ECG monitoring was performed when there was a
clinical suspicion of cardiac pathology.
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In OXVASC, patients received an antiplatelet agent (at least acetylsalicylic acid,
ASA), a statin and blood pressure lowering therapy where there are no
contraindications to treatment. In the OCSP, most patients received antiplatelet
therapy (eligible patients were randomised in the UK-TIA trial,13 and had a two in
three chance of receiving ASA), and hypertensive patients received blood pressure
lowering therapy. OXVASC patients with symptomatic severe carotid stenosis (>
70%) were referred for endarterectomy. The equivalent subgroup of patients in the
OCSP were randomized in the European Carotid Surgery Trial (ECST).14
Classification of stroke subtype
In OXVASC, patients routinely had Doppler scanning of the carotid and vertebral
arteries and echocardiography. Stroke aetiology was classified prospectively
according to the TOAST criteria, on completion of the investigations.15 In 50
consecutive OXVASC cases of ischaemic stroke, two observers independently
classified the aetiology according to the TOAST criteria to determine inter-observer
reproducibility. In the OCSP, the subtype of ischaemic stroke had been classified
according to the OCSP classification,16 but the investigators had also originally
prospectively categorized stroke according to aetiology. Detailed clinical and
imaging data were also collected. This allowed us to re-classify all ischaemic strokes
according to the same aetiological categories as used in the TOAST study, using a
simple algorithm.15-17 It has been shown that this method of TOAST classification can
be applied retrospectively and that this is accurate and reproducible.17We were able
to adhere to the exact TOAST criteria for all the aetiological categories with the
exception of large vessel strokes because Doppler ultrasound was not routinely
available at the time of the OCSP. Carotid disease (> 50% stenosis of an appropriate
vessel) was diagnosed by arterial angiography, which was only performed if large
vessel disease was suspected because of the clinical assessment. Therefore, the LAA
definition in the OCSP was based primarily on the angiographic imaging. However,
we also included some strokes where the original investigators had a high index of
clinical suspicion of LAA, but angiography could not be performed.
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Recurrent strokes
Patients in OXVASC were followed up at one, three, six, nine and twelve months,
and annually thereafter. OCSP patients were followed up at one, six and twelve
months and then annually. Recurrent vascular events were also identified at the
time of the event as part of the ongoing case ascertainment in the incidence study.
Recurrent stroke was defined as a new neurological deficit fitting the standard
definition of a stroke,10 which occurred after a period neurological stability or
improvement lasting at least 24 hours. This definition excluded any new deficit
which occurred within 24 hours, or which was thought to be attributable to edema,
mass effect or hemorrhagic transformation of the incident infarct. All recurrences
within 3 months were reviewed independently by two study neurologists.
Systematic review
To identify population-based stroke incidence studies that reported data on the
early risk of recurrent stroke according to the TOAST classification of ischaemic
stroke (or similar) we:
1. Identified all stroke incidence and prognosis studies referenced in previously
published reviews, and searched Medline and Embase for any follow-up or
secondary studies using the author and study names from the primary study.
2. Performed a further search of Medline using the following search terms: "stroke
and incidence" and "stroke and subtype".
3. Hand-searched the journals Stroke and Cerebrovascular Diseases from 1990-2002.
We had four main inclusion criteria. Firstly, studies had to be population-based
studies of stroke incidence and outcome that satisfied the 12 quality criteria
published previously.12 Secondly, studies should have ascertained strokes in all
sections of the population, rather than in specific racial groups.16 Thirdly, studies
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must have had a combined brain-imaging or autopsy rate of at least 80%. Finally,
studies must have reported the frequency of early recurrent stroke (within three
months) for incident cases of ischaemic strokes classified according to the TOAST
criteria or a comparable classification. Although the study designs had to be broadly
comparable, there are still likely to be differences between studies in the reliability
of identification of early recurrent strokes, and the differentiation between an early
recurrence and a deterioration of the primary event. Therefore, different rates of
recurrence were expected between studies and so we restricted our analyses to
within study comparisons.
Statistical analyses
Patients who suffered a recurrent stroke secondary to a vascular intervention, such
as endarterectomy or angiography, were excluded from the analyses. For patients in
OXVASC and OCSP, the actuarial risk of recurrent stroke was determined by
Kaplan-Meier analysis for each aetiological subtype for the first 90 days.
Ffeterogeneity was tested with the log-rank test. We compared the risk of recurrent
stroke between the subtypes (e.g. large artery vs the rest) in a Cox regression
analysis, and corrected for age, sex, treated diabetes, daily smoking, and treated
hypertension.
For each study in the meta-analysis, the number of recurrent strokes at seven days,
one month and three months was recorded for each aetiological subtype. We
compared the odds of having a recurrent stroke for each aetiological subtype with
the odds of recurrence in the remainder. We also compared the odds of having a
recurrent stroke between individual subtypes eg. large artery vs small vessel etc. In
the meta-analysis, the odds ratios from individual studies were combined to
produce pooled estimates using the Mantel-FFaenzel-Peto method.
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8.4. Results
OXVASC and OCSP stroke-free survival analyses
151 patients with proven ischaemic stroke in the OXVASC study (1st April 2002 -
31st March 2003) and all 577 patients with proven ischaemic stroke in the OCSP
(1981-1986) were included in the survival analyses (table 8.1). Combined brain
imaging and autopsy rates were 96% in OXVASC and 81% in OCSP.
Four patients (2.6%) in the OXVASC study underwent carotid endarterectomy
within three months. No patients in OXVASC underwent endarterectomy within 1
month. In the OCSP, four patients were randomized to surgery in the ECST. Of
these, one underwent endarterectomy within one month, and two patients
underwent endarterecomy after one month but within three months of symptoms.
No patients in either study suffered a recurrent stroke as a result of a vascular
intervention.
There was good inter-observer agreement for the assignment of the TOAST
classification in 50 consecutive patients in OXVASC (86%, kappa = 0.81, 95% CI =
0.67 - 0.94). There was no difference between the two studies in the relative
proportions of the four major TOAST subtypes (p = 0.1). Therefore the data in these
two studies were combined for the survival analyses.
There was heterogeneity between the four major TOAST subtypes for the three-
month risk of recurrent stroke (log rank p < 0.001). Patients with large artery
atherosclerosis (LAA) had the highest actuarial risk of recurrent stroke at three
months (19.2%, 95% CI = 11.2 - 27.2% vs 8.1%, 95% CI = 5.8 - 10.4% in the rest; OR =
2.6, 95% CI = 1.5 - 4.4, p = 0.001, figure 8.1). LAA was related to a higher risk of
recurrent stroke at three months compared to the rest after correction for source
study, age, sex, diabetes, hypertension and smoking (OR = 2.3, 95% CI = 1.3 - 3.9, p =
0.004).
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Table 8.1. Characteristics of patients included in the four studies included in the
meta-analysis.
Patient OXVASC OCSP Erlangen Rochester
characteristics
76 73 73 76
Mean age in (11) (13) (13) (*)
years (SD)
Male sex 70 281 315 184
(46.4%) (48.7%) (41.9%) (40.5%)
Hypertension** 88 270 305 331
(53.3%) (46.8%) (57.4%) (72.9%)
Diabetes 16 60 130 94
Mellitus*** (10.6%) (10.4%) (24.5%) (20.7%)
Current Smoking 28 154 71 221
(18.5%) (26.7%) (13.4%) (48.7%)
Recurrent stroke 23 40 17 33
< 3 months (15.2%) (6.9%) (3.2%) (7.3%)
Aetiological
subtypes:
Large artery 26 78 71 74
atherosclerosis (17.2%) (13.5%) (13.4%) (16.3%)
Small vessel 33 119 120 72
stroke (21.9%) (20.6%) (22.6%) (15.9%)
Cardioembolic 37 127 143 132
(24.5%) (22.0%) (26.9%) (29.1%)
Undetermined 54 220 188 164
(35.8%) (38.1%) (35.4%) (36.1%)
Other 1 33 9 12
(0.7%) (5.7%) (1.7%) (2.6%)
Total 151 577 531 454
data not available
history of hypertension or blood pressure > 160/95 prior to stroke
differences in the definition of diabetes mellitus existed between the studies
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Figure 8.1. Three-month survival free of recurrent stroke by TOAST subtype for
patients in OXVASC and the OCSP. The corresponding actuarial risks of recurrent













Actuarial recurrent stroke risks (95%
At 7 days At 1 month At 3 months
SVS
CE
0% 2.0% (0-4.2) 3.4% (0.5-6.3)
2.5% (0.1 —4.9) 4.6% (1.3-7.9) 11.9% (6.4-17.4)
UND 2.3% (0.5-4.1) 6.5% (3.4-9.6) 9.3% (5.6-13.0)
LAA 4.0% (0.2-7.8) 12.6% (5.9-19.3) 19.2% (11.2 - 27.2)
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Systematic review and meta-analysis
We identified 22 published population-based stroke incidence studies in which
brain imaging or autopsy had been performed in 80% or more. However, only two
studies reported the early risk of recurrent stroke by aetiological subtype of
ischaemic stroke.8-9 The meta-analysis therefore included these two previous studies,
the OXVASC study and the OCSP. The clinical characteristics for each study by
aetiological subtype have been reported previously.18 In the Rochester and Erlangen
studies, combined brain imagi ng and autopsy rates were 92% and 94%.
The total number of patients was 1713. The number of patients undergoing
endarterectomy or other vascular intervention were not available for the Rochester
or Erlangen study. However, it was reported in the Rochester study that four
patients who had LAA had a recurrent stroke within the first month secondary to
interventions. These patients were excluded from all analyses. There were no cases
in OXVASC or OCSP and no reported cases in the Erlangen study of intervention-
related stroke. Of the remaining 1709 patients, 30 (1.8%) suffered a recurrent stroke
within 7 days, 72 (4.2%) within 30 days, and 113 (6.6%) within three months.
Figure 8.2 compares the risk of recurrent stroke at one month of LAA strokes with
other aetiological subtypes. Patients with LAA had the greatest risk of recurrence at
one month (OR = 2.9, 95% CI = 1.7 - 4.9, p < 0.001) and also at 7 days (OR = 3.3, 95%
CI = 1.5 - 7.0, p = 0.003) and three months (OR = 2.9, 95% CI = 1.9 - 4.5, p < 0.001).
The patients with small vessel stroke showed the lowest risk of recurrent stroke at
one month (OR = 0.2, 95% CI = 0.1 - 0.6, p < 0.003), 7 days (OR = 0.2, 95% CI = 0.0 -
1.1, p = 0.05) and 3 months (OR = 0.2, 95% CI = 0.1 - 0.5, p < 0.001). The risks in
patients with cardioembolic stroke and in patients with undetermined aetiology
were not significantly different from the rest: 1 month OR = 1.0, 95% CI = 0.6-1.7, p =
1.0 and 1 month OR = 1.0, 95% CI = 0.6-1.6, p = 1.0, respectively. There was no
significant heterogeneity between the four studies in any of the comparisons.
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The one month odds ratio of recurrent stroke in the patients with LAA compared
with SMVD was 8.4, 95% CI = 2.9-24.3, p<0.001. While only 14.3% of the total
number of patients had LAA by TOAST criteria, this group accounted for 36.7% of
recurrent strokes within 7 days (table 8.2). In contrast, small vessel stroke, present in
20.1% patients, accounted for only 3.3% 7-day recurrences.
Figure 8.2. Odds ratios for risk of recurrent stroke at 1 month for LAA vs other











OXVASC 7/26 (26.9) 2/33 (6.1) 5.71 1.1-30.4
OCSP 5 / 78 (6.4) 1/119 (0.8) 8.08 0.9-70.6
Erlangen 2/71 (2.8) 0/120 (0.1) > 15.0 0.1->100
Rochester 9/70 (12.9) 1 /72 (1.4) 10.48 1.3-85.0
Subtotal 23/245 (9.4) 4/344 (1.2) 8.40 2.9-24.3
LAAvsCE
OXVASC 7/26 (26.9) 4/37 (10.8) 3.04 0.8-11.7
OCSP 5/78 (6.4) 3/127 (2.4) 2.83 0.7-12.2
Erlangen 2/71 (2.8) 5/143 (3.5) 0.80 0.2-4.2
Rochester 9/70 (12.9) 6/132 (4.5) 3.10 1.1-9.1
Subtotal 23/245 (9.4) 18/439 (4.1) 2.39 1.3-4.5
LAA vs undetermined
OXVASC 7/26 (26.9) 6/54 (11.1) 2.95 0.9-9.9
OCSP 5 / 78 (6.4) 11 /220 (5.0) 1.30 0.4-3.9
Erlangen 2/71 (2.8) 4/188 (2.1) 1.33 0.2-7.4
Rochester 9/70 (12.9) 5/164 (3.0) 4.69 1.5-14.6
Subtotal 23 / 245 (9.4) 26 / 626 (4.2) 2.35 1.3-4.2
LAA vs all
OXVASC 7/26 (26.9) 13/125 (10.4) 3.17 1.1-9.0
OCSP 5/7B (6.4) 15/499 (3.0) 2.21 0.8-6.3
Erlangen 2/71 (2.8) 9 / 460 (2.0) 1.45 0.3-6.9
Rochester 9/70 (12.9) 12/380 (3.2) 4.52 1.8-11.2
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Table 8.2. Proportions of recurrences by aetiological subtype of ischaemic stroke,
























14.3% 36.7% 31.9% 31.0%
Small vessel
stroke
20.1% 3.3% 5.6% 6.2%
Cardioembolic 25.7% 23.3% 25.0% 30.1%
Undetermined 36.6% 33.3% 36.1% 31.0%
Figures for strokes categorized as due to other causes are not shown because patient
numbers were small.
8.5. Discussion
We found that patients with large artery cerebrovascular disease have a high early
risk of recurrent stroke compared with other aetiological subgroups, whereas the
patients with small vessel strokes have the lowest risk. These findings have
important implications for targeting stroke prevention. Guidelines suggest that
patients with TIA and stroke should be seen soon after the onset of symptoms for
the implementation of stroke prevention strategies.4'5 However, most stroke
prevention treatments (e.g. cholesterol lowering agents and antiplatelet therapy) are
unlikely to have an immediate effect or may be unsafe if implemented too quickly
(e.g. anticoagulation, antihypertensives). In contrast, carotid endarterectomy is
beneficial if implemented quickly,19 but is only applicable to a small proportion of
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patients. However, we found that only 15% of patients have LAA (mostly carotid
stenosis), and one third of early recurrences occur in this group.
One potential shortcoming of the OCSP analysis was the retrospective assignment
of the TOAST classification. This was unavoidable because the OCSP was conducted
prior to the publication of the TOAST criteria.1015 However, the investigators had
prospectively categorized stroke aetiology using a very similar in-house
classification at the time of the study, as due to atherosclerosis, cardioembolism,
small vessel disease or some other cause. We were able to use these data to classify
the patients according to the TOAST criteria. The categories used were therefore the
same as those defined by TOAST,15 although imaging data were not always
available for the categorization of large vessel disease. However, although fewer
patients had imaging of their carotid arteries in the OCSP compared with OXVASC,
the prevalence of LAA was very similar (13.5% OCSP vs 17.2% in OXVASC, table
8.1), and there was no heterogeneity between the studies for the relative risks of
recurrent stroke in patients with LAA (figures 8.3). Therefore, we feel that the
classification used in the OCSP was reasonable.
There are shortcomings with all aetiological classifications of ischaemic stroke. We
used the TOAST classification because it is the most widely used system and
because it was used in the Erlangen and Rochester studies. However, there are
undoubtedly cases where aetiology, especially small vessel stroke, is not accurately
identified.20-21
There was some variability in the overall risk of recurrence (between 1 and 4% per
month) in the four studies. This may be explained by differences in the study
populations or study design. For example, the differentiation of an early recurrent
stroke from a deterioration resulting from the primary event, but any differences
between these studies are unlikely to affect the comparisons between aetiological
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subtypes of stroke within studies. The within study comparisons all showed
consistent results and there was no significant heterogeneity.
Even in our meta-analysis, the total number of recurrent strokes was still relatively
small because we have limited it to population-based studies. However, it is
important to estimate the early risk of recurrence in an unselected group of patients.
Hospitalized patients differ significantly from non-hospitalized patients in terms of
aetiological subtypes, risk factors and prognosis.18 Consequently, any estimation of
risk of recurrent stroke by subtype in hospital-based studies is likely to be
significantly biased because patients with milder symptoms who are not
hospitalized are not usually included, and it is in this group of patients that stroke
prevention is most crucial. Nevertheless, there are some data on early recurrent
stroke risk by aetiological subtype in hospitalized patients, which also suggest that
LAA is associated with the highest risk of recurrence in this population.22-23
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Major reduction in stroke incidence and related risk factors









The incidence of stroke is predicted to rise because of the rapidly ageing population.
However, over the past two decades, findings of randomised trials have identified
several interventions that are effective in prevention of stroke. Reliable data on time-
trends in stroke incidence, major risk factors, and use of preventive treatments in an
ageing population are required to ascertain whether implementation of preventive
strategies can offset the predicted rise in stroke incidence. We aimed to obtain these
data.
Methods
We ascertained changes in incidence of transient ischaemic attack and stroke, risk
factors, and premorbid use of preventive treatments from 1981-84 (Oxford
Community Stroke Project; OCSP) to 2002-04 (Oxford Vascular Study; OXVASC).
Results
Of 476 patients with transient ischaemic attacks or strokes in OXVASC, 262 strokes
and 93 transient ischaemic attacks were incident events. Despite more complete case
ascertainment than in OCSP, age-adjusted and sex-adjusted incidence of first-ever
stroke fell by 29% (relative incidence 0-71, 95% CI 0-61-0-83, p=0-0002). Incidence
declined by more than 50% for primary intracerebral haemorrhage (0-47, 0-27-0-83,
p=0-01) but was unchanged for subarachnoid haemorrhage (0-83, 0-44-1-57, p=0-57).
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Thus, although 28% more incident strokes (366 vs 286) were expected in OXVASC
due to demographic change alone (33% increase in those aged 75 or older), the
observed number fell (262 vs 286). Major reductions were recorded in mortality rates
for incident stroke (0-63, 0-44-0-90, p=0-02) and in incidence of disabling or fatal stroke
(0-60, 0-50-0-73, p<0-0001), but no change was seen in case-fatality due to incident
stroke (17-2% vs 17-8%; age and sex adjusted relative risk 0-85, 95% CI 0-57-1-28,
p=0-45). Comparison of premorbid risk factors revealed substantial reductions in the
proportion of smokers, mean total cholesterol, and mean systolic and diastolic blood
pressures and major increases in premorbid treatment with antiplatelet, lipid-
lowering, and blood pressure lowering drugs (all p<0-0001).
Conclusions
The age-specific incidence of major stroke in Oxfordshire has fallen by 40% over the
past 20 years in association with increased use of preventive treatments and major
reductions in premorbid risk factors.
9.2. Introduction
Stroke is the second leading cause of death worldwide1 and the main cause of long-
term neurological disability in adults, with more than half of survivors being left
dependent on others for everyday activities.2 It is also a major cause of depression,
dementia, epilepsy, and falls, and patients with stroke account for more hospital
and care-home bed days than any other disorder.2 The burden of stroke is predicted
to increase over the years ahead because of the rapid rise in the elderly population
in both the developed and developing world. However, over the past two decades,
findings of randomised trials have shown that several interventions are effective in
both the primary and secondary prevention of stroke,3-6 and researchers have
estimated that full implementation of currently available preventive strategies could
reduce stroke incidence by as much as 50-80%.7-8 Country-specific data on time-
trends in stroke incidence are required to assess whether implementation of these
preventive strategies has been associated with any such change.
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Stroke mortality rates fell from the 1950s to 1980s in North America and western
Europe,9-10 but this decline has since levelled off.11-13 Although apparent trends in
stroke mortality are very difficult to interpret because of changes over time in death
certification practices and case-fatality, stroke incidence also seemed to diminish in
the 1960s and 1970s in the USA,14-15 Asia,16 and Europe.17-19 However, findings of
most subsequent studies during the 1980s and 1990s, when effective preventive
treatments had become more widely available, have shown either no change20-24 or
an increase in age-adjusted and sex-adjusted incidence.25-31 Thus, as yet, no evidence
is available that preventive strategies have reduced the incidence of stroke on a
community level.
A population-based incidence study of stroke and transient ischaemic attack (the
Oxfordshire Community Stroke Project; OCSP)32-33 was undertaken in Oxfordshire,
UK, 20 years ago. Because little change has taken place in either the racial mix of the
population or in the organisation of the health-care system in the interim we had the
opportunity to ascertain reliably the change in the incidence of stroke and transient
ischaemic attack over the past 20 years. In collaboration with the original OCSP
investigators, and using the same methods, we aimed to remeasure the incidence of
stroke and transient ischaemic attack in the same population in 2002—04 (Oxford




The OXVASC study population comprised all individuals, irrespective of age,
registered with 63 family doctors in nine general practices in Oxfordshire, UK. In
the UK, most people register with a general practice, which provides their primary
health care and holds a lifelong record of all consultations with the family doctor
and secondary-care providers and details of medications, blood pressure, and
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investigations. OXVASC included all practices that had participated in OCSP apart
from two (Thame and Deddington were excluded because they no longer refer all
patients to Oxford hospitals). The remaining practices covered the same geographic
areas as in OCSP, had the same referral patterns, held accurate age-sex registers of
their patients, and were willing to refer any patient with a suspected
cerebrovascular event to the study and allow regular searches of their computerised
diagnostic coding systems. The OXVASC population was 94% white.34 Census data
suggest that this proportion has not changed since OCSP. To estimate social
deprivation in the population served by our practices we used the index of multiple
deprivation (IMD).35 The electoral wards containing our practices were significantly
less deprived than the rest of England (mean IMD score 8-69 vs 16-98, p<0-0001) but
had a broad range of deprivation, with two of nine wards ranking in the lower third
nationally. OXVASC was approved by our local research ethics committee.
Procedures
Diagnosis was designed to be as similar as possible to the OCSP. We used the same
definitions of stroke and transient ischaemic attack.36 Furthermore, since clinical
opinion about which clinical syndromes represent transient ischaemic attack or
stroke has evolved over the past 20 years, summaries of all potential cases were
reviewed by the principal investigator of OCSP (CPW) to ensure that the application
of definitions of events was comparable. Diagnosis was based on clinical findings
and CT brain imaging as in OCSP. Furthermore, all CT scans were reviewed by a
study neuroradiologist (PA) who was also involved in OCSP, and the same criteria
were used for haemorrhagic infarction and primary intracerebral haemorrhage in
both studies.
All events were categorised as first-ever incident or recurrent on the basis of clinical
history rather than findings on brain imaging. As in OCSP, a first-ever stroke that
happened in a patient with a previous transient ischaemic attack was coded as
incident, but a first-ever transient ischaemic attack in a patient with a previous
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stroke was coded as recurrent.33 The other OCSP requirements for definition of an
incident transient ischaemic attack were also adhered to.33 As in the OCSP, patients
who had an event while temporarily away from Oxford were included, but visitors
to Oxford who were not registered with one of the study family doctors were
excluded.
After a 3-month pilot study to develop rapid and effective case-ascertainment,
formal ascertainment began on April 1, 2002. This report concerns strokes and
transient ischaemic attacks happening up until March 31, 2004. We used the five
sources of ascertainment that were used in OCSP.
(1)Collaborating family doctors reported cases to the study doctors by telephone,
facsimile, or pager as soon as they became aware of a possible transient ischaemic
attack or stroke. Patients not requiring immediate hospital admission were seen in a
dedicated daily hospital clinic or at home if transfer to hospital was believed to be
clinically inappropriate.
(2) The study team maintained frequent personal contact with the general practices
by regular visits, a quarterly newsletter, and via a liaison family doctor in every
practice.
(3)Computerised hospital diagnostic codes were reviewed regularly. In OCSP, the
Oxford record linkage system37 was used. In OXVASC, the coding department for
the Oxford Radcliffe Hospitals Trust provided a monthly general practice-specific
list of all patients with ICD10 (International Classification of Diseases, 10th revision)
codes for transient ischaemic attack and stroke and all deaths in hospital. A similar
list was obtained from the Oxford Eye Hospital and local community hospitals.
(4)Hospital admission and emergency department registers were reviewed daily.
(5)Deaths out of hospital were identified via the Coroner's Office, by review of all
death certificates in the study practices, and by ICD10 vascular death codes from the
local Department of Public Health.
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Three methods of case-ascertainment that were not used in OCSP were used in
OXVASC.
(1)Daily visits to the acute medical admissions unit, acute stroke unit, neurology
wards, and stroke rehabilitation wards, and daily contact with hospital bereavement
officers to identify all patients brought into hospital dead or who died soon after
arrival.
(2)A computer-generated list of all requests for brain and cerebral vascular imaging
was reviewed on a monthly basis and all referrals for carotid Doppler ultrasound
were reviewed every week.
(3) Patients with visual symptoms due to retinal or cerebral ischaemia were referred
directly to the study from the eye emergency unit and department of
ophthalmology, and lead clinical staff in the other departments (eg, paediatrics,
obstetrics, etc) were contacted monthly to ascertain strokes in patients under their
care.
We used two additional methods that were not used in OCSP to test the
completeness of ascertainment by the methods listed above. First, all study general
practice computer systems were searched every month for all patients coded with a
cerebrovascular diagnosis. Second, we assessed a high-risk subset of our study
population by ascertaining on a daily basis all patients admitted to hospital with an
acute coronary syndrome or an acute peripheral vascular event (ruptured aortic
aneurysm, acute limb or bowel ischaemia, etc) and all patients undergoing elective
or emergency coronary, carotid, or peripheral vascular investigations or
interventions (eg, angiography, angioplasty, endarterectomy, arterial bypass, etc). In
these patients a detailed history was taken at baseline and at 1, 3, 6, and 12 months'
follow-up to identify any transient ischaemic attacks or strokes happening during
the study period.
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A study clinician assessed patients as soon as possible after the event in hospital, in
a daily dedicated clinic, or at home. Informed consent was sought, where possible,
or assent was obtained from a relative. A standard clinical history and examination
was done. As in OCSP, premorbid handicap and disability was assessed with the
Rankin score.38 If a patient died before assessment, we obtained an eyewitness
account of the clinical event and reviewed any relevant records. We aimed to obtain
CT brain imaging in every case. If death occurred outside hospital or before brain
imaging, the autopsy result was reviewed. In view of the high rate (98%) of imaging
and autopsy in OXVASC, strokes of unknown type were coded as ischaemic for this
analysis. In OCSP, strokes that did not have brain imaging or autopsy (12%) were
classified as haemorrhages only if clinical scoring systems indicated a high degree of
certainty.32 Otherwise they were coded as ischaemic for this analysis. Diagnosis of
subarachnoid haemorrhage32 and clinical subtyping of stroke39 were the same as in
OCSP.
Both OCSP and OXVASC recorded premorbid medication and vascular risk factors
from the patient or relative, hospital records, and general practice records. The most
recent measurement of blood pressure was recorded in both studies from the
general practice records. Total cholesterol concentration was measured at the time
of assessment after the transient ischaemic attack or stroke. All surviving cases were
followed up by a research nurse or therapist at 1, 3, 6, and 12 months from the time
of the stroke and the Rankin score was calculated. If a recurrent vascular event was
suspected the patient was assessed by a study doctor.
Statistical analysis
OCSP ascertained strokes and transient ischaemic attacks initially from Nov 1, 1981,
to Oct 31, 1984, and OXVASC from April 1, 2002, to March 31, 2004. The midpoints
of these dates are exactly 20 years apart (April 1, 1983, and April 1, 2003) and these
periods form our primary comparison. OCSP subsequently ascertained strokes
again in 198632 and continued to record transient ischaemic attacks during 1985 and
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1986.33 Data from these periods were analysed separately. The original individual
patient data and the 1981-84 and 1986 age-sex study population data from OCSP
were used to recalculate the original incidences for the nine general practices in
OXVASC. Confidence intervals for incidence were calculated assuming a Poisson
distribution for the number of events. Poisson regression models, adjusted for the
age and sex structures of the two populations, were used to calculate relative
incidence for OXVASC versus OCSP. In neither OCSP nor OXVASC was there
evidence of significant variation in incidence between general practices. Incidence of
strokes of differing severity were calculated based on the Rankin score at 1 month
and also in relation to the incidence of total anterior circulation strokes.39 All
incidences were standardised to the 2001 population of England and Wales.
Changes between OCSP and OXVASC in premorbid risk factors and medication
were ascertained and significance adjusted for differences in age and sex with
regression models.
9.4. Results
476 individuals had at least one transient ischaemic attack or stroke during the
study period. Of these, 262 were first-ever incident strokes (223 ischaemic strokes,
17 primary intracerebral haemorrhages, 16 subarachnoid haemorrhages, and six
unknown) and 76 were recurrent strokes. 138 people presented to medical attention
with at least one OCSP-compatible transient ischaemic attack during the study. Of
these, 20 had a previous transient ischaemic attack, 17 had a previous stroke, and
eight had both, leaving 93 individuals with an incident transient ischaemic attack. A
further eight patients were ascertained retrospectively after presenting with a stroke
but had not sought medical attention after their transient ischaemic attack. Such
cases were not classified as incident events in the OCSP and were therefore
excluded from this analysis. Nine of 355 incident events (2-5%, 95% CI 1-2-4-8)
happened in non-whites, which was not significantly different (p=0-18) to the
proportion in OCSP (nine of 728; 1-2%, 0-6-2-4)
- 200 -
Table 9.1 compares the age and sex structure of the midstudy populations. In
OXVASC, the proportion of individuals aged 75 years or older was increased by
33% and those aged 85 years or older by 41%. If the age specific incidence of stroke
had remained the same as in OCSP, the total number of incident strokes expected in
OXVASC would be 28% greater than in OCSP (366 vs 286). In fact, the observed
number of incident strokes in OXVASC was less than in OCSP (262 vs 286).
Table 9.1 Age and sex structure of the study populations and crude incidence per
1000 population of first-ever stroke
MM Women Total
Numtef/numbei at risk Rate (95% CI) Number/numbei at risk Rate (95% Q) Numkr/iiumber al risk Rate (95% CT)
OXY^SC (age, years!
<35 0/22910 .. 0/20063 • • 0/42973
35 44 4/7401 0-27 (0 07 0-69) 2/6360 0-16(0 02 0-57) 6/13761 0-22 (0-08 0-47)
45-54 9/6168 0-73 (0-33-1-38) 6/5577 0-54 (0-20-1-17) 15/11745 0-64 (0-36-1-05)
55-64 17/4798 1-77 (1'03-2-84) 16/4574 1-75(1-00-2-84) 33/9372 1-76(1-21-2-47)
65 74 44/3403 6-46(4 70 8-68) 28/3435 4-08(2-71 5-89) 72/6838 5 26(4-12 6-63)
75-84 35/1857 9-42 (6-56-13-10) 54/2570 10-51 (7-89-13-71) 89/4427 10-05 (8-07-12-37)
>85 17/431 19 72 (11 -49-31 -58) 30/995 15-08(10-17-21-52) 47/1426 16-47(12*10-21-91)
Total 126/46968 1 34(1-12 1 60) 336/43574 1-56(1-31 1-85) 262/90542 1-45 (1-28-1-63)
OCSP (age, years)
<35 2/25 031' 0*03 (0-00-0-19) 4/22587 0-06(0-00-0-25) 6/47621 0-01(0-01-0-15)
35 44 7/5959 0-39 (0-16 O'Sl) 3/5777 0-17(0-04 0*51) 10/11706 0-28(0-14 0-52)
45-54 10/4577 0-73 (0-35-1 ■ 34) 3/4467 0-22(0-05-0-65) 13/9044 0-48 (0-26-0-82)
55-64 44/3986 3-68 (2-67-4-94) 22/4058 1-81(1-13-2-74) 66/8014 2-73(2-12-3-48)
65 74 68/2766 8-19 (6-36 10-39) 56/31 OS 6-01(4-54-7-80) 124/5874 7-04(5-85 8-39)
75-84 65/1223 17-72(13-67-22-58) 92/2006 15-29(12-32-18-75) 157/3229 16-21 (13-77-18-95)
>85 14/234 19-94 (10-90-33-46) 39/735 17-69(13-58-24-18) 53/969 18-23 (13-66-23-85)
Total 210/43749 1-60 (1-39-1-83) 219/42738 1-71 (1-49-1-95) 429/86487 1-65 (1-504-82)
Population deyiominators refer to the whole study population without exclusions.
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24 patients with incident stroke died before assessment by a study doctor and one
had his event while abroad; he was fully investigated but refused assessment other
than allowing access to his medical records. 239 (91%) of 262 patients with incident
stroke were ascertained either in our daily clinic or during their admission to
hospital. 147 (56%) were inpatients. A study doctor assessed all but two of the
patients with incident transient ischaemic attack. The median (IQR) number of days
from onset to assessment was 3 (1-9) for incident strokes and 5 (3-12) for incident
transient ischaemic attacks compared with 4 (1-12) and 5 (3-11), respectively, in
OCSP. The median (IQR) number of days from onset to brain imaging was 6 (2-13)
in OXVASC and 8 (3-14) in OCSP.
Of the 262 incident strokes in OXVASC, 220 were ascertained by OCSP methods
alone. However, the two methods of direct assessment of ascertainment suggested
that this process in OXVASC was near complete. Only four incident strokes that had
not been identified by our primary methods were identified by monthly searches of
the primary care electronic patient records of the whole study population.
Assessment and follow-up of 1103 high-risk individuals (all those who had an acute
coronary or peripheral vascular event or a related elective investigation or
intervention during the study period [5-5% of our study population @60 years])
identified 16 incident strokes, all of which had already been ascertained by other
methods.
The crude incidence per 1000 population in OXVASC was 1-87 (95% CI 1-67-2-08)
for any stroke, 1-45 (1-28-1-63) for first-ever stroke, and 0-42 (0-33-0-53) for recurrent
stroke. Recurrent events were not included in OCSP. Table 9.1 shows the number of
incident strokes by age and sex in OXVASC and during 1981-84 in OCSP. Table 9.2
shows the overall incidence of first-ever stroke adjusted to the 2001 census
population of England and Wales. There was a 29% reduction in incidence of any
first stroke between 1981-84 and 2002-04 (relative incidence 0-71, 95% CI 0-61-0-83,
p=0-0002). The incidence of stroke in OCSP in 1986 was non-significantly lower than
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in 1981-84, but incidence in OXVASC remained lower than in the two OCSP periods
combined (0-73, 0-63-0-85, p=0-0003). The standardised rates (per 1000 population)
for recurrent stroke and any stroke (recurrent or incident) in OXVASC were 0-48
(0-37-0-59) and 2-10 (1-88-2-33), respectively.
Table 9.2 Standardised overall incidence per 1000 per year (95% CI) of first stroke in
OCSP and OXVASC stratified by sex, age, pathological type, and degree of
disability at follow-up 30 days after stroke




Men 2-26 (1-95 2-57) 1 -94(1-45 2-42) 1-50(1-24 1-77) 0-66(0-53 0-82) 0-006
Women 2-28 (1-M-2-S9) 2-07 ( .1-56-2 -59) 1-74(1-44-2 03) 0-76 (0-61-0-94) 0-04
Age >85 years 18-31 (13-4-23-3) 19-99 (10-8 29-2) 16-36(11-7 21 1) 0-89(0-60-1-32) 0-67
Age <85 years 1-95 (1-76 2-15) 1-65(1-34 1 -96) 1-33(1-15-I-51) 0-68(0-58 0-80) 0-0002
Overall 2-27 (2 -06 2-49) 2-01 (1-65 2-36) 1-62(1-43 1-82) 0-71 (0-61-0-83) 0-0002
Pathological type
Ischaemic stroke 1-93 (J-73-2-13) 1-73(1-40-2-07) 1-42 (1-24-1 -61) 0*73(0-62-0-86) 0-0009
Primary intracerebral 0-22 (0-15-0-28) 0-22(0-10-0-33) 0-10(0-05-0-15) 0-47 (0-27-0-83) 0-01
haciuoiibiigc
Subarachnoid haemorrhage O il (0-07-0-16) 0-05(0-00 0-11) 0-09 (0-05-0-14) 0-83(0 41-1-57) 0-57
Rankin score at 30 days
(>-1 0-52 (0-42-0-62) 0-49(0-32-0-65) 0-55 (0-44-0-67) 1-04 (0-79-1-39) 0-75
0-75 (0 63-0-8S) 0-78(0-57-1-00) 0-47(0-36-0-57) 0-61 (0-46-0-83) 0-002
46 1-00(0-86 1-15) 0-74(0-51 0-97) 0-60(0-48 0-72) 0-60(0-50 0-72) 0-0004
Table 9.2 shows incidence in 1981-84, 1986, and 2002-04 for types of stroke.
Incidence in 2002-04 was reduced from that in 1981-84 for ischaemic stroke (0-73,
95% CI 0-62-0-86, p=0-0009) and primary intracerebral haemorrhage (0-47, 0-27-0-83,
p=0-01) but not for subarachnoid haemorrhage (0-83, 0-44-1-57, p=0-57). Stratification
of incident strokes by severity revealed no apparent reduction in incidence of minor
stroke (Rankin 0-1 at 1 month; relative incidence 1-04, 95% CI 0-79-1-39, p=0-75) but
a significant decline in disabling or fatal stroke (Rankin ©2; 0-60, 0-50-0-73,
p<0-0001). Also, a 60% reduction from 1981-84 to 2002-04 was found in the adjusted
incidence of total anterior circulation stroke syndromes (0-56/1000 [95% CI 0-54-
0-67] vs 0-23/1000 [0-15-0-30]; relative incidence 0-40, 95% CI 0-31-0-65, p=0-0003).
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Adjusted mortality rates due to incident stroke (based on survival at 1 month) also
fell from 0-44/1000 (0-35-0-54) during 1981-84 to 0-28/1000 (0-20-0-37) during 2002-
04 (0-63, 0-44-0-90, p=0-02). However, 30-day case-fatality remained the same: 17-2%
(45/262) in 2002-04 versus 17-8% (99/557) in 1981-84 (age and sex-adjusted relative
risk 0-85, 95% CI 0-57-1-28, p=0-45).
Table 9.3 Overall incidence of transient ischaemic attack in OXVASC and OCSP by
sex and age
Annua] transient Ischaemic attack incidence per 1000 (95% CI)
1981-84 (OCSP) 1985-86 (OCSP) 2002-04 (OXVASC)
Crude incidence
Men 0-37 (0-28- 0-49) 0-42 (0-30 0-58) 0-35 (0-24 0-49)
Women 0-29(0-20 0-40) 0 32 (0 21 0-46) 0-69 (0-53-0-89)
Overall 0-33 (0-27-0-41) 0-37 (0-29-0 47) 0-51 (0-41-0-63)
Standardised incidence
Men 0-49 (0-35-0-63) 0-59 (0-40-0-77) 0-37(0-24-0-50)
Women 0-37 (0-25-0-49) 0-46 (0-29-0-63) 0-77 (0-57-0-96)
Overall 0-43(0-34-0-52) 0-52 (0-40-0-65) 0-58 (0-46-0-69)
Standardised incidence by age
>85 years 0-66(0-00-1 -56) 3-88(1-01 6*76) 6-41 (3-45 9-38)
<85 years 0-42(0-33-0-52) 0-45 (0-34-0-57) 0-46 (0-35-0-56)
<75 years 0-27(0-20-0-34 ) 0-33(0-23-0-43) 0-24 (0-17-0-32)
Direct standardisation to the 2001 census population ofEngland and Wales urns used.
By contrast with the reduction in stroke incidence, adjusted incidence of transient
ischaemic attack rose slightly in OXVASC (relative incidence 1-27, 95% CI 0-95-1-71,
p=0-12); however, changes in men and women were significantly different
(p=0-0006), with slightly reduced incidence in men (0-76, 0-49-1-19, p=0-25) but an
increase in women (1-98, 1-32-2-99, p=0-003, table 9.3). However, these findings
could be biased by under-ascertainment of transient ischaemic attack in OCSP.
Figure 9.1 compares the age-specific incidence curves for transient ischaemic attack
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in OXVASC and OCSP. The increase in incidence with age was less steep in OCSP
than in OXVASC at age 65 or older and incidence seemed to fall at age 85 or older in
OCSP. A slightly reduced incidence of transient ischaemic attack was noted in
OXVASC compared with 1981-84 and 1985-86 in individuals younger than 75
years, and the sex difference was less pronounced (p=0-05): males, relative incidence
0-63, 95% CI 0-36-1-09; females 1-47, 0-79-2-74.
To identify any similar under-ascertainment of stroke in the elderly, we compared
the incidence of minor stroke by age in 1981-84 and 2002-04 (figure 9.1). Premorbid
Rankin scores in elderly people are sometimes 2 or more 1981-84 (n=429) 1986
(n=128) 2002-04 (n=262) p* and thus a crude analysis of incidence of non-disabling
stroke by age (based on post-stroke Rankin score) would lead to an artifactual
reduction in incidence with age. We therefore analysed the incidence of any stroke
with a Rankin score of less than 2 at 1 month or any stroke in a patient with a
premorbid Rankin score of 2 or more in which the post-stroke Rankin score was
unchanged. A fall was recorded in incidence of minor stroke at age 85 or older in
OCSP but not in OXVASC. The age-sex incidence curves were, however, similar for
non-minor stroke (figure 9.1). The change in incidence of non-minor stroke (relative
incidence 0-61, 95% CI 0-50-0-75, p<0-0001) is likely, therefore, to provide the best
estimate of the true change in stroke incidence between 1981-84 and 2002-04.
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Figure 9.1 Age-specific incidence of transient ischaemic attack, minor stroke, and




















































Table 9.4 shows data for premorbid risk factors and vascular preventive medication
for patients with incident first-ever stroke in OCSP and OXVASC, and table 9.5
shows data for patients with incident first-ever transient ischaemic attack. Similar
changes were present in both analyses. Significant reductions were recorded in
mean values for the most recent premorbid measurements of systolic and diastolic
blood pressure and for mean total cholesterol concentration on admission or
assessment in 2002-04 compared with 1981-84. For example, in patients with
transient ischaemic attack, we recorded a 12-6/7-0 mm Hg reduction in blood
pressure and a 40% decrease in the proportion of patients with diastolic blood
pressure 90 mm Hg or more and with systolic blood pressure 160 mm Hg or more.
The median (IQR) time from most recent premorbid blood pressure measurement
was 7 months (2-23) in OXVASC and 11 months (3-34) in OCSP (p=0-007). Also, a
1-3 mmol/L reduction was noted in mean total cholesterol concentration between
1981-84 and 2002-04 and a nearly 50% reduction in patients with values of 6-0
mmol/L or greater. A significant reduction in the number of patients who were
regular smokers before the event was also seen. In both incident transient ischaemic
attacks and strokes, the proportions of patients taking antiplatelet drugs, blood
pressure lowering drugs and lipid-lowering drugs were all significantly greater. All
the above changes were independent of differences in age and sex between OCSP
and OXVASC cases.
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Table 9.4 Premorbid risk factors and medication in patients with incident stroke
1981-84 (n=429) 1986 (n= 128) 2002-ftt (n-262) P
Baseline eharacl eristic
Mate sex 210 (49 0%) 62 (48-4%) 126(48-1%) 0-83
Mean (SD) age 72.5 (12-7) 70-6(15-3) 73-6(11-9) 0-18
Premorbid medication
Treated hypertension 85(19-8%) 26(20-3%) 124 (47-3%) <0-0001
One drug 52(12-1%) 19(14-8%) 61 (23-3%)
Two drugs 31 (7-2%) 6(4-7%) 45(17-2%)
Three dings 2 (0-5%) 1 (0-8%) 18 (6-9%)
Antiplatelet agent 16 (2-9%) 6(4-7%) 88 (33 -6%) <0-0001
Anticoagulant 5 (11%) 0 (0%) 10(3-8%) 0-02
Lipid lowering drug 0 (0%.) 0 (0%) 29(111%) <0-0001
Premorbid risk factor
Total cholesterol (nimol/L>
Mean (95% CI) baseline 6-24 (6-10-6-39)' 6-2! (5-95-6-47)1 5-40 (5-26-5-54)' <0 0001
concentration
Proportion >6-0 203 (57 • 5%) 64(58-7%) 70(29-5%) <0-0001
mmol/L
Systolic blood pressure (mm Hgl
Mean (95% CI) most re¬ 156-3 (153-6-159-0)1 352-9 (147-9-157-9)" 147 -6 (144-8-150-4)" <0-0001
cent measurement
Proportion >150mm Hg 221 (60-9%) 67(56-3%) 118 (45-7%) 0-0002
Proportion >160nim .Hg 185 (51 0%) 48(40-3%) 69 (26-7%) <0-0001
Diastolic blood pressure (rum Hp]
Mean (95% CI) most re¬ 88-0(86-7 89-3)1 87-3(85-0-89-6)" 82-0(80-5 -S3-5)" <0-0001
cent measurement
Proportion >85 mm Hg 214 (59-0%) 67 (56-3%) 104 (40-3%) <0-0001
Proportion >90 nun Hg 190 (52-3%) 58 (48 -7%) 67 (26-0%) <0-0001
Smoking
123 (32-6%)'*Current 36(29-8%)* 47(18-1%)'* <0 0001
Ex 147 (37-1%) 42 (34 ■?%) 96(36-9%)
Never 123(31-3%) 47(38-8%) 117 (45 -0%)
Diabetes 45 (10-5%) 12(9-4%) 25(9-5%) 0-69
Previous transient 52 (12-1%) 16(12-5%) 41 (15-6%) 0 19
isdiaeniic attack
Known previous atrial Fib¬ 41 (9-6%) 17(13-3%) 44(16-8%) 0-005
rillation
Previous myocardial in 78 (18-2%) 14 (10-9%) 33(12-6%) 0-05
{auction
Angina 67 (15 -6%) 22(17-2%) 32(12-2%) 0-21
Peripheral vascular disease 50 (11 -7%) 10(7-8%) 22(8-8%) 0-23
Data are number of patients (%) unless othenvise indicated. *1981-84 vs 2002-04.
Unavailable in 176 (17.7%) cases, fl9 (14.8%), , § 25 (9.5%), J66 (15.4%), IInine (7.0%),
**4(1.5%), ff36(8.1%), fftwo(0.8%)
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Table 9.5 Premorbid risk factors and medication in patients with incident transient
ischaemic attack
1981-84 (n=87) 1985-86 (n=67) 2002-ft4(n=93) P
Baseline characteristic
Male sex 49 (56-3%) 39 (58-2%) 33 (35-5%) 0-005
Mean (SD) age 67 ■4(13.2) 69-8 (12-2) 74-1 (13-0) 0-0007
Premorbid medication
Treated hypertension 43 (46-2%)
One drug 17(18-3%)
Two drugs 17 (18-3%)
Three drugs 9(9-7%)
Antiplatelet agent 4 (4-6%) I (1 -5%) 35 (37-6%) <0-0001
Anticoagulant 2 (2' 3%) 2(3-0%) 6(6-5%) 0-28
Lipidioweiing diug 0 (0%) 1 (1 -5%) 20(21-5%) <0-0001
Premorbid risk factor
Total cholesterol (nunol/L)
Mean (95% CI) baseline 6-91 (6-54-7-28)1 6-86 (6-53-7-19) 5-61 (5-35-5-87)' <0 0001
concentration




Mean (95% CI) most re 159 1 (156-8 164-4)s 153-9 (147-3-160-5)' 146-5 (141-8 151 -1)" 0-002
cent measurement
Proportion >150mm Hg 53(67-1%) 40(61-5%) 41 (44-6%) 0-003
Proportion > 160mm Ilg 42(53-2%) 26(40-0%.) 27 (29-3%) 0-002
Diastolic blood pressure
(mm Hg)
Mean (95% CI) most re¬ 87-4 (84-6-90-2)$ 85 -3 (82-6-88 -0)1 80-4 (78-0-82-8)" 0-0002
cent measurement
Proportion >85 nun Hg 44(55-7%) 35 (53-8%) 32 (34-8%) 0-006
Proportion >90 mm Hg 37 (46-8%) 29 (44-6%) 23 (25-0%) 0-003
Smoking
Current 27 (31 -0%) 16 (23-9%) 14 (15-1%) 0-03
Ex 34 (39-1%) 33 (49-3%) 39 (41 -9%)
Never 26(29-9%) .18 (26-9%) 40 (43-0%)
Diabetes 8 (9- 2%) 3 (4-5%) 9(9-7%) 0-91
Known previous atrial fib¬ 9 (10-3%) 6(9-0%) 14(15-1%) 0-34
rillation
Previous myocardial in¬ 7 (S-1%) 5(7-5%) 10(10-8%) 0-53
farction
Angina 13(14-9%) 18 (26-9%) 14(15-1%) 0-98
Peripheral vascular disease 8 (9-2%) 10 (14-9%) 6(6-5%) 0-49
Data are number ofpatients (%) unless otherwise indicate *1981-84 vs 2002-04.. t4 cases, d
five, § eight, ^ two, II one.
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A lower frequency of symptomatic arterial disease was recorded in other vascular
territories in 2002-04 incident strokes than in 1981-84 (table 9.4). This difference was
less obvious in the transient ischaemic attacks (table 9.5) but the OXVASC patients
were significantly older. Figure 9.2 shows data for premorbid preventive medication
in patients with incident transient ischaemic attacks and with incident stroke
combined and stratified according to whether or not the individual had any
previous symptomatic vascular disease—ie, primary prevention versus secondary
prevention. Secondary prevention patients had a previous transient ischaemic attack
(in stroke cases), acute coronary syndrome, angina, or symptomatic peripheral
vascular disease.
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We have shown a major reduction in the age and sex specific incidence of stroke in
Oxfordshire, UK, over the past 20 years. As a result, the absolute number of strokes
has fallen despite a 33% rise in the population older than 75 years of age and
improved ascertainment of stroke in elderly people. This decline was associated
with increased use of preventive treatment and better control of vascular risk
factors.
Hospital-based studies are prone to bias because changes in patterns of referral,
admission, or both can significantly distort longitudinal trends, and major
international studies of cardiovascular disease, such as MONICA,11 are confined to
populations younger than 75 years, thereby excluding half of all strokes (52% in
OXVASC) and the age-group of greatest current interest. OCSP was one of the first
population-based studies to measure the incidence of transient ischaemic attack and
stroke, and OXVASC has had more rigorous case ascertainment and a higher brain
imaging and autopsy rate than any previous population-based stroke incidence
study.
Studies of time-trends in disease incidence can be undermined by changes in
diagnosis and investigations. To ensure comparability, we used the same criteria as
in OCSP, and had diagnosis and inclusion reviewed by both the original OCSP
principal neurologist and one of the study neuroradiologists. However, our
estimates of the reduction in incidence of stroke are probably conservative because
of under-ascertainment of minor stroke in OCSP, particularly in elderly people. The
apparent fall in incidence of transient ischaemic attack and minor stroke in elderly
patients in OCSP is contrary to all other reliable data, and is highly likely to
represent underascertainment.
To quantify exactly the difference in completeness of ascertainment between
OXVASC and OCSP is difficult. Indirect statistical modelling methods, such as
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capture-recapture, are poorly validated in stroke incidence studies and are unstable
or inappropriate in other similar situations.40-42 We therefore used two direct
methods to assess completeness of ascertainment in OXVASC, both of which
suggested that it was near complete. However, only 84% of incident strokes
ascertained in OXVASC were identified by methods that had been used in OCSP.
Also, some evidence suggested that the public might now be more likely to seek
medical attention after stroke-like symptoms than they were at the time of the
OCSP. First, in OCSP, 28 patients were identified who presented with a stroke and
who had had a previous incident transient ischaemic attack during the study period
but had not sought medical attention.33
In OXVASC, only eight such patients were identified (relative proportion 0-60, 95%
CI 0-28-1-27). Second, in our large cohort of patients presenting with
noncerebrovascular disease (5-5% of our total study population aged more than 60
years) we recorded no patients with symptoms suggestive of transient ischaemic
attack or stroke during the study period who had not presented to medical
attention. The true reduction in age-specific incidence of stroke between OCSP and
OXVASC is best determined with events for which completeness of ascertainment is
likely to have been comparable, such as moderately disabling stroke (Rankin 2-3;
39% reduction), major disabling or fatal stroke (Rankin 4-6; 40% reduction), and
fatal stroke (37% reduction), the reductions in which were highly consistent. The fall
in total anterior circulation ischaemic stroke syndromes was even greater but had
wide confidence intervals (35-69%). Some of this reduction might indicate
improvements in management of acute stroke since OCSP, but any such effect is
likely to have been small for several reasons. First, most stroke patients in
Oxfordshire hospitals are still not currently cared for on dedicated stroke units.
Second, the number of patients with severe strokes on initial assessment (before
treatment), particularly total anterior circulation stroke syndromes and primary
intracerebral haemorrhages, suggests a genuine reduction in the incidence of major
stroke. Third, a decline in incidence of major stroke is also consistent with the fall in
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mortality due to incident fatal stroke in the absence of a reduction in case-fatality of
incident stroke.
The 53% reduction in incidence of primary intracerebral haemorrhage confirms the
suggestion of a fall of this magnitude in UK mortality and hospital discharge data.43
A few strokes that did not have brain imaging or autopsy were classified as
haemorrhages in OCSP using clinical scoring systems, but this was only done when
the score indicated a high degree of certainty.32 The identification of less clinically
obvious haemorrhages due to the higher rate on imaging and autopsy in OXVASC
will, if anything, have underestimated the reduction in incidence. A similar fall in
the incidence of intracerebral haemorrhage has been reported in Sweden, as well as
an increase in minor ischaemic strokes.44
We noted major reductions between OXVASC and OCSP in premorbid systolic and
diastolic blood pressure, total cholesterol concentration, and smoking. Some data
were missing in patients with incident strokes, attributable partly to deaths before
assessment, but the results were very similar in patients with transient ischaemic
attack, in whom data were virtually complete. The changes do not seem to be due to
any systematic change in methods of measurement. Moreover, the measured
reductions in blood pressure and cholesterol concentration are consistent with the
measured increases in use of blood pressure and cholesterol lowering drugs.
We could not study changes in premorbid risk factors and medication in the whole
of our study population, but the findings in patients with incident transient
ischaemic attack and stroke are arguably more relevant because they show the
changes in a section of the population that was clearly at risk. However, they are
likely to underestimate the changes in the at-risk population as a whole because we
could not include those patients in whom an incident transient ischaemic attack or
stroke was successfully prevented. Nevertheless, our data provide a useful
conservative measure of the changes in risk factors and medication in patients at
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risk of stroke over the past 20 years. The proportion of the reduction in stroke
incidence that is due to these improvements in risk factor control and other
preventive treatments is uncertain. Although the changes that we measured,
particularly in premorbid blood pressure, are sufficient to account for the reduction
in incidence, and might even be expected to produce a greater reduction if
representative of changes in the wider at-risk population,45 we cannot prove that the
association is causal and other changes in diet, environment, or behaviour could
also be responsible.
The reduction in stroke incidence over the past 20 years should be qualitatively
generalisable to other health-care systems that have achieved similar risk factor
modification and improvements in preventive treatment. These improvements have
been fairly recent in most countries, which could explain why reductions in stroke
incidence have not been reported in other studies done in the 1980s and early
1990s.20"31 The only exception in a population based study is the fall in stroke
incidence in Perth, Australia, between 1989-90 and 1995.46
Our quantitative findings will be less generalisable to other settings. Even within
the UK, mortality due to stroke varies by nearly 50%, with fairly low rates in
Oxfordshire. However, nearly all this variation can be accounted for by differences
in the frequency of major risk factors,47 and therefore lends support to our general
conclusions. Moreover, the stroke incidence originally reported in OCSP was
consistent with other studies of comparable quality elsewhere in Europe, North
America, and Australia.24
In conclusion, there has been a major reduction in the age-specific and sex-specific
incidence of stroke in Oxfordshire, UK, over the past 20 years. Although we cannot
prove that the fall in stroke incidence is a direct result of the measured changes in
established risk factors, the size of the changes is consistent and the measured
increase in use of preventive medication would be expected to produce a significant
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reduction in stroke incidence. If the decline in stroke incidence is due in part to risk
factor modification and preventive treatment then further reductions are possible
with more widespread stroke prevention.
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Chapter 10
What proportion of all acute vascular events in the population are cerebrovascular?









Background: In most countries, provision of services for acute assessment,
investigation and treatment of TIA and acute stroke is much less than for acute
coronary syndromes (ACS). The relative burden of acute cerebrovascular events
(TIA, ischaemic stroke, intracerebral and subarachnoid haemorrhage), acute
coronary syndrome (ACS) and acute peripheral vascular events (PVE) has never
been measured in the same population at the same time. Service provision should
be guided both by overall vascular event rates and rates of events that are not
immediately fatal and that therefore require investigation, treatment and secondary
prevention. We have determined rates of all vascular events in a detailed
population-based study.
Methods: The Oxford Vascular Study (OXVASC) is a prospective population-based
study of all incident and recurrent acute vascular events in a population of 90,542 in
Oxfordshire, UK. All patients attending relevant hospital services and clinics were
identified daily and reviewed as soon as possible after the event. All vascular deaths
and other relevant events in the community were identified via primary care
physicians.
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Results: In 18 months we registered 1107 acute vascular events in 773 patients: 434
(27.0%) acute cerebrovascular events (125 TIA, 309 strokes); 586 (36.5%) ACS (67
definite cardiac deaths, 74 probable cardiac deaths including sudden death, 75
STEMI, 168 NSTEMI and 202 unstable angina); 87 (5.4%) acute PVE (52 acute or
critical limb ischaemia, 28 acute aortic disease, 6 acute bowel ischaemia and 1
ruptured gastroepiploic artery aneurysm). Most incident TIA and stroke (281,
98.9%) were non-fatal at time of presentation to secondary care compared to 262
(73.1%) ACS and 59 (79.7%) PVE. Crude annual incidence rates were 2.06, 1.93, and
0.43 per 1000 population respectively. Non-fatal first incident accounted for 46.7% of
all acute vascular events. Of all 206 incident strokes (179 infarcts, 13 primary
intracerebral haemorrhages and 8 subarachnoid haemorrhage), 96.1% had brain
imaging or autopsy and 38.2% were managed in outpatients. In total there were 269
incident acute coronary events and 64 incident PVE. Incident strokes accounted for
38.2% of all first-ever acute vascular events. Acute coronary and PVE events
accounted for 49.9% and 11.9% respectively. Annually, 1.3% of the over 40 age
group had an acute vascular event.
Conclusions: We have documented the relative burden of all acute atherosclerotic
disease. Rates of non-fatal acute cerebrovascular and coronary events requiring
acute management and secondary prevention are similar. Provision of acute
services should reflect this. Cerebrovascular events account for 40% of all acute
vascular events in the population. Provision of clinical services and research
funding should reflect this.
10.2. Introduction
The burden of a disease is most precisely measured using high quality population-
based incidence studies with accurate follow-up of case-fatality and long term
outcome.1 Arterial diseases are the leading cause of death and disability in the
developed world, and are rapidly increasing in importance in the developing
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world.2 Although death certificate data may be easily available in some countries
they may be inaccurate. Moreover, mortality data are likely to underestimate the
overall burden of a disease. Stroke, for example, is the leading cause of neurological
disability in the developed world.3 The detailed burden of all atherosclerotic disease
has never been measured in the whole population at the same time. Although the
MONICA Project has ongoing studies of both coronary4 and stroke5 events, several
within the same country, these have not included older patients. Rochester groups
have published on both stroke6 and coronary7 events in high-quality population-
based studies. Individual stroke incidence studies satisfying the Malmgren8 quality
criteria have provided data on stroke burden.9 There have also been large
epidemiological coronary heart disease registers but these have excluded older
populations4-1012 or have been predominantly hospital-based.13 There is general
agreement however that mortality from coronary heart disease has fallen in
developed countries.14 A similar decline has been seen in mortality from stroke but
data remain conflicting and the reasons for the apparent fall in stroke mortality
remain unclear.15 However, there are wide geographical differences with an
epidemic of cardiovascular disease emerging in developing countries.16
There are no recent UK-based data on the incidence of acute cerebrovascular,
coronary and peripheral vascular events. Moreover, there have been major changes
over the last 20 years in life-style, primary and secondary prevention treatments,
and particularly in population demographics. A formal comparison of incidence
and outcome would provide a firm basis on which to guide limited resources for
services. Service provision should also reflect rates of events that are not
immediately fatal and that therefore require investigation, treatment and secondary
prevention.
We have determined both the rates of events non-fatal at time of presentation to
secondary care and the overall incidence and case-fatality of all vascular events of
any kind in a detailed population-based study.
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10.3. Methods
The methods and population for the ascertainment of TIA and stroke were similar
to those in the Oxfordshire Community Stroke Project (OCSP, 1981-1986).17 In brief,
between 1st April 2002 and 30th September 2003, we covered a population of 90,542
in nine general practices with 63 Family Practitioners (FP). These practices were all
collaborators in OCSP. Patients with TIA and stroke, acute coronary syndrome
(ACS), or acute peripheral vascular disease (PVE) (ruptured aortic aneurysms, acute
ischaemic limb, acute bowel ischaemia etc) were ascertained prospectively from
hospitals and the community. Clinical data was also recorded from patients
undergoing elective vascular procedures for atherosclerotic disease (angioplasty,
endarterectomy and bypass). Clinical data were obtained retrospectively in those
who died in the community and in whom an acute vascular cause was suspected.
In the United Kingdom, patients register with a FP who provides their primary
health care and, when necessary, refers them for specialist advice. The FP receives
all relevant information about specialist consultations and hospital admissions even
if these do not occur locally. Thus the record held by the FP forms a lifelong record
of all medical events as well as recording details of each consultation with the FP
(including blood pressure recordings, blood counts etc). This individual record is
transferred to a new FP if the patient moves residence. The practices that
collaborated in the study routinely referred patients to the Oxford Hospitals, had an
accurate computerised age-sex register (ASR), were willing to notify us of all acute
vascular events and were computerised allowing searches for diagnostic codes. The
population was predominantly Caucasian (94%) as well as Asian (3.1%), Chinese
(1.5%) and Afro-Caribbean (1.4%) and included the full range of social deprivation.
We used hot and cold pursuit with multiple overlapping sources of ascertainment to
ensure complete case finding. Collaborating FPs notified the study office by
telephone or facsimile of any patient whom they thought might have had an
episode of acute neurological dysfunction caused by cerebrovascular disease. FPs
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also informed us of patients who had not been admitted to Oxford Hospitals with
an acute vascular event or died before reaching hospital of a suspected vascular
event. Patients who had an event whilst temporarily away from Oxford were
included, but visitors to Oxford who were not normally resident and registered with
a FP were excluded. A liaison FP in each practice checked with colleagues regularly
to ensure that all relevant patients were referred. A liaison administrator in each
practice assisted in searching computerised records for patients with suspected
vascular disease. The study team maintained frequent personal contact with liaison
FPs and our research nurse visited each practice at least twice a month. A quarterly
newsletter was sent to all collaborators and FPs. A pager was carried by a Study
Physician between 8am and 6pm from Monday to Friday.
Patients with TIA or stroke not requiring hospital admission were seen in a daily
clinic. Patients were referred from the Oxford Eye Emergency Department if
diagnosed with retinal ischaemia. Patients in whom hospital assessment was not
possible were assessed in the community by a Study Physician. Computer-
generated admission registers and a list of all patients undergoing troponin I
measurement (for suspected ACS) for each of the collaborating General Practices
were studied daily. The cardiothoracic, coronary care, medical admissions, vascular
surgery and acute stroke units were visited daily. The notes of all possible patients
were reviewed to identify any cases with acute vascular events. Day case units for
patients attending for coronary or peripheral angiography were visited daily. We
identified the causes of all hospital deaths.
Practice-specific computer-generated lists of patients admitted to Rehabilitation
wards and attending the outpatient clinics of other stroke physicians were reviewed
on a weekly basis. We were notified of all patients referred for a vascular surgical
opinion, endovascular or vascular surgical intervention.
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All referrals for brain and carotid imaging for patients registered with our
collaborating FPs were reviewed on a monthly basis for cases of suspected TIA or
stroke. Paediatricians and obstetricians were contacted monthly to ascertain patients
with acute vascular events occurring in their patients. All relevant patients coded on
discharge with ICD-10 acute vascular events or OPCS-4 vascular procedures were
identified. Regular visits to the practices and the Coroner's office identified deaths
in the community. Cases with an ICD-10 vascular code cause of death were
generated and supplied by the local Department of Public Health. FP databases
were searched for all patients with a relevant diagnosis in the study period on a
regular basis.
The patients were assessed as soon as possible after the event by a study clinician.
Patients were assessed in the daily stroke and TIA clinic, in hospital or at home.
Informed consent was sought if possible. If the patient was too unwell then relatives
were contacted to obtain assent. FP and hospital medical records were reviewed and
previous illnesses, premorbid medication and blood pressure measurements were
recorded. Relevant FPs were interviewed and all available documentation reviewed
to ascertain an accurate cause of death for fatal cases.
Standard definitions of TIA and stroke were used.18'19 We attempted to get brain and
carotid imaging in every TIA and stroke cases and echocardiography if clinically
indicated. Diagnoses were confirmed initially with a Consultant Neurologist (PMR)
and to ensure comparability with OCSP, by their lead investigator (CPW).
Unstable angina was defined clinically as symptoms of angina at rest, new-onset
angina on minimal exertion, or crescendo angina that was clinically more severe,
more prolonged or more frequent based on a pre-existing stable pattern20 resulting
in admission to hospital with no rise in cardiac markers of necrosis.
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Myocardial infarction was defined in the presence of two of three of an appropriate
clinical history, typical ECG changes and raised cardiac enzymes (troponin I or
standard cardiac enzymes CK and AST). A Consultant Cardiologist (AB) reviewed
diagnoses.
Critical limb ischaemia was defined as a combination of rest pain and / or gangrene
in patients often with multi-level arteriopathic disease. An acute peripheral vascular
event was defined as any acute vascular catastrophe of any part of the arterial
system leading to hospital admission. Consultant Vascular Surgeons caring for the
patient confirmed all diagnoses.
Patients were also included in the study if they attended for any endovascular or
vascular surgical intervention of the investigation or treatment of atherosclerotic
disease.
Survivors of acute vascular events were followed prospectively and interviewed by
Research Nurses at 1, 3, 6, and 12 months from the time of their event at home, clinic
or hospital. A standardised questionnaire was designed to detect recurrent vascular
events. If a recurrent stroke was suspected the patients was reassessed by a study
physician. More detailed information on functional ability, activities of daily living,
social and psychological functioning were also collected.
For the purpose of this analysis, all patient events have been recorded including
follow up vascular interventions, strokes, MI and PVE. Recurrent events were
defined as any further vascular event occurring after a prior period of 24 hours
stability. Death within 30 days to an acute vascular event was attributed to the




Between 1st April 2002 and 30th September 2003, 1909 patient events in 1346 patients
were considered for inclusion. After careful review 303 were excluded as they failed
to meet our diagnostic criteria for vascular events. Of the remaining 1606 patient
episodes, there were 434 (27.0%) acute cerebrovascular events, 586 (36.5%) ACS and
87 (5.4%) acute PVE. There were 188 (11.7%) acute endovascular or vascular surgical
interventions as a consequence of mainly the acute coronary and peripheral
vascular events. The remaining 311 (19.4%) patient episodes were endovascular or
surgical interventions performed to investigate atherosclerotic disease (Figure 10.1).
There were 1107 acute vascular events in 773 patients. Of 434 acute cerebrovascular
events, there were 125 (28.8%) TIA and 309 (71.2%) strokes. Of 586 ACS, 67 (11.4%)
were definite cardiac deaths, 74 (12.6%) probable cardiac deaths including sudden
death, 75 (12.8%) ST elevation myocardial infarction (STEMI), 168 (28.7%) non ST
elevation myocardial infarction (NSTEMI) and 202 (34.5%) cases of unstable angina.
Of 87 PVE, there were 37 (42.5%) episodes of acute limb ischaemia, 28 (32.1%) acute
aortic disease (21 abdominal, 7 thoracic), 15 (17.2%) critical limb ischaemia, 6 (10.3%)
acute bowel ischaemia and 1 (1.1%) ruptured gastroepiploic artery aneurysm
(Figure 1).
Of the 284 first-ever-in-a-lifetime acute TIA and strokes, 281 (98.9%) were non-fatal
at time of presentation to hospital or outpatient facilities. Of 358 incident ACS, 262
(73.1%) were non-fatal at time to presentation to secondary care facilities. Of the 74
acute PVE, 59 (79.7%) were non-fatal at time of presentation. The annual incidence
rates adjusted for England and Wales population (2001) were 2.34, 2.09, and 0.48 per
1000 population respectively (Figure 10.2).
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Figure 10.1. Burden of vascular events in first 18 months of OXVASC
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Figure 10.2. Population adjusted annualised / 1000 population rates of non fatal at










TIA & stroke ACS PVE
In patients aged > 65 years, the crude annualised rates were rates were 15.44, 9.04
and 2.52 respectively. Non-fatal first ever acute cerebrovascular events accounted
for 46.7% of all acute vascular events. Non-fatal incident acute coronary and PVE
events account for 43.5% and 9.8% respectively. TIA and stroke became more
common than ACS after age 65 (Figure 10.3).
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Table 10.1. Adjusted annualised incidence rates of TIA and stroke, ACS and PVE
non-fatal at time of presentation to secondary care.
Adjusted annual incidence rates per 1000 (95% CI)
to the population of England & Wales 2001
TIA & stroke ACS PVE
Males 2.02(1.66-2.37) 2.59 (2.19-2.98) 0.57 (0.39-0.76)
Females 2.64(2.22-3.06) 1.62 (1.3-1.94) 0.39 (0.23-0.56)
Overall 2.34(2.06-2.61) 2.09(1.84-2.35) 0.48(0.36-0.60)
Figure 10.3. Age specific incidence rates for non-fatal TIA and stroke, ACS and PVE
at time of presentation to secondary care
Age (years)
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There were 206 incident strokes with 100 (48.5%) males and a mean age of 74.4 (11.7)
years ranging between 38 and 94 years. 82 (39.8%) were managed wholly on an
outpatient basis. The combined brain imaging and autopsy rate for incident strokes
was 96.1%. There were 179 (86.9%) infarcts, 13 (6.3%) primary intracerebral
haemorrhages and 8 (3.9%) subarachnoid haemorrhage. 8 patients had neither brain
imaging nor autopsy. The overall age and sex adjusted 30-day case fatality (95% CI)
was 11.0% (7.2 - 14.7). It was 8.2% (4.9 - 11.5), 33.7% (13.7 - 53.7), 12.6% (1.8 - 25) for
cerebral infarction, PICH and SAH respectively.
There were 269 incident acute coronary events with 175 (65.1%) males and a mean
age of 71.8 (13) years ranging between 29 and 98 years. There were 57 (21.1%)
STEMI, 113 (42%) NSTEMI, 52 (19.3%) definite cardiac deaths and 47 (17.5%)
probable cardiac deaths including sudden deaths. The overall 30-day adjusted case
fatality of incident myocardial infarction including out-of-hospital deaths was
32.5%. (26-39). For ACS cases non-fatal at time of presentation, the age and sex
adjusted 30 day case fatality rates were 5.7% (3.0 - 8.4). The comparable case fatality
for non-fatal incident strokes was 11.9% (8.0 - 15.8).
There were 64 incident PVE, 38 (59.4%) males, mean age 73.6 (14.1) including 32
(50%) acute limb ischaemia, 27 (42.2%) acute aortic pathology, 5 (7.8%) acute
ischaemic bowel. Overall age and sex adjusted case fatality was 26.5% (16.1 - 36.9).
Case fatality for different acute vascular events are summarised in Table 10.3. The
incidence of ACS increased in parallel with stroke (Figure 10.4). Incident strokes
accounted for 38.2% of all incident acute vascular events. Acute coronary and PVE
events accounted for 49.9% and 11.9% respectively.
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Table 10.2. Adjusted annualised incidence rates of first-ever-in-a-lifetime major
acute vascular events - stroke, myocardial infarction (including cardiac and sudden
death) and PVE (excluding critical ischaemia)
Adjusted annual incidence rates per 1000 (95% CI)
to the population of England & Wales 2001
Stroke ACS PVE
Males 1.60(1.29-1.92) 2.76 (2.35-3.17) 0.61 (0.41-0.8)
Females 1.81 (1.46-2.15) 1.62(1.29-1.94) 0.45 (0.27-0.62)
Overall 1.71 (1.47-1.94) 2.17(1.91-2.43) 0.53(0.4-0.65)








Table 10.3. Age and sex adjusted 30 day case fatality rates for incident stroke,
myocardial infarction (including cardiac and sudden death) and PVE (excluding
critical ischaemia)
Adjusted 30 day case fatality rates (%) (95% CI)
to the population of England & Wales 2001
Stroke ACS PVE
Males 8.0 (5.0-12.2) 31.9 (23-40.8) 26.8 (13.2-40.4)
Females 12.8 (7.6-20.2) 33.1 (23.5-42.7) 26.0 (9.9-42.2)
Overall 11.0 (7.2-14.7) 32.5 (26-39) 26.5 (16.1-36.9)
During the 18 months studied there were 1098 acute vascular events in 761 patients
over the age of 40 in our population of 90542 (age >= 40, n=39301). Annually, 1.3% of
the over 40 age group had an acute vascular event. 1.6% of this age group had an
acute vascular event or an endovascular or vascular procedure for the investigation
or treatment of atherosclerotic disease.
10.5. Discussion
We have carefully detailed the relative burden of all incident and recurrent, acute
and elective atherosclerotic vascular events occurring in a well-defined population
in a high quality study. Our results have important implications.
Firstly, we have shown that the burden of incident non-fatal acute cerebrovascular
events (TIA and stroke) reaching either hospital or outpatients is similar, if not
greater than the number of ACS reaching hospital alive. We have included TIA
within this analysis as there is increasing evidence that this should be treated as a
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high-risk medical emergency21-22 akin to unstable angina. Non-fatal first-ever acute
cerebrovascular events accounted for 47% of all acute vascular events and become
increasingly more common with age. In contrast to acute cerebrovascular events, a
large proportion of ACS die prior to reaching hospital and thus their impact on
secondary care is limited. Moreover, the case-fatality for non-fatal acute
cerebrovascular events was double that for ACS reaching hospital alive (11.9% vs
5.7%). If all fatal and non-fatal major incident acute vascular events were included,
stroke still accounted for 38% of acute events. There is an urgent need for the
provision of services for the assessment, investigation and treatment of acute
cerebrovascular events that are at least equivalent to that for coronary events.
Secondly, the majority of incident strokes were admitted to hospital in our study
with 40% managed wholly in the outpatients considerably lower than the
proportion of non-hospitalised strokes in OCSP (59%).17 There is considerable
variation between developed countries in the proportion of incident strokes
managed as outpatients ranging from less than 10%23 25 to 25%.26 This rise in
admission for stroke may reflect a less nihilistic attitude to the management of
stroke in the UK. There has also been a realisation of the availability and importance
of brain imaging. Our combined brain imaging and autopsy rate of 96.1% is one of
the highest amongst quality population-based studies and allowed accurate
phenotyping of incident stroke cases.
Thirdly, the overall adjusted 30 day case fatality for incident strokes in our study
was 11%, markedly lower than OCSP (19%) done two decades ago. This fall in case
fatality is of a greater magnitude of the decline in case fatality reported in other
studies in Finland (33%),27- Japan (26%),28 Russia (24%)29 and Auckland (16%).30
Other groups in Perth31 and Rochester6 have not shown a fall in case-fatality. The
first year results from OXVASC have also shown a decrease in stroke incidence
particularly in severe strokes, (See Chapter 9) and these results together would
suggest that the decline in stroke mortality is associated with the greater recognition
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of more minor strokes and the reduction in incidence of severe stroke. These are
likely to be related to the consequence of blood pressure and cholesterol lowering
treatment. More minor strokes and the fall in severe strokes have lead to a fall in
case fatality. It may be that the latter is also associated with improved acute stroke
care in hospital.
Finally, our results confirm the heavy burden of atherosclerotic disease. Annually,
more than 1 in 100 (1.3%) patients in our population over the age of 40 had an acute
vascular event. 1.6% of this age group had an acute vascular event or needed an
endovascular or vascular procedure for the investigation or treatment of
atherosclerotic disease. The implications for resource provision in terms of both
primary and secondary care for assessment, investigation and secondary prevention
of this group are huge.
There are some potential problems with our study. In our analysis of non-fatal
stroke cases we included any patient who reached hospital alive even though they
may have died within 24 hours. There were 15 cases that died within 24 hours.
However, even if these were excluded from the burden analysis, non-fatal acute
cerebrovascular events would still have accounted for 45.6% of acute vascular
events. Death certification has inherent potential inaccuracies. However, we have
used all available data including FP records, post mortem reports and coding data
provided by the Department of Public Health to confirm cause of death. We also
had a close collaboration with FPs and discussed difficult cases of sudden death
were cause was unclear. The relatively low yield of acute stroke from death
certificates confirms the increasing knowledge that stroke is rarely a cause of
sudden death32 and the increased hospitalisation of patients with suspected stroke.
10.6. Conclusions
We have presented detailed information on the relative burden of all acute vascular
events. This provides evidence for a real need to properly resource the clinical
- 235 -
management of acute cerebrovascular events. It also highlights the importance of
redressing the considerable imbalance in clinical and research funding between
stroke and MI.33 Further research will be required to assess the disability and long
term outcome associated with different atherosclerotic diseases.
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The Oxford Vascular Study aims to study the incidence, outcome and long term
sequelae of all atherosclerotic events in the same population at the same time. This
thesis has aimed to introduce the reasons behind setting up this important study
and the methods that have been used. I have presented results from data collected
from the first 18 months of the study with particular emphasis to acute
cerebrovascular disease. There is a great deal more data, including that collected for
ACS and PVE, that will provide further excellent research opportunities in the
future.
11.2. Case definition
I have also examined the effect of case definition on measured stroke incidence rates
(see Chapter 4). Case definition for stroke is not uniform and there are subtle but
perhaps important differences. These differences are unlikely to have a major
impact on incidence but there remains a strong case for clarity in the presentation of
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inclusion and exclusion criteria. Moreover, there is a real need to assess and follow-
up cases of 'possible TIA' or 'possible stroke' as the comparison of the prognosis of
these events with other definite events may often be the best (and only) guide to the
nature of the initial diagnosis. It is these data that can often be so important in
guiding further clinical practice. We have been collecting these 'possible' cases and
we hope once we have sufficient numbers that we can make real progress in
defining these events more clearly.
11.3. Case ascertainment
Although I have presented only a small part of the available data for analysis, one of
the specific aims of the first year was to ensure that case ascertainment was reliable
and complete. This study was only possible because of the important contribution of
our collaborating GPs. We have been able to show that our ascertainment was near
complete using our multiple overlapping sources of ascertainment (see Chapter 5).
Moreover, we have used a novel method of direct assessment of ascertainment by
interviewing patients with other vascular disease at high risk of further vascular
events to try and ascertain acute cerebrovascular events. Despite interviewing more
than 5% of the at risk population of our practices, we found no TIA or strokes that
we had not ascertained through other methods already.
11.4. Capture - recapture
There has been a great deal of interest in the application of capture-recapture
techniques1 to stroke incidence studies to assess completeness of ascertainment (see
Chapter 5). We feel there is now an excellent opportunity to assess the validity of
this technique in a population where other methods have ensured near complete
ascertainment so the number of strokes is actually known. We plan to use the
capture-recapture model on our data using different methods of ascertainment and
various covariates to assess this technique further.
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11.5. Further research
We have collected detailed data (see Chapter 3) on a large number of patients with
actue vascular events and those attending for elective endovascular or vascular
surgical procedures. There remains a great deal of data to be analysed on many
areas including triggers for vascular events, life events, dietary habit, sleep disorder,
cognition and mood disorder. Once larger numbers have been enrolled into the
study, it is hoped that it will be possible to compare between acute vascular events
and to register community case controls from the collaborating practices. The
collection of premorbid data including blood pressures, lipids and other
biochemical and haematological markers will provide an exciting resource for
further study. Moreover, the collection and storage of blood from actue vascular
cases will allow further study of novel risk factors that may be discovered in the
future.
11.6. The daily clinic and the early risk of recurrence
Our daily rapid access TIA and minor stroke clinic has provided an important
clinical service to our collaborating GPs as well as providing an excellent vehicle for
research. This clinic sees a wide variety of cases with many neurological and general
medical diagnoses (see chapter 4). It is also clear that only through this type of
research is it possible to really measure the high early risk of recurrence after TIA or
minor stroke (see Chapter 7). Further study has shown that the patients most at risk
are those with large artery disease (see Chapter 8). We have also shown that the
early risk of recurrence after stroke can be falsely low if the definition of recurrence
is restrictive (see Chapter 6). Data from OXVASC and OCSP2 needs to be analysed
to determine the risk of neurological deterioration within the first 24 hours of their
initial event.
11.7. The further development of the daily 'clinic'
There is a real need from a service perspective to continue providing patients with
rapid expert assessment after their TIA or stroke, with early if not same day brain
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imaging, and the urgent need to address the aetiology of their event with carotid or
cardiac imaging. In the near future we plan to start admitting patients referred by
our collaborating practices with TIA or stroke for urgent assessment, brain imaging
with MRI including diffusion weighted sequences and CT angiography to image
both the arch of aorta and carotid system both extracranial and intracranial. With
this detailed information, we would hope to treat patients more aggressively
potentially with early anti-platelet therapy, statins and ACE inhibitors if
appropriate. By comparing these cases with those registered in the first two years of
the study, there may be the power to show a benefit in the reduction of risk of early
recurrence after TIA or minor stroke.
There has been considerable debate regarding the diagnosis of TIA in the context of
infarction on brain imaging.3 With the above rapid assessment and brain imaging
protocols we should be able to add to this debate with detailed, well phenotyped
population-based data. Moreover, it will be potentially possible to more accurately
define the aetiology of stroke by using the existing TOAST4 classsification or
developing other classifications based on the results of further study.
11.8. Incidence and time trends in TIA and stroke
We have shown a marked reduction in the incidence of stroke since OCSP using
comparable methods particularly in severe stroke (see Chapter 9). We have also
shown an increase in TIA but this is likely to be explained by a more informed
public and medical profession as well as better ascertainment. Alongside this we
have shown the increase in use of anti-platelet therapy, blood pressure lowering and
cholesterol lowering treatment and a reduction in the mean systolic and diastolic
blood pressure cholesterol level since the 1980s. There has also been an important
decline in case fatality. These results should be however treated with caution. They
represent data from only the first year of study and numbers are small, and
although the differences that have occurred over the last 20 years are highly
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statistically significant, we should await more results over a longer time period with
greater numbers.
11.9. Burden of vascular disease
OXVASC has also provided preliminary population-based data on the
epidemiology of the other acute vascular events. There are few high quality
population-based studies studying the burden of acute peripheral vascular disease.
Moreover, studies of coronary disease have often excluded more elderly groups. In
preliminary data presented in this thesis (see chapter 10), we have shown the
continued increasing incidence of myocardial infarction in parallel to stroke with
age. This is an important result in coronary heart disease epidemiology and requires
further study.
11.10. Conclusions
The burden of atherosclerotic disease is huge (see Chapter 10). OXVASC has and
will provide high quality up-to-date information for politicians, service providers
and clinicians to help guide the prioritisation of limited resources to best fit the
needs of the population. Future study of this population-based cohort will allow the
comparion and measurement of the burden of long-term disability in this large
group of patients.
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Appendix 3 GP 'K84' codes
19 Beaumont Street K84016
East Oxford Health Centre K84032
Berinsfield Health Centre K84023
The Malthouse Surgery K84027
Exeter Health Centre K84022
Kidlington & Yarnton Medical Group K84082
Church Street Practice K84033
Marcham Road Family Health Centre K84041
The Abingdon Surgery K84054
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Cerebral infarction - stroke non specified
Cerebral artery occlusion and dissection of cerebral arteries
Acute and chronic cerebrrovascular diseases
ICD-10 Ischaemic Heart Disease
1200 -1209
1210 -1 469
Angina or unstable angina
Myocardial infarction, complications or atherosclerotic
cardiovascular disease
ICD-10 Peripheral Vascular Disease
1700 -1798 All peripheral vascular disease, aortic disease















Evac haematoma temp lobe brain - Drainage of subdural
Coronary artery byp ass surgery
Coronary angiography and intervention
Aortic surgery
Carotid and cerebral artery procedures
Peripheral arterial surgery or endovascular intervention
Amputations








Visual loss unknown cause
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1219 Ischaemic heart disease
1251 Ischaemic heart disease
1249 Ischaemic heart disease
1259 Ischaemic heart disease
1710 Diseases of arteries, arterioles and capillaries
1711 Diseases of arteries, arterioles and capillaries
1713 Diseases of arteries, arterioles and capillaries
1714 Diseases of arteries, arterioles and capillaries
1718 Diseases of arteries, arterioles and capillaries
1723 Diseases of arteries, arterioles and capillaries
1739 Diseases of arteries, arterioles and capillaries
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Appendix 6 Invitation letter to ACS cases ascertained late
Dear
We are a group of researchers based in the Radcliffe Infirmary working closely with your General Practice.
We are carrying out a research study called the Oxford Vascular Study (OXVASC). We hope you may be able
to help us with this important study. We understand from [GP] that you may have had some heart problems
in the recent past. Our study aims to find out how common heart problems are in Oxfordshire and to try and
explain the reasons for the changes in the frequency of this common disease over the last twenty years. We
hope that the information will help to reduce the risk for other people in the future.
The study involves an interview to ask a few questions about any previous medical problems that you may
have had. It also involves gathering information about risk factors from both your hospital and GP notes. We
have enclosed a copy of our information sheet. It is entirely voluntary. We would be pleased to answer any
questions that you may have. Please telephone 01865 228642 during working hours or leave a message on
our 24 hour OXVASC line on 01865 224132 leaving a contact telephone number and we can get back in touch
with you.
We will contact you within the next month to ensure you have received this letter. If you would be willing to
help telephone either of the numbers above and we will contact you to arrange a convenient time. We would
be happy to interview you in your home, our clinic or another place of your choice.




On behalf of the Oxford Vascular Study
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Appendix 7 Invitation letter to relatives in event of patients death
Dear
I am very sorry to trouble you so soon after the death of your spouse / relative. We understand from
[GP] that your [spouse / relative] may have died in the recent past and the cause of death may have
been related to disease of the blood vessels such as heart attack or stroke. We are carrying out a
research study called the Oxford Vascular Study (OXVASC) and we hope you may be able to help us
with this important study of how common these problems are in Oxfordshire. The study is done in
collaboration with your General Practice and will try to explain the reasons for the changes in the
frequency of these common diseases over the last twenty years. We hope that the information will help
to reduce the risk for other people in the future.
The study involves an interview to ask a few questions about any previous medical problems that your
[spouse / relative] may have had. It also involves gathering more information from both hospital and
GP records. We have enclosed a copy of our information sheet.
We would be pleased to answer any questions that you may have. Please telephone 01865 228642
during working hours or leave a message on our 24 hour OXVASC line on 01865 224132 leaving a
contact telephone number and we can get back in touch with you.
We will contact you within the next month to ensure you have received this letter. If you would be
willing to help telephone either of the numbers above and we will contact you to arrange a convenient
time. We would be happy to interview you by telephone, in your home, our clinic or another place of
your choice.




On behalf of the Oxford Vascular Study
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Appendix 8 Information sheet
UNIVERSITY OF OXFORD
Oxford Radcliffe Hospitals NHS Trust
The Stroke Prevention Researc h Unit





Department of Primary Health Care





OXFORD VASCULAR STUDY (OXVASC)
You are being invited to take part in a research study. Before you decide, it is important for you to
understand why the research is being done and what it will involve. Please take time to read the
following information. Ask us if anything is not clear or if you would like more information.
The purpose of this study is to find out how common vascular disease (e.g. heart attacks, strokes,
transient ischaemic attacks and other circulatory problems) is in Oxfordshire and how it affects
people's lives. This has never been done before for different types of vascular disease at the same time
and in the same population. We hope the study will provide us with useful information on the best
way of providing a service for those who suffer from these common problems. We hope we can build
up a detailed picture of the way that people recover and the subsequent changes in health over one
year.
There is no obligation to take part in the study and your normal care will not be affected in any way
whether or not you participate. If you decide to take part you would be given this information sheet
and asked to sign a consent form. You are free to withdraw at any time and without giving a reason.
If you decide to take part you would agree to an interview and a clinical examination by the
researcher. It would also involve an extra blood test in the hospital or clinic. We would also like to
gather some information on risk factors for vascular disease from both your hospital and GP notes. The
study would also involve being followed up by telephone or at home by a researcher in thirty days
time and at three monthly intervals during the next year. All the information collected will be
completely confidential. No investigations, new drugs or other treatments will be tested.
This study is being co-ordinated by the Stroke Prevention Research Unit in collaboration with the
Department of Primary Health Care, the Department of Cardiology and your participating General
Practice. The local ethics committee has approved the study. The results will be published in medical
journals after analysis.
If you would like any further information please ask the researcher who is discussing this information
sheet with you.
Thank you for reading this.
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Appendix 9 Consent UNIVERSITY OF OXFORD
Oxford Radcliffe Hospitals NHS Trust
The Stroke Prevention Research Unit








Department of Primary Health Care






OXFORD VASCULAR STUDY (OXVASC)
Dr Peter Rothwell, Dr Andrew Coull, Louise Silver, Linda Bull, Dr Matthew
Giles, Mr Jack Fairhead, Dr Ursula Schulz, Dr Enrico Flossmann, Dr
Andrew Farmer, Sarah Welch, Dr Cath Sackley and Jo Copley.
1. I confirm that I have read and understand the information sheet dated for the
above study and have had the opportunity to ask questions.
2. I agree to take part in the above study.
3. I understand that sections of any ofmy medical notes may be looked at by
responsible individuals where it is relevant to my taking part in research. I give
permission for these individuals to have access to my records.
4. I agree to take part in the follow up study that involves being interviewed at home
or a place of my choice, by telephone or in person at 1, 6 and 12 months.
5. I understand that my participation is voluntary and that I am free to withdraw at







Name of Patient Date Signature
Name ofWitness Date Signature
Researcher Date Signature




Oxford Radcliffe Hospitals NHS Trust
The Stroke Prevention Research Unit





Department of Primary Elealth Care








OXFORD VASCULAR STUDY (OXVASC)
Dr Peter Rothwell, Dr Andrew Coull, Louise Silver, Linda Bull, Sarah Welch, Dr
Matthew Giles, Mr Jack Fairhead, Dr Ursula Schulz, Dr Enrico Flossmann, Dr
Andrew Farmer, Dr Cath Sackley and Jo Copley.
Please initial box
1. I confirm that I have read and understand the information sheet dated for the
above study and have had the opportunity to ask questions. □
2. I understand that the participation ofmy relative is voluntary and that they are
free to withdraw at any time, without giving any reason, without their medical care
or legal rights being affected.
□
3. I understand that sections of any ofmy relative's medical notes may be looked
at by responsible individuals where it is relevant to taking part in research. I give
assent for these individuals to have access to my records
I agree for my relative to take part in the above study.
□
□
Name of Next of Kin Date Signature
Researcher Date Signature
Copies: 1 for patient; 1 for researcher; 1 to be kept with hospital notes
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Appendix 11 TIA and stroke data collection form (page 1)
ID NO:
Patient identification label






Beaumont street 01 East Oxford
Malthouse 05 Kidlington
















4. Retinal artery occlusion
Is this the first ever in a lifetime (incident) stroke? Y / N / U
Is this the first ever in a lifetime (incident) TIA? Y / N / U
Date of notification event
Event leading to notification
Location of interview:
1=JRH in patient / 2=RI in patient / 3=community hospital / 4=outpatients
/ 5=home / 6=other (specify)
Follow-up plan at 1 month
1=RI TIA clinic / 2=ACS-Primary Care / 3=Refused follow-up / 4=other/
5=CVA-Primary Care
Information on form obtained from l=patient / 2=relative / 3=GP /
4=hospital records / 5=death certificate / 6=other
Source of first notification GP=1 / JRH admissions=2 / other hospital=3 /
other referrals=4 / health authority search=5 / death=6 / troponin=7/other=9
Other sources of notification(include 1
Please specify
If one had not identified the patient via the route of first notification would
patient been identified by other source of ascertainment? Y / N
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Appendix 11 TIA and stroke data collection form (page 2)
Narrative history & examination
Notification event date
(The event that led to GP notification)
What did you think was wrong?
time
Were you alone? Y / N
If you were with someone who was it?
Who called for help?
If you did not call for help at time of event, why not?
Who did you (or person with you) first call for help? l=medical / 2=non medical
dateFirst call for help
(if medical code '9s')
First call to GP / A&E date
/ 999 i.e medical




Seen by GP / A&E date
GP notification to date
OXVASC/ascertainment







Appendix 11 TIA and stroke data collection form (page 3)
Duration of symptoms (if TIA in minutes)
If onset on wakening from sleep Y / N time awake
Activity at onset (within two hour of onset)
Estimated no. of met: asleep (1 met); sedentary (2 met); mild-mod activity (3-5 met);
strenuous (>6 met) (need list)
What were you doing in the same 2 hours on the day prior to the event? Estimated no. of
met: asleep (1 met); sedentary (2 met); mild-mod activity (3-5 met); strenuous (>6 met) (need
list)
Exact circumstances at time of onset of event Y / N
Standing Sitting Lying down
Drugs within previousl hour
Record exact activity
Meal within previous one hour
Location of event
Was there a further event between notification event and assessment? Y / N
Number of events between notification event (event that led to referral)
and seeing GP / other medical opinion (Include notification event)
Number of events between seeing GP and notification by GP to OXVASC
Number of events between notification by GP and OXVASC assessment
Were there any events in the month preceding the notification event? Y / N
How many events in the since 1st April before notification event?
Has this patient had a 'high early risk'? Y / N
i.e >= 2 events between notification event and OXVASC assessment
or within study period
Total number of events since 1st April 2002
(Include notification event)
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Appendix 11 TIA and stroke data collection form (page 4)
History of events between notification and assessment (use extra piece of paper if necessary).
Please also describe any events prior to event that led to notification (after 1/4/02).
Patp and description of further event
Date and descriotion of further event
If admitted (use yellow ambulance sheet)
Arrival of emergency service date
Arrival in hospital date
(If not on ambulance sheet use blue admissions)
time
time
Any previous acute vascular event (ACS - note STEMI or NSTEMI if known, TIA, CVA,








Date of most recent
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Appendix 11 TIA and stroke data collection form (page 5)
Calculated times
Delay from onset of symptoms to call for help
Delay from call for help to arrival ambulance / GP OPD
Delay from call for help to arrival hospital / GP
Were there any event(s) between 1st April 2002 and notification event?
Y/N
If YES fill in table below (include notification event)






















Vertebrobasilar stroke XXX xxxxx
Vertebrobasilar TIA




Retinal infarction right XXX xxxxx
Left XXX xxxx
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Appendix 11 TIA and stroke data collection form (page 6)
Background Medical History
Angina Y / N
Hypertension Y / N
Myocardial infarction Y / N
Diabetes mellitus Y / N
Treatment: Diet
Insulin Y / N






Tablets Y / N
Age at diagnosis





Age at first interventioi
Type: angiogran
Result
Atrial fibrillation Y/N Age at dia
l=Current / 2=Previous
l=Cardioversion, 2=paroxsymal/ 3=persistent, 4=permanent
Pacemaker Y/N Type
Hyperlipidaemia Y / N / DK
Treatment: Diet Y/N Statin Y / N
Age at diagnosis
Other
Cardiac failure Y/N Age at diagnosis Treated
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Appendix 11 TIA and stroke data collection form (page 7)
Migraine Y / N With aura Y / N
Prolonged aura (>lh) Y / N
Epilepsy Y / N
Cardiac intervention Y / N
Angiogram angioplasty
Age at diagnosis
age at first interventic
stent bypass
Result angiogram






Carotid endarterectomy Y / N Age at operation Side
AsthmaY / N
COAD Y / N
Liver disease Y / N
Peptic ulcer disease
Any previous venous thromboses Y / N
Give details below
No.
Any other past medical history
SLE (look in notes) Y / N Age of diagnosis
Anticardiolipin antibodies (aCL)
Lupus anticoagulant (LA)
Y / N / DK
Y / N / DK
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Appendix 11 TIA and stroke data collection form (page 8)
Autoimmune disease Y / N
If so give diagnosis:
Allergies
Nosebleeds Y / N
Any cancer
Bleeding after dental extraction Y / N
End stage renal failure / dialysis











Aspirin Resistance (ask re drugs in 10 days prior to assessment)
Were you on aspirin before this event? Y/N Date started?
Have you had aspirin since this acute event? Y/N
What doses? (date & dose)
Were you on clopidogrel before this event? Y/N Date started?
Have you had clopidogrel since this acute event?Y / N
What doses? (date & dose)
Have you had any anti inflammatories in 10 days
prior to assessment? Y/N
What drug and doses?
Do you take vitamin supplements? Y/N
B6 Y / N FOLATE Y / N B12 Y/N
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Appendix 11 TIA and stroke data collection form (page 9)
List names of supplements
Other medication : scroll ofother drugs on database
Was your BP measured at any time prior to the notification event?
Date of most recent BP measurement prior to notification event
How many times have you had your BP measured in the last year?
Over the last 10 years how many times have you had your BP
measured? l=none, 2=one to two times, 3=three to five times,
4=more than five times, 9=don't know






















Vertebrobasilar stroke XXX xxxxx
Vertebrobasilar TIA




Retinal infarction right XXX xxxxx
Left XXX xxxx
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Appendix 11 TIA and stroke data collection form (page 10)
FAMILY HISTORY
dad num sib 1 sib 2 sib 3 sib4 sib5
Family history stroke (yes=1, no=2, dk=CXX""
Family history Ml (code other box ageXXxxxx
Family history PVD (extent) XXXxXXx
Family history brain haemorrhage ,x
Family history diabetes (treatment) XXX XX
Family history hyperlipidaemia /
Family history hypertension XxxxxXx
Adopted Y / N
Twin Y / N
Total number of siblings (include interviewee)
Mother Alive / dead Age at death







Alive / dead M / F Age at death
Alive / dead M / F Age at death
Alive / dead M / F Age at death
Alive / Dead M / F Age at death
Alive / Dead M / F Age at deathSibling 5
(Youngest)









Appendix 11 TIA and stroke data collection form (page 11)
Family Tree (number siblings and children)
No of children


























Appendix 11 TIA and stroke data collection form (page 12)
Premorbid modified Rankin Y / N
Do you have any symptoms?
Are you able to look after yourself and carry out normal activities?
Does anyone else help pay the bills, do the shopping, cleaning etc?
Do you need someone to help you walk?
Do you need help to wash yourself?
Do you need to be lifted in and out of bed?
0 = no symptoms at all
1 = no significant disability despite symptoms: able to carry out all usual duties and activities
2 = slight disability: unable to carry out all previous activities but able to look after own affairs
without assistance
3 = moderate disability: requiring some help, but able to walk without assistance
4 = moderately severe disability: unable to walk without assistance, and unable to attend to own
bodily needs without assistance
5 = severe disability: bedridden, incontinent, and requiring constant nursing care and attention
6 = death
Rose PVD: IHD questionnaire
Part A
1. Have you ever had any pain or discomfort in your chest? l=yes 2= no go to part c
2. Do you get the pain or discomfort when you walk up hill or hurry? l=yes 2=no go to part b
3. Do you get it when you walk at an ordinary pace on the level? l=yes 2=no
4. When you get any pain or discomfort in your chest what do you do? l=stop 2=slow down
3=continue at same pace
5. Does it go away when you stand still l=yes 2=no
6. How soon? 1=10 minutes or less 2= more than 10 minutes
Part B
1. Have you ever had severe pain across the front of your chest lasting half an hour or more?
l=yes 2=no
PartC
1. Do you get pain in either leg when you are walking? l=yes 2=no (go to next question)
2. Does this pain ever begin when you are standing still or sitting? l=yes 2=no
3. Do you get this pain in your calf (or calves) l=yes 2=no
4. Do you get it when you walk up hill or hurry? l=yes 2=no
5. Do you get it when you walk at an ordinary pace on the level? l=yes 2=no
6. Does the pain ever disappear while you are still walking? l=yes 2=no
7. What do you do if you get it when you are walking? l=stop 2=slow down 3=continue at
same pace
8. What happens if you stand still? l=usually continues for more than 10 minutes 2= usually
disappears in 10 minutes or less
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1 = independent (or in shower)
Grooming
0 = needs help with personal care
1 = independent face/hair/teeth/shaving (implements provided)
Dressing
0 = dependent
1 = needs help but can do about half unaided
2 = independent (including buttons, zips, laces, etc.)
Bowels
0 = incontinent (or needs to be given enemas)
1 = occasional accident
2 = continent
Bladder
0 = incontinent, or catheterised and unable to manage alone




1 = needs some help, but can do something alone
2 = independent (on and off, dressing, wiping)
Transfers (bed to chair and back)
0 = unable, no sitting balance
1 = major help (one or two people, physical), can sit
2 = minor help (verbal or physical)
3 = independent
Mobility (on level surfaces)
0 = immobile
1 = wheelchair independent, including corners, > 50 metres
2 = walks with help of one person (verbal or physical) > 50 metres








Appendix 11 TIA and stroke data collection form (page 14)
ORIENTATION TO TIME RESPONSE SCORE
What is the... year?
season?
month of the year?
day of the week?
date?
ORIENTATION TO PLACE*








"■Alternative place words that are appropriate for the setting and
increasingly precise may be substituted and noted.
REGISTRATION*
Listen carefully. I am going to say three words. You say them back after
I stop. Ready?
Here they are...APPLE [pause], PENNY [pause], TABLE [pause]. Now





Now keep those words in mind. I am going to ask you to say them again
in a few minutes.
"Alternative word sets (e.g., PONY, QUARTER, ORANGE) may be
substituted and noted when retesting an examinee.
ATTENTION AND CALCULATION [Serial 7s]*
Now I'd like you to subtract 7 from 100. Then keep subtracting 7 from
each answer until I tell you to stop.
What is 100 take away 7? (93)
If needed, say: Keep going. (86}
If needed, say: Keep going. {79}
If needed, say: Keep going. (72)
If needed, say: Keep going. (65)
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Substitute and score this item only if the examinee refuses to perform the Serial 7s task.
Spell the word WORLD forward, then backward, correct forward spelling ifmisspelled,
but score only the backward spelling
(D = 1) (L = 1) (R = 1) (O = 1) (W = 1) (0-5)
RECALL





What is this? [Point to a pencil or pen. ]
What is this? [Point to a watch]





Listen carefully because I am going to ask you to do something.
Take this paper in your right hand [pause], fold it in half [pause], and put it on the floor (or table).




PUT ON FLOOR (or TABLE) ^
READING
Please read this and do what it says. [Show the examinee the words on the stimulus form]
CLOSE YOUR EYES
REPETITION
Now I am going to ask you to repeat what I say. Ready? "NO IFS, ANDS, OR BUTS."
say that. [Repeat up to 5 times, but score only the first trial.]
NO IFS, ANDS, OR BUTS.
WRITING
Please write a sentence. [Ifexaminee does not respond, say: Write about the
weather.]
Place the blank piece of paper (unfolded) in front of the examinee and provide a 0 1
pen or pencil. Score 1 point if the sentence is comprehensible and contains a
subject and a verb. Ignore errors in grammar or spelling.
DRAWING
Please copy this design. [Display the intersecting pentagons on the stimulus form.] 0 1
Score 1 point if the drawing consists of two 5-sided figures that intersect to form a
4-sided figure.
TOTAL SCORE (maximum 30)
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2 Busy (but not hassled)
3 Mildly angry (irritated, and hassled, but does not show)
4 Moderately angry (so hassled it shows in your voice)
5 Very angry (body tense, clenching fists or teeth)
6 Furious (almost out of control, very angry, pound table)
7 Enraged (lost control, throwing objects, hurting yourself or
In the two hours prior to the event what best describes
your emotional state from the above list (1 - 7)1
In the exact same two hours on the day prior to your
event which best describes your mood (1 - 7)1
If you had your event on wakening how were you in the
two hours before you went to bed (1 - 7)1
Interviewer's perception of patient personality (see scale below)?
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Appendix 11 TIA and stroke data collection form (page 17)
In general with regard to stress what kind of
person do you think you are? l=Very relaxed,
2=Fairly relaxed, 3=Average, 4=Prone to stress, 5=Highly stressed
Place of residence: l=Home, 2=home of relative,
3=home of friend, 4=warden housing,
5=care home, 9=other(specify)
Do you live alone? Y / N If no with whom
Are you a carer? Y / N
Physical help to wash / dress / transfer or walk
Does anyone assist you at home?
l=Spouse, 2=relative, 3=private carer,
4=community services (specify)
Marital status
married=l, widow=2, single=3, separated=4, partner=5, 9=not 1
Contacts with close friends and relatives
How many times do you see a friend or relative each week?
0-1 2-3 4-7 >7
Employment status
Working f/t=l, p/t=2, caring for home=3,
unemployed=4, unable to work=5, retired=6, student=7
Most recent occupation
(husband occupation if not employed)
Socioeconomic class (I - VI)
Ethnic origin
l=white, 2=black Caribbean, 3=black african, 4=indian,
5=pakistani, 6=bangladeshi, 7=chinese, 8=other
Exercise
Clinician judgement on amount of physical activity
(age corrected) per week. l=None, 2=Below average,
3=Normal, 4=Above average
Alcohol units per week
Education Age left school





Appendix 11 TIA and stroke data collection form (page 18)
Sleep
What is the likelihood of you dozing in the following situation?
0 = no chance of dozing, 1 = slight chance of dozing,
2 = moderate chance of dozing,3= high chance of dozing
Sitting and reading 0 12 3
Lying down to rest in the afternoon 0 12 3
when circumstances permit
Sitting and talking to someone 0 12 3
On average how many hours sleep do you get per night?
Do you snore? Y / N
Have you been told by someone that you stop breathing at night?
Do you take medications for high blood pressure? Y / N
People tell me that I snore
(Use scale below:score 1-8)
I have been told by other people that I gasp, choke or snort while
I am sleeping
(Use scale below:score 1-8)
l=Never, 2=Rarely (1-2X / year), 3=Occasionally (4-8X / year), 4=sometimes (1-2X / month),
5=Often (1-2X / week), 6=Usually (3-5X / week), 7=Always (every night), 8=1 don't know
Nutrition
How is your appetite? Good normal poor uncertain
Do you think you have a healthy diet? Y / N / DK
On average how many portions of fish do you eat per week?
l=Less than once per week, 2=once per week, 3=twice a week,
3=>=three times per week
Do you add salt to your food? Y / N
Do you drink full fat (1) or low fat (2) milk
On average how many portions of fresh fruit
and vegetables do you eat? l=Less than once per week, 2=one
portion per week, 3=several portions per week, 4=once per day,
5=2-4 portions per day, 6=>=5 portions per day
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Appendix 11 TIA and stroke data collection form (page 19)
Mood
Do you often feel sad or depressed? Y / N
Driving
Do you drive? Y / N
Handedness
R=Right / L=left / B=both / DK=not known
Clinician impression of frailty (corrected for age)
l=Frail 2=Normal
Life events
Has any of the following unpleasant things happened to you over the last year?
For each answer yes or no Y=1 N=2
Then ask how upset were you by these events?
Very much (1) / moderately (2) / not too much (3)
Death or serious illness of close friend or relative?
Financial difficulty
Divorce or break up of close friends or relatives
Major conflict with children or grandchildren
Muggings / robberies / accidents
Other (specify)
For women
Age of first pregnancy
Age of last pregnancy
Miscarriage Y / N




No. of years on HRT/OCP
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Waist / hip ratio
Weight (kg)
BMI
Arcus Y / N
Xanthelasma Y / N
Nicotine staining Y / N
Hip measurement (cm)
Height (m)
Ear crease Y / N
Own teeth / denture
Temperature on admission (if inpatient)
Pulse on admission
l=Bradycardia (<60) 2=Normal (60 -99) 3=Tachycardia >=100
l=sinus rhythm 2=AF
Blood pressure on admissio
Pulse at assessment










Cardiac murmur Y / N CCF Y /N
Any pre-existing neurological disability? Y / N
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Appendix 11 TIA and stroke data collection form (page 21)
Stroke
Prestroke disability (Rankin <3)
Symptoms at onset Y / N /DK
Findings on examination
Date
Predicted 30 day Rankin
Time
Weakness sensory visual other
ups nil
Right left right left right left dysphasia
Face face hemianopi a dysarthria
Arm arm monocular vertigo
Hand hand yes no headache
Leg leg diplopia
Findings on examination
GCS Eyes / 4 Motor / 6 Verbal / 5
Weakness sense ry eyes / vision other other
Right left right left yes no yes no
Face face heminopia dysphasia
Arm arm gazepalsy dysarthria




















Appendix 11 TIA and stroke data collection form (page 22)
Prognosis
Date of following prognostic markers






Limb deficit Y / N
Able to lift both harms to
horizontal MRC>=3
Unable to sit independently Y / N
Unable to stand independently Y/N
Unable to walk independentlyY/N


























Appendix 11 TIA and stroke data collection form (page 24)
Discharge
Length of stay in acute hospital
Length of stay rehab hospital
Total length of stay
Readmission before 30 days r
Number of readmissions
30 day case fatality l=alive 2=dead
Clinical diagnosis at discharge
Copy immediate discharge letter
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ST elevation Y / N
ST elevation - No Lytic
Troponin >0.2 Y / N














ST elevation - Lytic Y / N
CK rise (>2X) Y/N
New LBBB
Is this the first ever in lifetime (incident) ACS? Y/N
Date of notification event
Event leading to notification
Location of interview:
1=JRH in patient / 2=RI in patient / 3=community hospital / 4=outpatients
/ 5=home / 6=other (specify)
Follow-up plan at 1 month
1=RI TIA clinic / 2=ACS-Primary Care / 3=Refused follow-up / 4=other/
5=CVA-Primary Care
Information on form obtained from l=patient / 2=relative / 3=GP /
4=hospital records / 5=death certificate / 6=other
Source of first notification GP=1 / JRH admissions=2 / other hospital=3 /
other referrals=4 / health authority search=5 / death=6 / troponin=7/other=9
2 3.Other sources of notification(include 1
Please specify
If one had not identified the patient via the route of first notification would
patient been identified by other source of ascertainment? Y/N
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Appendix 12 STEMI data collection form (page 2)
Narrative history & examination
Symptoms Chest pain Y / N
SOB Y/N
Duration of chest pain in minutes
Notification event date
(The event that led to GP notification)
What did you think was wrong?
Radiation to arms or neck Y/ N
Description
time
Were you alone? Y/N
If you were with someone who was it?
Who called for help?
If you did not call for help at time of event, why not?
Who did you (or person with you) first call for help? l=medical / 2=non medical
date
□
First call for help
(if medical code '9s')
First call to GP / A&E date
/ 999 i.e medical
time
time
Outcome of first call for medical assistance
Seen by GP / A&E date
GP notification to date
OXVASC/ascertainment







Appendix 12 STEMI data collection form (page 3)
If onset on wakening from sleep Y / N time awake
Activity at onset (within two hour of onset)
Estimated no. of met: asleep (1 met); sedentary (2 met); mild-mod activity (3-5 met);
strenuous (>6 met) (need list)
What were you doing in the same 2 hours on the day prior to the event? Estimated no. of
met: asleep (1 met); sedentary (2 met); mild-mod activity (3-5 met); strenuous (>6 met) (need
list)
Exact circumstances at time of onset of event Y / N
Standing Sitting Lying down
Drugs within previousl hour
Record exact activity
Meal within previous one hour
Location of event
If admitted (use yellow ambulance sheet)
Arrival of emergency service date
Arrival in hospital date
(If not on ambulance sheet use blue admissions)
time
time
Any previous acute vascular event (ACS - note STEMI or NSTEMI if known, TIA, CVA,








Date of most recent
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Appendix 12 STEMI data collection form (page 4)
Delay from onset of symptoms to call for help
Delay from call for help to arrival ambulance / GP OPD
Delay from call for help to arrival hospital / GP
Background Medical History
Angina Y / N
Hypertension Y / N




Diabetes mellitus Y / N
Treatment: Diet
Insulin Y / N
Valvular heart disease Y / N
Nature:
Age at diagnosis
Tablets Y / N
Age at diagnosis









Atrial fibrillation Y/N Age at diagnosis
l=Current / 2=Previous
l=Cardioversion, 2=paroxsymal, 3=persistent, 4=permanent
Pacemaker Y/N Type
Hyperlipidaemia Y / N / DK




Appendix 12 STEMI data collection form (page 5)
Cardiac failure Y / N Age at diagnosis Treated
Migraine Y / N With aura Y / N













COAD Y / N
Age at diagnosis
age at first interventic
stent bypass
Age at operation Side
Liver disease Y/N
Peptic ulcer disease
Any previous venous thromboses Y/N
Give details below
No.
Any other past medical history
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Appendix 12 STEMI data collection form (page 6)
SLE (look in notes) Y / N Age of diagnosis
Anticardiolipin antibodies (aCL) Y/ N / DK
Lupus anticoagulant (LA) Y / N / DK
Autoimmune disease Y / N
If so give diagnosis:
Allergies
Nosebleeds Y / N
Any cancer
Bleeding after dental extraction Y / N
End stage renal failure / dialysis












Aspirin Resistance (ask re drugs in 10 days prior to assessment)
Were you on aspirin before this event? Y/N
Have you had aspirin since this acute event? Y/N
What doses? (date & dose)
Were you on clopidogrel before this event? Y/N Date started?
Have you had clopidogrel since this acute event?Y / N
What doses? (date & dose)
Have you had any anti inflammatories in 10 days
prior to assessment? Y/N
What drug and doses?
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Appendix 12 STEMI data collection form (page 7)
Do you take vitamin supplements? Y / N
B6 Y/N FOLATE Y / N B12Y/N
List names of supplements
Other medication : scroll of other druvs on database
Was your BP measured at any time prior to the notification event?
Date of most recent BP measurement prior to notification event
How many times have you had your BP measured in the last year?
Over the last 10 years how many times have you had your BP
measured? l=none, 2=one to two times, 3=three to five times,
4=more than five times, 9=don't know






















Vertebrobasilar stroke XXX xxxxx
Vertebrobasilar TIA




Retinal infarction right XXX xxxxx
Left XXX xxxx
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Appendix 12 STEMI data collection form (page 8)
FAMILY HISTORY
dad num sib 1 sib 2 iih ? dif- A sib5
Family history stroke (yes=1, no=2, dk=:
Family history Ml (code other box age x
Family history PVD (extent)
Family history brain haemorrhage
Family history diabetes (treatment)
Family history hyperlipidaemia
Family history hypertension u
Adopted Y / N
Twin Y / N
Total number of siblings (include interviewee)








Alive / dead M / F Age at death
Alive / dead M / F Age at death
Alive / dead M / F Age at death
Alive / Dead M / F Age at death
Alive / Dead M / F Age at deathSibling 5
(Youngest)









Appendix 12 STEMI data collection form (page 9)
Family Tree (number siblings and children)
No of children


























Appendix 12 STEMI data collection form (page 10)
Premorbid modified Rankin Y / N
Do you have any symptoms?
Are you able to look after yourself and carry out normal activities?
Does anyone else help pay the bills, do the shopping, cleaning etc?
Do you need someone to help you walk?
Do you need help to wash yourself?
Do you need to be lifted in and out of bed?
0 = no symptoms at all
1 = no significant disability despite symptoms: able to carry out all usual duties and activities
2 = slight disability: unable to carry out all previous activities but able to look after own affairs
without assistance
3 = moderate disability: requiring some help, but able to walk without assistance
4 = moderately severe disability: unable to walk without assistance, and unable to attend to own
bodily needs without assistance
5 = severe disability: bedridden, incontinent, and requiring constant nursing care and attention
6 = death
Rose PVD: IHD questionnaire
Part A
1. Have you ever had any pain or discomfort in your chest? l=yes 2= no go to part c
2. Do you get the pain or discomfort when you walk up hill or hurry? l=yes 2=no go to part b
3. Do you get it when you walk at an ordinary pace on the level? l=yes 2=no
4. When you get any pain or discomfort in your chest what do you do? l=stop 2=slow down
3=continue at same pace
5. Does it go away when you stand still l=yes 2=no
6. How soon? 1=10 minutes or less 2= more than 10 minutes
Part B
1. Have you ever had severe pain across the front of your chest lasting half an hour or more?
l=yes 2=no
PartC
1. Do you get pain in either leg when you are walking? l=yes 2=no (go to next question)
2. Does this pain ever begin when you are standing still or sitting? l=yes 2=no
3. Do you get this pain in your calf (or calves) l=yes 2=no
4. Do you get it when you walk up hill or hurry? l=yes 2=no
5. Do you get it when you walk at an ordinary pace on the level? l=yes 2=no
6. Does the pain ever disappear while you are still walking? l=yes 2=no
7. What do you do if you get it when you are walking? l=stop 2=slow down 3=continue at same
pace
8. What happens if you stand still? l=usually continues for more than 10 minutes 2= usually
disappears in 10 minutes or less
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1 = independent (or in shower)
Grooming
0 = needs help with personal care
1 = independent face/hair/teeth/shaving (implements provided)
Dressing
0 = dependent
1 = needs help but can do about half unaided
2 = independent (including buttons, zips, laces, etc.)
Bowels
0 = incontinent (or needs to be given enemas)
1 = occasional accident
2 = continent
Bladder
0 = incontinent, or catheterised and unable to manage alone




1 = needs some help, but can do something alone
2 = independent (on and off, dressing, wiping)
Transfers (bed to chair and back)
0 = unable, no sitting balance
1 = major help (one or two people, physical), can sit
2 = minor help (verbal or physical)
3 = independent
Mobility (on level surfaces)
0 = immobile
1 = wheelchair independent, including corners, > 50 metres
2 = walks with help of one person (verbal or physical) > 50 metres








Appendix 12 STEMI data collection form (page 12)
ORIENTATION TO TIME RESPONSE SCORE
What is the... year?
season?
month of the year?
day of the week?
date?
ORIENTATION TO PLACE*








*Alternative place words that are appropriate for the setting and
increasingly precise may be substituted and noted.
REGISTRATION*
Listen carefully. I am going to say three words. You say them back after
I stop. Ready?
Here they are...APPLE [pause], PENNY [pause], TABLE [pause]. Now





Now keep those words in mind. I am going to ask you to say them again
in a few minutes.
*Alternative word sets (e.g., PONY, QUARTER, ORANGE) may be
substituted and noted when retesting an examinee.
ATTENTION AND CALCULATION [Serial 7s[*
Now I'd like you to subtract 7 from 100. Then keep subtracting 7 from
each answer until I tell you to stop.
What is 100 take away 7? (93)
If needed, say: Keep going. (86}
If needed, say: Keep going. {79}
If needed, say: Keep going. (72)
If needed, say: Keep going. (65)
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Appendix 12 STEMI data collection form (page 13)
RESPONSE SCORE
(circle one)
Substitute and score this item only if the examinee refuses to perform the Serial 7s task.
Spell the word WORLD forward, then backward, correct forward spelling if misspelled,
but score only the backward spelling
(D = 1) (L = 1) (R = 1) (O = 1) (W = 1) (0-5)
RECALL





What is this? [Point to a pencil or pen.]
What is this? [Point to a watch]








Now I am going to ask you to repeat what I say. Ready? "NO IFS, ANDS, OR BUTS." Now you
say that. [Repeat up to 5 times, but score only the first trial.]
NO IFS, ANDS, OR BUTS.
COMPREHENSION
Listen carefully because I am going to ask you to do something.
Take this paper in your right hand [pause], fold it in half [pause], and put it on the floor (or table).
TAKE IN RIGHT HAND
FOLD IN HALF
PUT ON FLOOR (or TABLE)
READING
Please read this and do what it says. [Show the examinee the words on the stimulus form]
CLOSE YOUR EYES
WRITING
Please write a sentence. [Ifexaminee does not respond, say: Write about the
weather.]
Place the blank piece of paper (unfolded) in front of the examinee and provide a 0 1
pen or pencil. Score 1 point if the sentence is comprehensible and contains a
subject and a verb. Ignore errors in grammar or spelling.
DRAWING
Please copy this design. [Display the intersecting pentagons on the stimulus form.] 0 1
Score 1 point if the drawing consists of two 5-sided figures that intersect to form a
4-sided figure.
TOTAL SCORE (maximum 30)
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2. Busy (but not hassled)
3. Mildly angry (irritated, and hassled, but does not show)
4. Moderately angry (so hassled it shows in your voice)
5. Very angry (body tense, clenching fists or teeth)
6. Furious (almost out of control, very angry, pound table)
7. Enraged (lost control, throwing objects, hurting yourself
In the two hours prior to the event what best describes
your emotional state from the above list (1 - 7)1
In the exact same two hours on the day prior to your
event which best describes your mood (1 - 7)1
If you had your event on wakening how were you in the
two hours before you went to bed (1 - 7)1
Interviewer's perception of patient personality (see scale below)?
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Appendix 12 STEMI data collection form (page 15)
In general with regard to stress what kind of
person do you think you are? l=Very relaxed,
2=Fairly relaxed, 3=Average, 4=Prone to stress, 5=Highly stressed
Place of residence: l=Home, 2=home of relative,
3=home of friend, 4=warden housing,
5=care home, 9=other(specify)
Do you live alone? Y / N If no with whom
Are you a carer? Y / N
Physical help to wash / dress / transfer or walk
Does anyone assist you at home?
l=Spouse, 2=relative, 3=private carer,
4=community services (specify)
Marital status
married=l, widow=2, single=3, separated=4, partner=5, 9=not i
Contacts with close friends and relatives
How many times do you see a friend or relative each week?
0-1 2-3 4-7 >7
Employment status
Working f/t=l, p/t=2, caring for home=3,
unemployed=4, unable to work=5, retired=6, student=7
Most recent occupation
(husband occupation if not employed)
Socioeconomic class (I - VI)
Ethnic origin
l=white, 2=black Caribbean, 3=black african, 4=indian,
5=pakistani, 6=bangladeshi, 7=chinese, 8=other
Exercise
Clinician judgement on amount of physical activity
(age corrected) per week. l=None, 2=Below average,
3=Normal, 4=Above average
Alcohol units per week
Education Age left school





Appendix 12 STEM! data collection form (page 16)
Sleep
What is the likelihood of you dozing in the following situation?
0 = no chance of dozing, 1 = slight chance of dozing,
2 = moderate chance of dozing,3= high chance ofdozing
Sitting and reading 0 12 3
Lying down to rest in the afternoon 0 12 3
when circumstances permit
Sitting and talking to someone 0 12 3
On average how many hours sleep do you get per night?
Do you snore? Y / N
Have you been told by someone that you stop breathing at night?
Do you take medications for high blood pressure? Y / N
People tell me that I snore
(Use scale below:score 1-8)
I have been told by other people that I gasp, choke or snort while
I am sleeping
(Use scale below:score 1-8)
l=Never, 2=Rarely (1-2X / year), 3=Occasionally (4-8X / year), 4=sometimes (1-2X / month),
5=Often (1-2X / week), 6=Usually (3-5X / week), 7=Always (every night), 8=1 don't know
Nutrition
How is your appetite? Good normal poor uncertain
Do you think you have a healthy diet? Y / N / DK
On average how many portions of fish do you eat per week?
l=Less than once per week, 2=once per week, 3=twice a week,
3=>=three times per week
Do you add salt to your food? Y / N
Do you drink full fat (1) or low fat (2) milk
On average how many portions of fresh fruit
and vegetables do you eat? l=Less than once per week, 2=one
portion per week, 3=several portions per week, 4=once per day,
5=2-4 portions per day, 6=>=5 portions per day
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Appendix 12 STEMI data collection form (page 17)
Mood
Do you often feel sad or depressed? Y / N
Driving
Do you drive? Y / N
Handedness
R=Right / L=left / B=both / DK=not known
Clinician impression of frailty (corrected for age)
l=Frail 2=Normal
Life events
Has any of the following unpleasant things happened to you over the last year?
For each answer yes or no Y=1 N=2
Then ask how upset were you by these events?
Very much (1) / moderately (2) / not too much (3)
Death or serious illness of close friend or relative?
Financial difficulty
Divorce or break up of close friends or relatives
Major conflict with children or grandchildren
Muggings / robberies / accidents
Other (specify)
For women
Age of first pregnancy
Age of last pregnancy
Miscarriage Y / N




No. of years on HRT/OCP
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Waist / hip ratio
Weight (kg)
BMI
Arcus Y / N
Xanthelasma Y / N
Nicotine staining Y / N
Hip measurement (cm)
Height (m)
Ear crease Y / N
Own teeth / denture
Temperature on admission (if inpatient)
Pulse on admission
l=Bradycardia (<60) 2=Normal (60 -99) 3=Tachycardia >=100
l=sinus rhythm 2=AF
Blood pressure on admissio
Pulse at assessment










Cardiac murmur Y / N CCF Y /N
Any pre-existing neurological disability? Y / N
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Appendix 12 STEMI data collection form (page 19)
Myocardial Infarction
Time and date of reperfusion treatment
(No thrombolysis=9)
Delay from arrival in hospital to reperfusion treatment
Time and date first cardiac arrest
(no cardiac arrest=9)
Territory l=Anterior/ 2=LBBB, 3=Inferior, 4=other
Cardiac arrest
l=no arrest, 2=before ambulance, 3=after ambulance,
4=A&E, 5=CCU, 6=medical ward, 7=elsewhere in hospit;
Presenting rhythm
l=no arrest, 2=asystole, 3=VF/pulseless VT,
4=EMD 9=N/A or DK
Outcome
l=no return circulation
2=return spontaneous circulation died in hospital
3=discharged from hospital with neuro deficit
4=discharged no neuro deficit
5=resuscitation not attempted
6=no arrest
9=not known / not applicable
Admission diagnosis
l=definite MI, 2=probable MI, 3=unstable angina,
4=chest pain, 5=other initial diagnosis
6=already in hospital
ECG determining treatment
1=ST elevation, 2=LBBB, 3=ST depression,
4=T wave change, 5=other, 6=normal,
9=not known
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Appendix 12 STEMI data collection form (page 20)
Reperfusion attempted
l=thrombolysis, 2=ptca, 3=rescue ptca, 5=not attempted
9=not known
Did patient receive aspirin
l=already on, 2=given out of hospital, 3=after arrival,
4=ci to aspirin, 5=other antiplatelet, 6=none,
7=on warfarin, 8=not known
Admission unit
l=ccu, 2=AMAU, 3=gen med ward, 4=ITU, 5=other,
6=died A&E, 7=cardiac ward, 8=stepdown
Killip 1=1 2=11 / III / IV
Diuretic initiated or increased for heart failure?
l=yes 2=no 9=unknown
Cardiac enzymes













Age (>=75 = 3 / 65-74 = 2)
DM or HBP or angina = !
SBP<100 = 3
HR>100 = 2
Killip II-IV = 2
Weight<67kg = 1
Anterior STE / LBBB =1
Time to Tx > 4 = 1
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Appendix 12 STEMI data collection form (page 22)
Discharge
Length of stay in acute hospital
Length of stay rehab hospital
Total length of stay
Readmission before 30 days
Number of readmissions
30 day case fatality l=alive 2=dead
Clinical diagnosis at discharge
Copy immediate discharge letter
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Appendix 13 Acute peripheral vascular event data collection form (page 1)
ID NO:
Patient identification label






























Is this the first ever (incident PVD) event? Y / N
Date of notification event
Event leading to notification
Location of interview:
1=JRH in patient / 2=RI in patient / 3=community hospital / 4=outpatients
/ 5=home / 6=other (specify)
Follow-up plan at 1 month
1=RI TIA clinic / 2=ACS-Primary Care / 3=Refused follow-up / 4=other/
5=CVA-Primary Care
Information on form obtained from l=patient / 2=relative / 3=GP /
4=hospital records / 5=death certificate / 6=other
Source of first notification GP=1 / JRH admissions=2 / other hospital=3 /
other referrals=4 / health authority search=5 / death=6 / troponin=7/other=9
Other sources of notification(include lsl 2 3.
Please specify
If one had not identified the patient via the route of first notification would
patient been identified by other source of ascertainment? Y / N
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Appendix 13 Acute peripheral vascular event data collection form (page 2)
Narrative history & examination
Notification event date
(The event that led to GP notification)
What did you think was wrong?
time
Were you alone? Y / N
If you were with someone who was it?
Who called for help?
If you did not call for help at time of event, why not?
Who did you (or person with you) first call for help? l=medical / 2=non medical
dateFirst call for help
(if medical code '9s')
First call to GP / A&E date
/ 999 i.e medical




Seen by GP / A&E date
GP notification to date
OXVASC/ascertainment







Appendix 13 Acute peripheral vascular event data collection form (pg 3)
If onset on wakening from sleep Y / N time awake
Activity at onset (within two hour of onset)
Estimated no. of met: asleep (1 met); sedentary (2 met); mild-moc
strenuous (>6 met) (need list)
5 met);
What were you doing in the same 2 hours on the day prior to the event? Fctimatp




Exact circumstances at time of onset of event Y / N
Standing Sitting Lying down
Location of event
Drugs within previous! hour Meal within previous one hour
Record exact activity
If admitted (use yellow ambulance sheet)
Arrival of emergency service date
Arrival in hospital date
(If not on ambulance sheet use blue admissions)
time
time
Any previous acute vascular event (ACS - note STEMI or NSTEMI if known, TIA, CVA,








Date of most recent
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Appendix 13 Acute peripheral vascular event data collection form (pg 4)
Delay from onset of symptoms to call for help
Delay from call for help to arrival ambulance / GP OPD
Delay from call for help to arrival hospital / GP
Background Medical History
Angina Y / N
Hypertension Y / N




Diabetes mellitus Y / N
Treatment: Diet
Insulin Y / N
Valvular heart disease Y / N
Nature:
Age at diagnosis
Tablets Y / N
Age at diagnosis









Atrial fibrillation Y/N Age at diagnosis
l=Current / 2=Previous
^Cardioversion, 2=paroxsymal, 3=persistent, 4=permanent
Pacemaker Y/N Type
Hyperlipidaemia Y / N / DK




Appendix 13 Acute peripheral vascular event data collection form (pg 5)
Cardiac failure Y / N Age at diagnosis Treated
Migraine Y / N With aura Y / N
Prolonged aura (>lh) Y / N
Epilepsy Y/N Age at diagnosis
Cardiac intervention Y/N age at first intervention
Angiogram angioplasty stent bypass
Result angiogram








COAD Y / N
Liver disease Y/N
Peptic ulcer disease
Any previous venous thromboses Y/N
Give details below
No.
Any other past medical history
SLE (look in notes) Y/N Age of diagnosis
Anticardiolipin antibodies (aCL)
Lupus anticoagulant (LA)
Y / N / DK
Y / N / DK
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Appendix 13 Acute peripheral vascular event data collection form (pg 6)
Autoimmune disease Y / N
If so give diagnosis:
Allergies
Nosebleeds Y / N
Any cancer
Bleeding after dental extraction Y / N
End stage renal failure / dialysis











Aspirin Resistance (ask re drugs in 10 days prior to assessment)
Were you on aspirin before this event? Y/N Date started?
Have you had aspirin since this acute event? Y/N
What doses? (date & dose)
Were you on clopidogrel before this event? Y/N Date started?
Have you had clopidogrel since this acute event?Y / N
What doses? (date & dose)
Have you had any anti inflammatories in 10 days
prior to assessment? Y/N
What drug and doses?
Do you take vitamin supplements? Y/N
B6Y/N FOLATE Y/N B12Y/N
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Appendix 13 Acute peripheral vascular event data collection form (pg 7)
List names of supplements
Other medication : scroll of other druQS on database
Was your BP measured at any time prior to the notification event?
Date of most recent BP measurement prior to notification event
How many times have you had your BP measured in the last year?
Over the last 10 years how many times have you had your BP
measured? l=none, 2=one to two times, 3=three to five times,
4=more than five times, 9=don't know






















Vertebrobasilar stroke XXX xxxxx
Vertebrobasilar TIA




Retinal infarction right XXX xxxxx
Left XXX xxxx
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Appendix 13 Acute peripheral vascular event data collection form (pg 8)
FAMILY HISTORY
dad num sib 1 sib 2 sib 3 sib4 sib5
Family history stroke (yes=1, no=2, dk=:
Family history Ml (code other box age
Family history PVD (extent) l/
Family history brain haemorrhage
Family history diabetes (treatment) X
Family history hyperlipidaemia
Family history hypertension
Adopted Y / N
Twin Y / N
Total number of siblings (include interviewee)
Mother Alive / dead Age at death Cause of death
Father Alive / dead Age at death Cause of death
Sibling 1 Alive / dead M / F Age at death Cause of death
(Oldest)
Sibling 2 Alive / dead M / F Age at death Cause of death
Sibling 3 Alive / dead M / F Age at death Cause of death
Sibling 4 Alive / Dead M / F Age at death Cause of death
Sibling 5 Alive / Dead M / F Age at death Cause of death
▼ (Youngest)
Continue on separate page if necessary
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Appendix 13 Acute peripheral vascular event data collection form (pg 9)
Family Tree (number siblings and children)
No of children


























Appendix 11 TIA and stroke data collection form (page 12)
Premorbid modified Rankin Y / N
Do you have any symptoms?
Are you able to look after yourself and carry out normal activities?
Does anyone else help pay the bills, do the shopping, cleaning etc?
Do you need someone to help you walk?
Do you need help to wash yourself?
Do you need to be lifted in and out of bed?
0 = no symptoms at all
1 = no significant disability despite symptoms: able to carry out all usual duties and activities
2 = slight disability: unable to carry out all previous activities but able to look after own affairs
without assistance
3 = moderate disability: requiring some help, but able to walk without assistance
4 = moderately severe disability: unable to walk without assistance, and unable to attend to own
bodily needs without assistance
5 = severe disability: bedridden, incontinent, and requiring constant nursing care and attention
6 = death
Rose PVD: IHD questionnaire
Part A
1. Have you ever had any pain or discomfort in your chest? l=yes 2= no go to part c
2. Do you get the pain or discomfort when you walk up hill or hurry? l=yes 2=no go to part b
3. Do you get it when you walk at an ordinary pace on the level? l=yes 2=no
4. When you get any pain or discomfort in your chest what do you do? l=stop 2=slow down
3=continue at same pace
5. Does it go away when you stand still l=yes 2=no
6. How soon? 1=10 minutes or less 2= more than 10 minutes
Part B
1. Have you ever had severe pain across the front of your chest lasting half an hour or more?
l=yes 2=no
PartC
1. Do you get pain in either leg when you are walking? l=yes 2=no (go to next question)
2. Does this pain ever begin when you are standing still or sitting? l=yes 2=no
3. Do you get this pain in your calf (or calves) l=yes 2=no
4. Do you get it when you walk up hill or hurry? l=yes 2=no
5. Do you get it when you walk at an ordinary pace on the level? l=yes 2=no
6. Does the pain ever disappear while you are still walking? l=yes 2=no
7. What do you do if you get it when you are walking? l=stop 2=slow down 3=continue at same
pace
8. What happens if you stand still? l=usually continues for more than 10 minutes 2= usually
disappears in 10 minutes or less
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1 = independent (or in shower)
Grooming
0 = needs help with personal care
1 = independent face/hair/teeth/shaving (implements provided)
Dressing
0 = dependent
1 = needs help but can do about half unaided
2 = independent (including buttons, zips, laces, etc.)
Bowels
0 = incontinent (or needs to be given enemas)
1 = occasional accident
2 = continent
Bladder
0 = incontinent, or catheterised and unable to manage alone




1 = needs some help, but can do something alone
2 = independent (on and off, dressing, wiping)
Transfers (bed to chair and back)
0 = unable, no sitting balance
1 = major help (one or two people, physical), can sit
2 = minor help (verbal or physical)
3 = independent
Mobility (on level surfaces)
0 = immobile
1 = wheelchair independent, including corners, > 50 metres
2 = walks with help of one person (verbal or physical) > 50 metres








Appendix 13 Acute peripheral vascular event data collection form (pg 12)
ORIENTATION TO TIME RESPONSE SCORE
What is the... year? 0
season? q
month of the year? q
day of the week? q
date? n
ORIENTATION TO PLACE*








*Alternative place words that are appropriate for the setting and
increasingly precise may be substituted and noted.
REGISTRATION*
Listen carefully. I am going to say three words. You say them back after
I stop. Ready?
Here they are...APPLE [pause], PENNY [pause], TABLE [pause]. Now





Now keep those words in mind. I am going to ask you to say them again
in a few minutes.
*Alternative word sets (e.g., PONY, QUARTER, ORANGE) may be
substituted and noted when retesting an examinee.
ATTENTION AND CALCULATION [Serial 7s]*
Now I'd like you to subtract 7 from 100. Then keep subtracting 7 from
each answer until I tell you to stop.
What is 100 take away 7? (93)
If needed, say: Keep going. (86]
If needed, say: Keep going. {79}
If needed, say: Keep going. {72}
If needed, say: Keep going. (65}
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Appendix 13 Acute peripheral vascular event data collection form (pg 13)
RESPONSE SCORE
(circle one)
Substitute and score this item only if the examinee refuses to perform the Serial 7s task.
Spell the word WORLD forward, then backward, correct forward spelling if misspelled,
but score only the backward spelling
(D = 1) (L = l) (R = l) (O = 1) (W = 1) (0-5)
RECALL





What is this? [Point to a pencil or pen.]
What is this? [Point to a watch]
'Alternative common objects (e.g. eyeglasses, chair, keys may be substituted and
noted.
REPETITION
Now I am going to ask you to repeat what I say. Ready? "NO IFS, ANDS, OR BUTS." Now you
say that. [Repeat up to 5 times, but score only the first trial.]
NO IFS, ANDS, OR BUTS. Q
COMPREHENSION
Listen carefully because I am going to ask you to do something.
Take this paper in your right hand [pause], fold it in half [pause], and put it on the floor (or table).
TAKE IN RIGHT HAND
FOLD IN HALF
PUT ON FLOOR (or TABLE)
READING
Please read this and do what it says. [Show the examinee the words on the stimulus form]
CLOSE YOUR EYES
WRITING
Please write a sentence. [Ifexaminee does not respond, say: Write about the
weather.]
Place the blank piece of paper (unfolded) in front of the examinee and provide a
pen or pencil. Score 1 point if the sentence is comprehensible and contains a
subject and a verb. Ignore errors in grammar or spelling.
DRAWING
Please copy this design. [Display the intersecting pentagons on the stimulus form.]




TOTAL SCORE (maximum 30)
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2. Busy (but not hassled)
3. Mildly angry (irritated, and hassled, but does not show)
4. Moderately angry (so hassled it shows in your voice)
5. Very angry (body tense, clenching fists or teeth)
6. Furious (almost out of control, very angry, pound table)
7. Enraged (lost control, throwing objects, hurting yourself or
In the two hours prior to the event what best describes
your emotional state from the above list (1 - 7)?
In the exact same two hours on the day prior to your
event which best describes your mood (1 - 7)?
If you had your event on wakening how were you in the
two hours before you went to bed (1 - 7)?
Interviewer's perception of patient personality (see scale below)?
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Appendix 13 Acute peripheral vascular event data collection form (pg 15)
In general with regard to stress what kind of
person do you think you are? l=Very relaxed,
2=Fairly relaxed, 3=Average, 4=Prone to stress, 5=Highly stressed
Place of residence: l=Home, 2=home of relative,
3=home of friend, 4=warden housing,
5=care home, 9=other(specify)
Do you live alone? Y / N If no with whom
Are you a carer? Y / N
Physical help to wash / dress / transfer or walk
Does anyone assist you at home?
l=Spouse, 2=relative, 3=private carer,
4=community services (specify)
Marital status
married=l, widow=2, single=3, separated=4, partner=5, 9=not I
Contacts with close friends and relatives
How many times do you see a friend or relative each week?
0-1 2-3 4-7 >7
Employment status
Working f/t=l, p/t=2, caring for home=3,
unemployed=4, unable to work=5, retired=6, student=7
Most recent occupation
(husband occupation if not employed)
Socioeconomic class (I - VI)
Ethnic origin
l=white, 2=black Caribbean, 3=black african, 4=indian,
5=pakistani, 6=bangladeshi, 7=chinese, 8=other
Exercise
Clinician judgement on amount of physical activity
(age corrected) per week. l=None, 2=Below average,
3=Normal, 4=Above average
Alcohol units per week
Education Age left school





Appendix 13 Acute peripheral vascular event data collection form (pg 16)
Sleep
What is the likelihood of you dozing in the following situation?
0 = no chance of dozing, 1 = slight chance of dozing,
2 = moderate chance of dozing,3= high chance of dozing
Sitting and reading 0 12 3
Lying down to rest in the afternoon 0 12 3
when circumstances permit
Sitting and talking to someone 0 12 3
On average how many hours sleep do you get per night?
Do you snore? Y / N
Have you been told by someone that you stop breathing at night?
Do you take medications for high blood pressure? Y / N
People tell me that I snore
(Use scale below:score 1-8)
I have been told by other people that I gasp, choke or snort while
I am sleeping
(Use scale below:score 1-8)
l=Never, 2=Rarely (1-2X / year), 3=Occasionally (4-8X / year), 4=sometimes (1-2X / month),
5=Often (1-2X / week), 6=Usually (3-5X / week), 7=Always (every night), 8=1 don't know
Nutrition
How is your appetite? Good normal poor uncertain
Do you think you have a healthy diet? Y / N / DK
On average how many portions of fish do you eat per week?
l=Less than once per week, 2=once per week, 3=twice a week,
3=>=three times per week
Do you add salt to your food? Y / N
Do you drink full fat (1) or low fat (2) milk
On average how many portions of fresh fruit
and vegetables do you eat? l=Less than once per week, 2=one
portion per week, 3=several portions per week, 4=once per day,
5=2-4 portions per day, 6=>=5 portions per day
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Appendix 13 Acute peripheral vascular event data collection form (pg 17)
Mood
Do you often feel sad or depressed? Y / N
Driving
Do you drive? Y / N
Handedness
R=Right / L=left / B=both / DK=not known
Clinician impression of frailty (corrected for age)
l=Frail 2=Normal
Life events
Has any of the following unpleasant things happened to you over the last year?
For each answer yes or no Y=1 N=2
Then ask how upset were you by these events?
Very much (1) / moderately (2) / not too much (3)
Death or serious illness of close friend or relative?
Financial difficulty
Divorce or break up of close friends or relatives
Major conflict with children or grandchildren
Muggings / robberies / accidents
Other (specify)
For women
Age of first pregnancy
Age of last pregnancy
Miscarriage Y/N




No. of years on HRT/OCP
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Waist / hip ratio
Weight (kg)
BMI
Arcus Y / N
Xanthelasma Y / N
Nicotine staining Y / N
Hip measurement (cm)
Height (m)
Ear crease Y / N
Own teeth / denture
Temperature on admission (if inpatient)
Pulse on admission
l=Bradycardia (<60) 2=Normal (60 -99) 3=Tachycardia >=100
l=sinus rhythm 2=AF
Blood pressure on admissio
Pulse at assessment










Cardiac murmur Y / N CCF Y /N
Any pre-existing neurological disability? Y / N
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Appendix 13 Acute peripheral vascular event data collection form (pg 21)
Discharge
Length of stay in acute hospital
Length of stay rehab hospital
Total length of stay
Readmission before 30 days
Number of readmissions
30 day case fatality l=alive 2=dead
Clinical diagnosis at discharge
Copy immediate discharge letter
- 323 -
Appendix 14 Unstable angina and NSTEMI data collection form (page 1)
ID NO:
Patient identification label























Non ST elevation MI Y / N
Peak troponin I level
ST depression
(>=0.5mm) Y / N
New Q waves Y / N
Unstable anginaY/ N
CK rise (>2X) Y / N
ST / T wave changes
Is this the first ever in lifetime (incident) ACS? Y / N
Date of notification event
Event leading to notification
Location of interview:
1=JRH in patient / 2=RI in patient / 3=community hospital / 4=outpatients
/ 5=home / 6=other (specify)
Follow-up plan at 1 month
1=RI TIA clinic / 2=ACS-Primary Care / 3=Refused follow-up / 4=other/
5=CVA-Primary Care
Information on form obtained from l=patient / 2=relative / 3=GP /
4=hospital records / 5=death certificate / 6=other
Source of first notification GP=1 / JRH admissions=2 / other hospital=3 /
other referrals=4 / health authority search=5 / death=6 / troponin=7/other=9
3.Other sources of notification(include 1
Please specify
If one had not identified the patient via the route of first notification would
patient been identified by other source of ascertainment? Y / N
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Appendix 14 Unstable angina and NSTEMI data collection form (page 2)
History of Notification Event
Narrative history & examination
Typical lschaemic chest pain - central / radiates / exertonal / relieved GTN - assess rest
exertion >20mins / new onset < 2months / acceleration of severity <2months / change
duration / frequency / angina threshold /
Symptoms Chest pain Y/N Radiation to arms or
neckY/N
SOB Y / N










New onset angina within last 2months with minimal exertion
ECG changes compatible with ischaemia Y/N
Transient ST elevation >lmm in 2 contiguous leads,
ST depression, (0.5 / 1.0mm), New Twave inversion of >=lmm,
Pseudonormalisation of previously inverted T waves.
History of, or new, positive exercise test Y/N
Prior or new percutaneous catheterisation (>=50% stenosis)
Prior or new coronary intervention or CABG
Any potential secondary aetiology
Arrhythmia, anaemia, thyroid disease, sepsis, surgery:
Please specify
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Appendix 14 Unstable angina and NSTEMI data collection form (page 3)
Notification event date
(The event that led to GP notification)
What did you think was wrong?
time
Were you alone? Y / N
If you were with someone who was it?
Who called for help?
If you did not call for help at time of event, why not?
Who did you (or person with you) first call for help? l=medical / 2=non medical
date
□
First call for help
(if medical code '9s')
First call to GP / A&E date
/ 999 i.e medical
time
time
Outcome of first call for medical assistance
Seen by GP / A&E date
GP notification to date
OXVASC/ascertainment







Appendix 14 Unstable angina and NSTEMI data collection form (pg4)
Any previous acute vascular event (ACS - note STEMI or NSTEMI if known, TIA, CVA,








Date of most recent
Background Medical History
Angina Y / N
Hypertension Y / N
Myocardial infarction Y / N
Diabetes mellitus Y / N
Treatment: Diet
Insulin Y / N
Valvular heart disease Y / N
Nature:








Tablets Y / N
Age at diagnosis
Age at diagnosis




Appendix 14 Unstable angina and NSTEMI data collection form (pg5)
Atrial fibrillation Y / N Age at diagnosis
l=Current / 2=Previous
^Cardioversion, 2=paroxsymal, 3=persistent, 4=permanent
TypePacemaker Y / N
Hyperlipidaemia Y / N / DK
Treatment: Diet Y / N Statin Y / N
Age at diagnosis
Other
Cardiac failure Y / N Age at diagnosis Treated
Migraine Y / N With aura Y / N





age at first interventic
stent bypass
Result angiogram






Carotid endarterectomyY/N Age at operation Side
AsthmaY / N




Appendix 14 Unstable angina and NSTEMI data collection form (pg 6)
Any previous venous thromboses Y / N
Give details below
Number
Any other past medical history
SLE (look in notes) Y / N
Anticardiolipin antibodies (aCL)
Lupus anticoagulant (LA)
Autoimmune disease Y / N
If so give diagnosis:
Age of diagnosis
Y / N / DK
Y/N/DK
Allergies
Nosebleeds Y / N
Any cancer
Bleeding after dental extraction Y / N
End stage renal failure / dialysis












Appendix 14 Unstable angina and NSTEMI data collection form (pg 7)
Aspirin Resistance (ask re drugs in 10 days prior to assessment)
Were you on aspirin before this event? Y/N Date started?
Have you had aspirin since this acute event? Y/N
What doses? (date & dose)
Were you on clopidogrel before this event? Y/N Date started?
Have you had clopidogrel since this acute event?Y / N
What doses? (date & dose)
Have you had any anti inflammatories in 10 days
prior to assessment? Y/N
What drug and doses?
Do you take vitamin supplements? Y/N
B6 Y / N FOLATE Y / N B12 Y/N
List names of supplements
Other medication : scroll of other drucs on database
Was your BP measured at any time prior to the notification event?
Date of most recent BP measurement prior to notification event
How many times have you had your BP measured in the last year?
Over the last 10 years how many times have you had your BP
measured? l=none, 2=one to two times, 3=three to five times,
4=more than five times, 9=don't know
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Appendix 14 Unstable angina and NSTEMI data collection form (pg 8)






















Vertebrobasilar stroke XXX xxxxx
Vertebrobasilar HA




Retinal infarction right XXX xxxxx
Left XXX xxxx
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Appendix 14 Unstable angina and NSTEMI data collection form (pg 8)
FAMILY HISTORY
dad num sib 1 sib 2 sib 3 sib4 sib5
Family history stroke (yes=1, no=2, dk=: X^XX^X ^X
Family history Ml (code other box age x//
Family history PVD (extent) /X/i/X
Family history brain haemorrhage XXXXX ^x
Family history diabetes (treatment) //Xx"//x^
Family history hyperlipidaemia XXXXX ^x
Family history hypertension x"x"
Adopted Y / N
Twin Y / N
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Appendix 14 Unstable angina and NSTEMI data collection form (pg 9)








Age at death Cause of death
Age at death Cause of death
Alive / dead
Alive / dead
Alive / dead M / F Age at death Cause of death
Alive / dead M / F Age at death Cause of death
Alive / dead M / F Age at death Cause of death
Alive / Dead M / F Age at death Cause of death
Alive / Dead M / F Age at death Cause of deathSibling 5
(Youngest)
Continue on separate page if necessary
Family Tree (number siblings and children)
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Appendix 14 Unstable angina and NSTEMI data collection form (pg 9-10)
No of children


























Appendix 14 Unstable angina and NSTEMI data collection form (pg 10)
Premorbid modified Rankin Y / N
Do you have any symptoms?
Are you able to look after yourself and carry out normal activities?
Does anyone else help pay the bills, do the shopping, cleaning etc?
Do you need someone to help you walk?
Do you need help to wash yourself?
Do you need to be lifted in and out of bed?
0 = no symptoms at all
1 = no significant disability despite symptoms: able to carry out all usual duties and activities
2 = slight disability: unable to carry out all previous activities but able to look after own affairs
without assistance
3 = moderate disability: requiring some help, but able to walk without assistance
4 = moderately severe disability: unable to walk without assistance, and unable to attend to own
bodily needs without assistance
5 = severe disability: bedridden, incontinent, and requiring constant nursing care and attention
6 = death
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Appendix 14 Unstable angina and NSTEMI data collection form (pg 11)
Rose PVD: IHD questionnaire
Part A
1. Have you ever had any pain or discomfort in your chest? l=yes 2= no go to part c
2. Do you get the pain or discomfort when you walk up hill or hurry? l=yes 2=no go to part b
3. Do you get it when you walk at an ordinary pace on the level? l=yes 2=no
4. When you get any pain or discomfort in your chest what do you do? l=stop 2=slow down
3=continue at same pace
5. Does it go away when you stand still l=yes 2=no
6. How soon? 1=10 minutes or less 2= more than 10 minutes
Part B
1. Have you ever had severe pain across the front of your chest lasting half an hour or more?
l=yes 2=no
PartC
1. Do you get pain in either leg when you are walking? l=yes 2=no (go to next question)
2. Does this pain ever begin when you are standing still or sitting? l=yes 2=no
3. Do you get this pain in your calf (or calves) l=yes 2=no
4. Do you get it when you walk up hill or hurry? l=yes 2=no
5. Do you get it when you walk at an ordinary pace on the level? l=yes 2=no
6. Does the pain ever disappear while you are still walking? l=yes 2=no
7. What do you do if you get it when you are walking? l=stop 2=slow down 3=continue at same
pace
8. What happens if you stand still? l=usually continues for more than 10 minutes 2= usually
disappears in 10 minutes or less
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1 = independent (or in shower)
Grooming
0 = needs help with personal care
1 = independent face/hair/teeth/shaving (implements provided)
Dressing
0 = dependent
1 = needs help but can do about half unaided
2 = independent (including buttons, zips, laces, etc.)
Bowels
0 = incontinent (or needs to be given enemas)
1 = occasional accident
2 = continent
Bladder
0 = incontinent, or catheterised and unable to manage alone




1 = needs some help, but can do something alone
2 = independent (on and off, dressing, wiping)
Transfers (bed to chair and back)
0 = unable, no sitting balance
1 = major help (one or two people, physical), can sit
2 = minor help (verbal or physical)
3 = independent
Mobility (on level surfaces)
0 = immobile
1 = wheelchair independent, including corners, > 50 metres
2 = walks with help of one person (verbal or physical) > 50 metres












9 Busy (but not hassled)
10 Mildly angry (irritated, and hassled, but does not show)
11 Moderately angry (so hassled it shows in your voice)
12 Very angry (body tense, clenching fists or teeth)
13 Furious (almost out of control, very angry, pound table)
14 Enraged (lost control, throwing objects, hurting yourself or
In the two hours prior to the event what best describes
your emotional state from the above list (1 - 7)?
In the exact same two hours on the day prior to your
event which best describes your mood (1 - 7)?
If you had your event on wakening how were you in the
two hours before you went to bed (1 - 7)1
Interviewer's perception of patient personality (see scale below)?
In general with regard to stress what kind of
person do you think you are? l=Very relaxed,
2=Fairly relaxed, 3=Average, 4=Prone to stress, 5=Highly stressed
Place of residence: l=Home, 2=home of relative,
3=home of friend, 4=warden housing,
5=care home, 9=other(specify)
Do you live alone? Y / N If no with whom
Are you a carer? Y / N
Physical help to wash / dress / transfer or walk
Does anyone assist you at home?
l=Spouse, 2=relative, 3=private carer,
4=community services (specify)
Marital status
married=l, widow=2, single=3, separated=4, partner=5, 9=not know;
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Contacts with close friends and relatives
How many times do you see a friend or relative each week?
0-1 2-3 4-7 >7
Employment status
Working f/t=l, p/t=2, caring for home=3,
unemployed=4, unable to work=5, retired=6, student=7
Most recent occupation
(husband occupation if not employed)
Socioeconomic class (I - VI)
Ethnic origin
l=white, 2=black Caribbean, 3=black african, 4=indian,
5=pakistani, 6=bangladeshi, 7=chinese, 8=other
Exercise
Clinician judgement on amount of physical activity
(age corrected) per week. l=None, 2=Below average,
3=Normal, 4=Above average
Alcohol units per week
Education Age left school
Age left full time education
Nutrition




Good normal poor uncertain
Do you think you have a healthy diet? Y / N / DK
On average how many portions of fish do you eat per week?
l=Less than once per week, 2=once per week, 3=twice a week,
3=>=three times per week
Do you add salt to your food? Y / N
Do you drink full fat (1) or low fat (2) milk
On average how many portions of fresh fruit
and vegetables do you eat? l=Less than once per week, 2=one
portion per week, 3=several portions per week, 4=once per day,
5=2-4 portions per day, 6=>=5 portions per day
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Appendix 14 Unstable angina and NSTEMI data collection form (pg 15)
Mood
Do you often feel sad or depressed? Y / N
Driving
Do you drive? Y / N
Handedness
R=Right / L=left / B=both / DK=not known
Clinician impression of frailty (corrected for age)
l=Frail 2=Normal
Life events
Has any of the following unpleasant things happened to you over the last year?
For each answer yes or no Y=1 N=2
Then ask how upset were you by these events?
Very much (1) / moderately (2) / not too much (3)
Death or serious illness of close friend or relative?
Financial difficulty
Divorce or break up of close friends or relatives
Major conflict with children or grandchildren
Muggings / robberies / accidents
Other (specify)
For women
Age of first pregnancy
Age of last pregnancy
Miscarriage Y / N




No. of years on HRT/OCP
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Appendix 14 Unstable angina and NSTEMI data collection form (pg 16)
Investigations
Cardiac enzymes






Coded ECG 1=AF 2=BBB 3=STsegment change 4=LVH
5=Acute MI 6=01d MI 7=Normal 9=Other
Need copies
For NSTEMI
TIMI - NSTEMI Score
Age >=65 = 1
>=3 CAD Risk factors = 1
FHx HBP Raised chol DM
Known CAD = 1
Stenosis>=50%
ASA use in past 7 days =1
Recent (<=24h) severe angina = 1
Raised cardiac markers = 1
ST deviation >=0.5mm = 1
TIMI - score NSTEMI
Notes
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Appendix 14 Unstable angina and NSTEMI data collection form (pg 18)
Discharge
Length of stay in acute hospital
Length of stay rehab hospital
Total length of stay
Readmission before 30 days
Number of readmissions
30 day case fatality l=alive 2=dead
Clinical diagnosis at discharge
Copy immediate discharge letter
Diagnosis after review by Dr Banning




Non - cardiac Stable angina
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Appendix 15 Vascular intervention data collection form (page 1)
ID NO:
Patient identification label


























Is this the first ever (incident) vascular intervention event? Y / N
Date of notification event
Event leading to notification
Location of interview:
1=JRH in patient / 2=RI in patient / 3=community hospital / 4=outpatients
/ 5=home / 6=other (specify)
Follow-up plan at 1 month
1=RI TIA clinic / 2=ACS-Primary Care / 3=Refused follow-up / 4=other/
5=CVA-Primary Care
Information on form obtained from l=patient / 2=relative / 3=GP /
4=hospital records / 5=death certificate / 6=other
Source of first notification GP=1 / JRH admissions=2 / other hospital=3 /
other referrals=4 / health authority search=5 / death=6 / troponin=7/other=9
Other sources of notification(include V
Please specify
2 3. 4.
patient been identified by other source of ascertainment? Y / N
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Appendix 15 Vascular intervention data collection form (page 2)
Narrative history & examination
Any previous acute vascular event (ACS - note STEMI or NSTEMI if known, TIA, CVA,








Date of most recent
Angina Y / N
Hypertension Y / N
Myocardial infarction Y / N
Diabetes mellitus Y / N
Treatment: Diet
Insulin Y / N






Tablets Y / N
Age at diagnosis









Appendix 15 Vascular intervention data collection form (page 3)
Atrial fibrillation Y / N Age at dia
l=Current / 2=Previous
l=Cardioversion, 2=paroxsymal, 3=persistent, 4=permanent
Pacemaker Y / N Type
Hyperlipidaemia Y / N / DK
Treatment: Diet Y / N
Cardiac failure Y / N
Statin Y / N
Age at diagnosis
Other
Age at diagnosis Treated
Migraine Y / N With aura Y / N
Prolonged aura (>lh) Y / N
Epilepsy Y / N
Cardiac intervention Y / N
Angiogram angioplasty
Result angiogram


















Appendix 15 Vascular intervention data collection form (page 4)
Any other past medical history
SLE (look in notes) Y / N
Anticardiolipin antibodies (aCL)
Lupus anticoagulant (LA)
Autoimmune disease Y / N
If so give diagnosis:
Age of diagnosis
Y / N / DK
Y / N / DK
Allergies
Nosebleeds Y / N
Any cancer
Bleeding after dental extraction Y / N
End stage renal failure / dialysis











Do you take vitamin supplements? Y/N
B6Y/N FOLATE Y / N B12 Y/N
List names of supplements
Other medication : scroll of other druvs on database
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Vertebrobasilar stroke XXX xxxxx
Vertebrobasilar TIA




Retinal infarction right XXX xxxxx
Left XXX xxxx
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Appendix 15 Vascular intervention data collection form (page 5)
FAMILY HISTORY
dad num sib 1 sib 2 sib 3 sib4 sib5
Family history stroke (yes=1, no=2, dk=:
Family history Ml (code other box age
Family history PVD (extent)
Family history brain haemorrhage
Family history diabetes (treatment)
Family history hyperlipidaemia
Family history hypertension
Adopted Y / N
Twin Y / N
- 349 -
Appendix 15 Vascular intervention data collection form (page 6)
Total number of siblings (include interviewee)
Mother Alive / dead Age at death







Alive / dead M / F Age at death
Alive / dead M / F Age at death
Alive / dead M / F Age at death
Alive / Dead M / F Age at death
Alive / Dead M / F Age at deathSibling 5
(Youngest)









Appendix 15 Vascular intervention data collection form (page 6-7)
Family Tree (number siblings and children)
No of children


























Appendix 15 Vascular intervention data collection form (page 7)
Interviewer's perception of patient personality (see scale below)?
In general with regard to stress what kind of
person do you think you are? l=Very relaxed,
2=Fairly relaxed, 3=Average, 4=Prone to stress, 5=HighIy stressed
Place of residence: l=Home, 2=home of relative,
3=home of friend, 4=warden housing,
5=care home, 9=other(specify)
Do you live alone? Y / N If no with whom
Are you a carer? Y / N
Physical help to wash / dress / transfer or walk
Does anyone assist you at home?
l=Spouse, 2=relative, 3=private carer,
4=community services (specify)
Marital status
married=l, widow=2, single=3, separated=4, partner=5,
9=not known
Contacts with close friends and relatives
How many times do you see a friend or relative each week?
0-1 2-3 4-7 >7
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Employment status
Working f/t=l, p/t=2, caring for home=3,
unemployed=4, unable to work=5, retired=6, student=7
Most recent occupation
(husband occupation if not employed)
Socioeconomic class (I - VI)
Ethnic origin
l=white, 2=black Caribbean, 3=black african, 4=indian,
5=pakistani, 6=bangladeshi, 7=chinese, 8=other
Exercise
Clinician judgement on amount of physical activity
(age corrected) per week. l=None, 2=Below average,
3=Normal, 4=Above average
Alcohol units per week
Education Age left school





How is your appetite? Good normal poor uncertain
Do you think you have a healthy diet? Y / N / DK
On average how many portions of fish do you eat per week?
l=Less than once per week, 2=once per week, 3=twice a week,
3=>=three times per week
Do you add salt to your food? Y / N
Do you drink full fat (1) or low fat (2) milk
On average how many portions of fresh fruit
and vegetables do you eat? l=Less than once per week, 2=one
portion per week, 3=several portions per week, 4=once per day,
5=2-4 portions per day, 6=>=5 portions per day
Mood, Do you often feel sad or depressed? Y / N
Driving Do you drive? Y / N
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Handedness
R=Right / L=left / B=both / DK=not known
Clinician impression of frailty (corrected for age)
l=Frail 2=Normal
Life events
Has any of the following unpleasant things happened to you over the last year?
For each answer yes or no Y=1 N=2
Then ask how upset were you by these events?
Very much (1) / moderately (2) / not too much (3)
Death or serious illness of close friend or relative?
Financial difficulty
Divorce or break up of close friends or relatives
Major conflict with children or grandchildren
Muggings / robberies / accidents
Other (specify)
For women
Age of first pregnancy
Age of last pregnancy





No. of years on HRT/OCP
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1 = independent (or in shower)
Grooming
0 = needs help with personal care
1 = independent face/hair/teeth/shaving (implements provided)
Dressing
0 = dependent
1 = needs help but can do about half unaided
2 = independent (including buttons, zips, laces, etc.)
Bowels
0 = incontinent (or needs to be given enemas)
1 = occasional accident
2 = continent
Bladder
0 = incontinent, or catheterised and unable to manage alone




1 = needs some help, but can do something alone
2 = independent (on and off, dressing, wiping)
Transfers (bed to chair and back)
0 = unable, no sitting balance
1 = major help (one or two people, physical), can sit
2 = minor help (verbal or physical)
3 = independent
Mobility (on level surfaces)
0 = immobile
1 = wheelchair independent, including corners, > 50 metres
2 = walks with help of one person (verbal or physical) > 50 metres








Appendix 15 Vascular intervention data collection form (page 11)
Premorbid modified Rankin Y / N
Do you have any symptoms?
Are you able to look after yourself and carry out normal activities?
Does anyone else help pay the bills, do the shopping, cleaning etc?
Do you need someone to help you walk?
Do you need help to wash yourself?
Do you need to be lifted in and out of bed?
0 = no symptoms at all
1 = no significant disability despite symptoms: able to carry out all usual duties and activities
2 = slight disability: unable to carry out all previous activities but able to look after own
affairs without assistance
3 = moderate disability: requiring some help, but able to walk without assistance
4 = moderately severe disability: unable to walk without assistance, and unable to attend to
own bodily needs without assistance





Appendix 16 Troponin > 1 data collection form (page 1)
ID NO:
Patient identification label






















Summary of events and diagnosis (Presentation, timing, diagnosis, comments)


































(thyroid, RA, PA etc)
Any other relevant past medical history























Appendix 17 Brain imaging data collection form (Page 1)
OXVASC ID No.
Date of scan Days from notification event
CT done Y / N MRI Y / N If not why?
Describe main lesions
1) Acute lesion 2) Acute lesion 3) Old lesion 4) Old lesion 5) Other lesion 6) Others
r——— mm ~~1 ■>-— •• —~ 1 "I
Drain sufestanna
.1







I t3 Ponm# operculum
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Appendix 17 Brain imaging data collection form (Page 2)
Scan quality
1=Good/ 2= Poor quality, diagnostic/ 3=Poor quality, nondiagnostic/ 4=not relevant




l=Stroke lesion, 2=non stroke lesion, 3=normal,
4= abnormal, 9=uncertain
Signs for acute lesions
l=Appropriate to signs, 2=inappropriate,
9=uncertain
Pathology
l=Infarct, 2= definite PICH, 3= definite infarct with
haemorrhagic transformation, 4=SAH, 9=uncertain
Side
l=right, 2=left, 3=midline, 9=uncertain
Territory
l=Posterior, 2=deep anterior, 3=superficial anterior,
4=both, 5=watershed
For cerebral infarct
l=No haemorrhagic transformation, 2=Haemorrhagic
transformation without haematoma, 3=Haemorrhagic
transformation with haematoma, 4=Haemorrhagic
transformation with intraventricular blood, 9=primary
intracerebral haemorrhage
For primary intracerebral haemorrhage
^Intraventricular blood, 2=No intraventricular blood,
3=Uncertain, 9=cerebral infarct
Amount of haematoma
l=Petechial haemorrhage, 2=up to 2cm,
3=2cm and over, 9=uncertain
Mass effect
0=Scarring and ventricular dilatation/
l=No swelling / 2=Effacement sulci over infarct
3=Minor effacement adjacent lateral ventricle
4=Complete effacement of the lateral ventricle
5=Effacement of lateral and third ventricle
6=Shift of midline away from side of ventricle
7=Effacement of the basal cisterns
Periventricular white matter lucencies Y / N Mild/ Moderate/ Severe
Atrophy for age Y/ N Cortical/ Central/ Cortical and central/ Cerebellar
Focal/ Diffuse
Mild/ Moderate/ Severe
Change of radiological diagnosis after unblinding Y/ N
What was the change?
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Appendix 19 Follow-up data collection form
OXREG CO2.043 OXVASC ID No.
Date Follow up
Circle 1 12







Chest pain (requiring admission)




























Smoking Y / N
BP
Seizures (treated)Y / N
Rankin (0 - 6)
MMSE (/30)
Driving Y / N
WorkingY / N
Depression (treated) Y / N
Barthel (/ 20)
Survival Y / N
Screen for TIA / Stroke: Have you had any sudden onset of severe headache, visual loss, speech disturbance, double
vision, slurred speech, weakness or numbness of face,arm or leg?
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Appendix 20 Recurrent event data collection form (page 1)
ID NO:
Patient identification label Date of Notification Event
2
GP Details
Beaumont street 01 E
Malthouse 05 E
Marcham Rd 08 S
Date of recurrent event
Acute vascular recurrent event
,ast Oxford 03 Berinsfield 04
Cidlington 06 Wantage 07
tert street 09 Other 10
Chest pain (requiring admission) Unstable angina NSTEM1 STEMI Y/N
No chest pain troponin > 1
TIA (<24h sudden onset focal neurological disturbance)
Stroke (>24h)
Acute PVD event (eg embolus, aneurysm)
Death
Summary history of recurrent event
Include date of presentation, medical attention and ascertainment. Presenting history. Medication on
admission. Diagnosis and subsequent management.
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Peak troponin I level
ST / T wave changes
NIH score
Cause of death (if applicable)
ST depression
TIMI - NSTEMI score


















2nd most recent: Height
2nd Most recent: Height











Blood Pressure Date of diagnosis
On treatment for BP Y/N
Most recent BP
2nd Most recent BP
3rd most recent BP


































Appendix 21 Pre-morbid risk factors data collection form (page 2)
Blood Pressure
Highest measurement prior to 1990 Date
First ever recording:
Cholesterol Date of diagnosis
On treatment for high cholesterol Y/N
































Prior aspirin / warfarin / dipyridamole
Any other relevant information





Appendix 22 Informant Questionnaire on Cognitive Decline
1. Remembering things cbcut Much A bit Net much A bit worse Much worse
family and friends eg. Imprc/ed improved change
occupations, birthdays,
eddresses 1
2. Remembering things that Much A bit. Net much A bit worse Much worse
have happened recently Improved improved change
3. Recalling conversations a
few days later
Much A bit Not much
Impro /ed improved change
A bit worse Much worse
4. Remembering his/her address Much A bit Net much A bit worse Much worse
end telephone number Imprc /ed improved chcnge
5. Remembering what day and Much A bit Not much A bit worse Much worse
and month it is impro/ed improved chcnge
6. Remembering where things Much A bit
ere usucily kept improved Improved
7. Remembering where to find Much A bit
things which heve been put in impra/ed improved
a different piece from usucl
3. Knowing haw to work famiiiar Much A bit
machines crcund the house imprc/ed imcrcved
9. Learning to use a new gadget Much A bit
or mcchine around the house improved imcrcved
Net much A bit worse Much worse
chcnge












A bit worse Much worse
A b:.~ worse Much worse i
A bit worse Much worse
A bit worse Much worse
11. Following a story in a book Much A bit Not much A bit worse Much worse
or on TV improved Improved chcnge
12. Making decisions cn
everyday matters






14. Hcndling financial matters Much A bit
eg. the pension, dealing with Improved improved
the bank
15. Hcndiing other everyday
arithmetic problems eg.
knowing how long between











A bit worse Much worse
A bit worse Much worse
A bit worse Much worse
A bit wcrse Much worse
16. Using his/her Intelligence to Much A bit
understand what's going on Improved Improved
and to reason things through
Net much A bit wcrse Much wcrse
chcnge
